var title_f25_17_25872="Differential splicing";
var content_f25_17_25872=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F68285&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F68285&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 555px\">",
"   <div class=\"ttl\">",
"    Differential splicing of DNA",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 535px; height: 324px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFEAhcDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKbKnmRum5l3AjcpwR7j3rnP8AhE/+o/4g/wDAz/61AGV8ZUWTwX5bjKPfWqsPUGZcivL/AOwtL/58YfyruPifoH2Dw3Dcf2tq9ztv7UeXc3O9DmZRyMVzNe/lFOMqcuZX1Pp8ipQnSk5JPX9DN/sLS/8Anxh/Ksbxc+ieGNCm1S70wTQxMqlIlG47iB3I9a6uuV+J2iXniLwfdadpqo1zI8ZUO20cMCefwr0q1KKpycIq9tND18RRjGlJ04Lms7aLcq6fcadLa3lzqXhm80yC2QOWnhDF/wDdCEkn8O9WPCMuheKNHGo2WmeVCZGjCyqA3ynrwapeDtIvNAttTe08L2NhNIqFI4b9nE7DOAzMDtxk8471J8LtJ1fQtIn0/V7OGFRK0ySx3Hmb9xyQRgYxxznmsKcLyipR0d76fd0X5HNSheUFKCs07+71vprZfkjo/wCwtL/58Yfyo/sLS/8Anxh/KtKiuz2NP+Vfcd/1el/KvuR6h8LiT8O/DpJJP2GLk/7tdRXm/wAOfDX2nwHoU/8AbWtw+ZaRt5cV1tRcjoBjgV0f/CJ/9R/xB/4Gf/Wr4p7n55LdnA+INKsdS8d+I3v7WK4aOWBVMgztHkRnA/Emof8AhGNE/wCgZbf98VZjs/sHizxJb/abm52zwnzLh97nNvGeTV+vcw0IulFtH5TnuKrwzCrGM2lfu+yPLdF8QeG9av8A7Pp3g3WJoRdfZHu1s0MMbBgCWYPwozk8dO1SXmt+G7DXYbDUfCeoWdtPeGwhv5rVRDJLuIGPmztODg45HPSue8GeCNU0bxALjUfCK3Mh1JrhdRGsmPyYy4wfJU4baMnB69K1dZsvGWqeNoL/AFLw1De6Tp0+/T7ZdSjiVWBwJpOCWbGCBxj3rJX5buOvp/wDtqOn7ZxhV923/PxLXpb3nr629D0L/hGNE/6Blt/3xXQ/Cuzt7DxB4jt7OJYYBFaMETgZPm5P6Cq1R+EdI/tPxVr5/tDUbPy4LQYtJ/LDZ87rwc0Y6EVSukHC2JrVMdyzm2rPdvyPVa8++LNtDezeGre6jWWB72TcjdGxBIRn8a3P+ET/AOo/4g/8DP8A61cn410X+zNW8NSf2lqd3uu5V2XU/mKP9Hk5Ax1r5fNpOOBrSi7NRl+R+nYZJ1Yp90cX40Hhjwjoh1PUdG86ESLFstolZyzHA4JA/Ws+3vdHm0y8uz4E1yJrdo1W3lsVEk5ckfIA5yBjLEkYBFXvjH4f1DxN4MbT9Jt1uLk3EUnltIIwVU8/MelZXhrTdU0LRNVGneBUtJJmjBtG1wzm5Qhg2HfhCoI+ufavzTD1ubCKbqN1ObZztpdd5J6662fnbc92cbVLKOlu3r5F3wfc+HPEl5qVj/wjsunahpxQXFveQqGUOCVIIJByBXffDuwtdO8dXcVjAkEb6aGZUGAT5uM15z8KfDeq6Nq2u3dzpq6Jpd4YzBpn2oXLI4GGcuCevpnv7V3+iaZ/afjuVPtt9abNNB3Wkvllv3vQ8HIr1corP+2Y06dRyhb+a6vy69WtH5v1Zz4mP+yuUlZ+nmesVwfxrUP4GZG5R721Vh6gzLkVr/8ACJ/9R/xB/wCBn/1q4/4q6B9g8LR3H9ravc7b61Hl3FzvQ5mUcjFff4ptUZtdn+R83jG1h6jX8r/I85/sfT/+fSL8qwvE17o3h+Wxin0m4u5r12SKO1jDsSMHoWHrXWVw3xL0C91q40SSzsBfw2ssjzQm48jcCBgbuo6dq/OMFXlUrKNao+XX7Vujt1XXzPyXLsTOriIwr1ZKOv2mujtq2utuqNCG40j+xJ9UvdJudPhhJBiuotsjdMYUE5ySAPU1L4Yk0bxHo8WpWViY4JCyhZlAbgkHoSO3rWTZ+F7y603TlhQ+HzZXDzLbGT7crsQNrlmPUfNgds5q58L9E1HQPDCWequBIHZlhG0iMEn+Idc9fauitUjGjKUKr5k1pd7a+qfR3Tfb16sRVjGhOcK751JWXM9tezaeyd1JrW3rr6jpNimn3TpbRqyxMQR2ODX0j4aJPhzSiSSTaRZJ/wBwV8+ap/yDLz/ri/8A6Ca9g8O+FvM8P6Y/9u68u61iO1bzAHyDgcdK9zhirOpCpzyb23+Z9JwbWqVYVvaSb1W7v3O1orG0vQf7PuxP/aurXWAR5dzc70574x1rZr6o+1CiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAMHxroDeJdDOnpd/ZH86KZZfL8zBRww+XIz09a4/wD4Vpqn/Qyw/wDgt/8AttenUVtTxFSkrQlY3o4qtRVqcmjzH/hWmqf9DLD/AOC3/wC20f8ACtNU/wChlh/8Fv8A9tr06itPruI/nZt/aOK/5+M8x/4Vpqn/AEMsP/gt/wDttH/CtNU/6GWH/wAFv/22vTqKPruI/nYf2jiv+fjPMf8AhWmqf9DLD/4Lf/ttH/CtNU/6GWH/AMFv/wBtr06ij67iP52H9o4r/n4zL8L6SNC8O6dpQmM4s4Fh80rt34GM4ycVqUUVynEcPrHgq+u9f1DUrDWorVbxkZopLLzcFUVOG3jso7VW/wCEH1v/AKGS2/8ABZ/9tr0GitY16kVZSPPq5Vg603UqUk2+tjz7/hB9b/6GS2/8Fn/22j/hB9b/AOhktv8AwWf/AG2vQaKr6zV/mZn/AGJgP+fMfuPPv+EH1v8A6GS2/wDBZ/8Aba2fB3hi40G81G6vNSW+mvFiUlLfyQgTdjjc2c7zXUUVE605q0nc3w+W4XDT56NNRfdBXOeMvDk3iBdOa1v1sp7KZpldoPNDZRkII3L2b1ro6KwqU41YOE1dPRo7oycXdbnn/wDwhGt/9DJa/wDgs/8AttH/AAhGt/8AQyWv/gs/+216BRXmf2Fl3/PmP3G/1ut/Mzz/AP4QjW/+hktf/BZ/9trT8K+E7rR9an1K+1VL6SS3Fuqpa+SFG7dn7zZrraK2w+VYPDTVSjTUZLqkTPEVZrllK6CsDxv4ePifQW05bv7I5mimWXy/MwUcMPlyM9PWt+iu+UVJOL2Zzyippxlszyr/AIVXqH/Qyxf+C7/7ZR/wqvUP+hli/wDBd/8AbK9Vorz/AOycF/z6X3Hmf2Hl/wDz5j9x5V/wqvUP+hli/wDBd/8AbKP+FV6h/wBDLF/4Lv8A7ZXqtFH9k4L/AJ9L7g/sPL/+fMfuPJp/hNfTQSRP4lj2upU407nBGP8AnpXqGm2osdOtbQMXEESRbsY3bQBn9Ks0V00MLRw11Rio37HXhsFh8ImqEFG+9goooroOoKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAorlfih4ofwf4J1DVraEXF+oWGyt8FjNcSELGoUcn5iCQOcA1q+FNctfE3hrTNasD/o19Ak6AnJXI5U+4OQfcUAatFFFABRRRQAUUUE4GT0oAKK4D4U/ESDx42vLHCYTYXjLBkEefasSIphns21/yrv6ACiiigAooooAKK8u8C/ES4134m+IdHuYtmkMWGjT4wJ/s5Edzg/xfOwI9ga9RoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiuU8Y+O9J8MTw2LifUdcuB/o2lWCebcy++0fdX1ZsDg80AdXRXmH2v4qQ/8TySw0Se3b73huOQidI+xW5PytL6ggJjoc8103g3xzo/ip5ra1eaz1a3H+k6Xex+TdQf7yHqOR8wyOetAHU0UUUAFFFFABRRRQAUUUyaVIIXlmYJHGpZmY4AA5JNAD6K4v4U+PbT4g+Hp9StYWt3hupIXhcEMFzuibn+9GyNn1J9K7SgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiquq39vpWl3moX0gitLSF55nP8KKpYn8gaAOB1n/AIqr4waXpX39M8MQjVLoZypvJQUt1PuqeY/4ik+HQ/4Rjxr4l8GP8toznWtKB6eRM372MeyS549JBVz4M6fcL4Ym1/VIzHq3iO4bVbhWOTGj48mPPXCxBBjsc1W+MMT6RHo3ja0Rmn8O3O+6CDJksZMJOuO+Btcf7lAHo1FMhljnhjlhdZInUMjqchgeQQfSn0AFFFFABXC/GTVLq18I/wBlaS+3WNenTSbMjqjS5Dycc4RA7Z9hXdV5vY/8VT8Zru7OW03wnbfZIT/C17OA0jA+qRbV9i5oAoeJ9Ltfh5rvg3xBpqeTpNtFH4d1Aels5AgkY/7EoGT1/eH3r1esrxVodr4l8N6lot+M219A8DnGSuRww9wcEe4rA+EeuXWseD44NXI/tvSZX0vURnOZ4Tt3/wDA12v/AMCoA7SiiigArkvip4gn8OeCL+609S+q3G2y0+MdXuZWCRgeuGbd9FNdbXm+rf8AFU/GPTdNHz6b4Wt/7SuR1VryYFIFPuqeY/8AwIUAZfjDwp/whvw28OX2iRmW98FlLwFOGuIsEXYP++jOx9wK9VsLuDULG3vLORZba4jWaKRejowyCPqCKkljSaJ4pUV43UqysMhgeCCK89+Dskmkxa34KunZpvDl15dsznJeylzJbnPsCyf8AoA9FooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAqhrmsadoOmTajrN7BZWUIy80zhVHt7n0A5NcbrXxDN1qU+ieAbD/hIdajOyaZX22Nkf+m03TI/uLljgjil0P4difU4tc8d3/wDwkWuRndCsibLOy9oIegPT52yxwDxQBQ/tvxX4/wDk8KRS+G/Db9dZvYf9KuV/6d4G+4D/AM9H9cgcV1ng7wXovhGGUaVbs13cHdc31w5lublv70kh5PPOOg7AV0dFABXM+MfBOi+LFhfUYHh1C25tdRtXMN1bN6pIOR9DkHuK6aigDzD+3fFngLKeLoH8R+HV6a1YQ4ubdfW4gX7wHd4/TJHNegaFrOm6/pkOo6LfW99ZSjKTQOGU+3HQjuDyKv1wGu/DqNdTm1vwTfv4b16Q7pWgQNa3Z9J4Putn+8MNznJoA7+ivOtM+IsmlX8OkfEaxXw/qUjeXDeqxfT7w/8ATOY/cJ/uPgjjk5r0QEMAQQQeQRQAtFFFABXn/wAabuebw1a+GtPkKaj4luk0uNl6pC2Wnk+ixK/4kV6BXnGjf8VR8YtW1Rvn0/wxb/2XanqDdygPOw91Ty0/E0AVdatYPh94+0PWbGNbfQNXjh0PUI14WKRBi0lP6xEngArXqNY3jLw/a+KvC+paJfErDeRFA46xt1Vx7qwDD3FZHwr8QXWu+FxFrGF17S5W07U0/wCm8fBcezja4P8AtUAdhRRRQAUUUUAFFFFABRRRQAUVU1WO/ltCuk3NrbXWRiS5t2nTHcbVdDn33Vi/Y/GP/Qd8P/8Aglm/+S6AOZ+K99qEGvaBaWOpXllDNbXksn2Z9hdka3C547b2/OuT+1ax/wBDFrP/AIED/CtP4gw6xD4s0H+277T7vNle+V9ksnt9v7y1zu3Sybs8YxjGD1zxl19FluHpVKHNOKbufV5RhKNXDKU4Ju76C/atY/6GLWf/AAIH+FYviDxivh54U1nxhq1q0wJjDTE7gMZ6KfUVs15j8UrW9bxb4avLWDWPIt47gSXGl25lli3KAMcEc9Oe2a6MRh6NOHNGCvp08zqxeFoUqfPCmr6dPM7VPGSNof8AbA8Z6mNNJIE7XG0Eg4IAK5JyOmK1bXUdTuraK4g8S6y8MqCRGFx95SMg9K838VJ9v+Fxgk07WtSvZN6QG8sC1yj7jh2UD5OOA3pj1rsfBc7TeF9NEltdW0kMCQvHcwtE4ZVAPB5xnvU06NGU+VwWyexNHD0J1OSVOOye3U3PtWsf9DFrP/gQP8KzPEUd7qemiw1LWdWurG6uLeCeCS4+WRGmRWU4AOCCa0qo6yJWtoBbuiTG7tgjOhZVbz0wSARkZ7ZH1FaYjCUI0pNQWzNMTgcPGjNqCuk+nkfQqKqKqooVVGAAMACor21gvrOe0u4lltp42iljbo6MMEH2IJrA+x+Mf+g74f8A/BLN/wDJdH2Pxj/0HfD/AP4JZv8A5Lr5M+IPLvBlrex+E9Jjh13Wo4o7ZERFuuFUDAAyOgAArQ1KebTLGa9v/E+swWsK7pJHuuFHqeKi8Gbh4V0veQW8hckDAJ+lZvxXt5rr4da9BbRSTTPbEJHGpZmORwAOTXuKjTVPm5Vex+VyzPGSxrpe2kouVt9lexHpnjHSdUN0LDx1qM/2WBrmbbd/6uJcbnPy9BkVN4b8UWHiWaaLQ/GuqXcsI3OiXRDAdM4KgkcjkcVxHw1vVstOuRqD6/epb6XmWyudIEaYUKGRDtBc9gCeRzS/DzUjrvxFudd1XS9R0++mtjZ2ls1k6RQwqd2XkIALnHHp0+mUYwfLeK18jvrVsVBVXGrO0Vo+br6WT+eiXmeqfZ9Q/wChh1v/AMCf/rV03wcsIbLwSrxl3mur27uLiWRtzyyGdwWY9zhQPwrFqf4d2viZ/Cdu2navo0FqZ7nZHPpcsrqPtEnVxcKDzn+EVlj6cIJcqsd/CmNxGKqVFXm5WS3Z6VXkfiLTDbfE7XJNOvr+wN5YWVzcC1m2CSTdcR7iOedsSD8K7f7H4x/6Dvh//wAEs3/yXXFX8WpRfEDU11m7s7q4/suyKva2rW6hfNusAq0jknOec9xxxk/JcRV6lDLqlSlJqStqv8SP0DBQjOvGMlda/kYXiDxHZeHZootb8aapZSSqWRZbvG4DjI+Wqd9420Wx06zv7rx3qSWl5u+zyC5LeZtba2AFzweK4/4wW90PiF4dvYv7Uht4rSZXurCy+0tGTnA2kEc+9aGo67Z23hDTobm58RW888UmzUo9JAmIDsGjZdpCE46YGRg5r46nXxTpUantqknPe0npv/dfa/V+XU9NwpqUlypW8vTzO90q5fV9PhvtM8VavdWkwzHLHdgq3OD29Riun+D9jHbafr1wZJp7u61WVp7id98km1URcn0CqABXm/wWtbuy+Hem299p39nyIZNsTKUZlLEh2UkkMc5I/pXdeALfxDLZ6s2k6ppNtbf2lPiO502Sd88ZO5Z0GPbbXq8O4qvPMK1CpVc4xTtd32klc58bTgqMZqNm/wDI9Nrx74vQPZeOtD1HTbq6sb66066gmmtpNpkjjlgKKfoZX/Ou8+x+Mf8AoO+H/wDwSzf/ACXXnHxOh1iHxP4f/tu+0+7zZ3vlfZLJ7fb89tndulk3Z4xjGMHrnj6jNKkqeEqTg7NI+XzmrOjgatSm7NLRoxv7S1z/AKGPWP8Av+P8KxdV8dnSbs2uo+NNRt7gAMUe45wen8NadeTeLIriH4i3lzv1S2gezjQTWdl9o3HP3eQQK+LwGLxOJqOM60tFff08n+R+e5Zj8Zi6soVK8kkm9G/Lyf5Hp154uubLTIdRuvF+pRWUwUxzNcgBgwyMcdxzWimqa06hl8R6wVIyD54/wrx34h6XrWpaHNdLai8sVtbdLTO5Z48lC7mEL98ng8jCg+9eoaQbg6Xam8jSK48sb0RiwBx6kCniMViaVGNSNdtttNX22a8+uvmPF43F0cPCrHEybbaa5ttE15311vbU3tC1jWo/E+hpJrmpzwzXqRSRSyhlZSDkEYr3qvnO2W5fXtBWxlhhujqEXlyTRGVFPPJUMpI9twr2f7H4x/6Dvh//AMEs3/yXX03D9epXwrnVk27vf5H2PC2Jq4nBOdaTk+Z6v0R0tFZ+jxarFFINZvbG7kJ+RrS0e3Cj0IaWTJ/EVoV7h9GFFUNYi1SWBBo15ZWkwbLtd2jXClcdAFkjwc45yfpWT9j8Y/8AQd8P/wDglm/+S6AOK+IuoamPHctna6tf2dtHpttMI7aTYC7y3AYnj0RR+FYX2rWP+hi1n/wIH+FWPFUWpRfEC8XWLuzurj+y7Qq9ratbqF825wCrSOSc55z3HHGTWr6XL8NRnh4ylFN6/mz6/K8JQqYWEpwTevTzYv2rWP8AoYtZ/wDAgf4Vg6944h0C8S11jxlq1rcPGJVRpWOVJIB4U9wfyrdryj4gW18nxJtb+CLX0tRpYiNzpNqZWDea52k4I6YJ79K0xOHpUoc0YLfsa4vDUaMOaFNXv2/4Y7668ZJaaNBqtz4z1OKwnGYpGuMb+cfKu3J/Ktr7VrH/AEMWs/8AgQP8K8p+Jtu+qfDywgh0rVtQ1ORR5MstiXniwy79+B8hYD2zj2r0zTrtb+yiuUhuIFkBPl3EZjkXnHKnkUUqFGU3BwWye3fcKOGoTqOEqcdEnt33/T7y19q1j/oYtZ/8CB/hVW7gvdYvNL0vU9c1qfT768jguYftbIJIzklSVwcHGDz0qzULLcvrGhLYyww3R1CLy5JojKinnkqGUn/voUYrC0Y0ZSjFXsGNwWHhh5yjBJpPoe4aLpOn6HpsOn6PZwWVlCMJDAgVR+A7+p6mk1+aS30LUpoWKSx20jow6ghSQayfsfjH/oO+H/8AwSzf/JdZ/iKz8Wjw/qZl1vQWjFrLuVdGmUkbDkA/ajg/ga+WPizjtMXU7jTbSaTxDre+WFHbFz3KgntUes3zaJYPfar4q1e1tEIDSyXXAJOB/D61c0P/AJAun/8AXvH/AOgiuK+PNpc33w01CCyt5ridpISI4ULscSLngc17s6NOMHJRWx+U4fMsZWxcaMq8knK2+yuaVn4x0m9sr27tfHWoy21koe4kW74jBOAT8vc8Vb8N+ILXxNFLJoXjLVbwRECQJdYZM9MqVBGcHn2rkPC+sx2Gia7d3Y8Qa2kKROLe60hYWJ3EAIAo3ckE+m3NN+Et0dT8U65rOp2N9aa1qSK7RPZvFDBEmFVA7Ab35BJ9uKyjCm3Fcq18jurYjFwp1ZqrP3bWfN6aWsns276LZa3PSvs+of8AQw63/wCBP/1q7/wBdz3/AIE8N3l5K011cabbSyyN1d2iUkn6kk1xlXPh3aeKm+H/AIZa11rQ47c6XamNJNIldlXylwCwuQCQOpAGfQdK58fTjDl5Vbf9D1+EsZXxXtvbzcrctru/8x3mp6fZ6pYzWWpWsN3ZzLtkhnQOjj0IPBrxvTdFbRdY8QaRo+r6zZ6XYXqx2trHeMyQo1tDIVXdkgbpGwM969I+x+Mf+g74f/8ABLN/8l1wtml5H4l8Vrqc9vcXY1CPfJbwtCjf6HbYwhdyOMD7x5546D47ifEVcNgHUoycXdao++wEIzrWkrow9d8VaboF6LPWPG+p2lyUEgjku8Hac4P3fY1W1TxvoulpZtf+O9TiF3Es8H+kk742yA3Cng4PPtXCfESG7g+Lj3ofWLS1bSUiF1p+n/ast5mdhBUgcDOevA9a0/HOsWcnhWHTmk8Q297PpyAXEOl/NeqUYeU/y/KSSSV+XG7ivl6dXEtUX7ao+dXdpPT/AMle3z+W53uMFze6tPL/AIJ6XZG4vbSG6tPE+sTW8yh45I7sMrqehBxXVfByxhsfA0Xlb2knvLueaWRtzyyG4kyzHuTgc+1cJ8N4Lq28C6JBf2K6fcx2yq1soI2Y6ZBJIJGCQeck11Pw7tfEz+FLdtO1fRoLUz3OyOfS5ZXUfaJOri4UHnP8Ir1OF8XiK2Jr06tRzUdru/VnPj6cI04SjG1z0mvDfH8MulfFDVZtHvbzTnvtPs7i5+zSbRLIHnQMR67UUfhXpv2Pxj/0HfD/AP4JZv8A5LryvxzFqUXxAuV1i7s7q4/sy1Kva2rW6hfNueCrSOSc55z3HHGT9DnVWdHBTnTdmrar1R8lxDWqUMuqVKUrSVtV/iRT/tLXP+hj1j/v+P8ACsC++IUdhdy2t5431CK4iO10a55U+n3a2K8cmW4s/GfiKWWTWLWKW5Vk+y6f56ygDnkqcfh618lgMVicQ5KdaWivo33S7P8AI+FyvG4vFuaqV5+6rqzeuqXZ/keuap4ovdK8j+0fFup2/nv5cYe5ALt6Dir39pa5/wBDHrH/AH/H+FePfEXSdenvjeyWMN0v22JbVopGZoogScbAvGTyzZ9PSvV4DI0EZnVUlKguqnIDY5APcVGIxeJpUqc4123K99fT/MjF47GUKFOpHEyble/vbbf5636nReB9W1g+OtFtrnWdQura4aZZIp5QytiF2Hb1Ar22vnzw6l9J430BdLuLa2ujJNtkuYGmQDyHzlFdCeP9ofjXr32Pxj/0HfD/AP4JZv8A5Lr6zIq1Stg1Oo7u73PuOGsRVxGAjUrScnd6v1OloqlpMeoxWpXV7q0urncTvtbZoE29htaRznrzn8KK9g94u0UUUAcD8SfDmsaxq+jXujQ2s4tYLmGVJ5zF/rGhKkEK2f8AVH8xXM/8Ij4u/wCgZpn/AIMG/wDjVeyUV1UcbWox5IOy9Ed1DMcRh4clOVl6I8b/AOER8Xf9AzTP/Bg3/wAao/4RHxd/0DNM/wDBg3/xqvZKK1/tPE/zfgjb+2cX/N+C/wAjxv8A4RHxd/0DNM/8GDf/ABqj/hEfF3/QM0z/AMGDf/Gq9koo/tPE/wA34IP7Zxf834L/ACPG/wDhEfF3/QM0z/wYN/8AGqY3gnxXcTWqzWOmxRJcwSu63zMQqSq5wPLGThfWvZ6KUsxxE4uLlo/JEzzbFTi4ylo/JBRRRXCeaeR6R4Y8WabpltZ/2ZpsogQJv/tArux3x5XFXP7G8W/9AfTf/Bkf/jVeoUV0rGVkrJnhz4by6pJzlT1eu7/zPL/7G8W/9AfTf/Bkf/jVH9jeLf8AoD6b/wCDI/8AxqvUKKf12t3/ACI/1Yy3/n3+Mv8AM8v/ALG8W/8AQH03/wAGR/8AjVdh4D0u70bwtaWWorEt0jyu6xPvUb5XcAHAzww7V0FFZ1a86uk2d2ByrC4BuWHja++rf5sK8/8AFeg67N4wn1PSbSzubaawt7Yia6MLK0ck7HjY2QRKPyNegUVw4vCUsZSdCsrxe/TZ36HqU6kqUlOO55j/AGP4t/6A+m/+DI//ABqj+x/Fv/QH03/wZH/41Xp1FeL/AKq5X/z7/wDJpf5nV/aFf+b8EeY/2P4t/wCgPpv/AIMj/wDGq6f4faTf6RpF1HqscMdzPeS3GyGQyKobGBuIGenpXT0V3YHJsHl83Uw8LNq27f5syrYqpWVpsK89+KHhjWNd1TRbvRYrWUWkNzFKs85i/wBY0JUjCtn/AFbfmK9CorvrUYV6bp1FdM4cRh6eJpyo1VeL3PEP+EG8X/8AQP0v/wAD2/8AjdH/AAg3i/8A6B+l/wDge3/xuvb6K8r/AFfwH8n4v/M8X/VbLP8An3/5NL/M8Q/4Qbxf/wBA/S//AAPb/wCN0f8ACDeL/wDoH6X/AOB7f/G69voo/wBX8B/J+L/zD/VbLP8An3/5NL/M8a0XwN4nj8Q6Rc3trp0Nta3STyMl4XbAB4A2D19a9loor0cLhKWEh7OirLc9XBYGhgafsqCtG992/wAwooorpOsKKKKAPNPHXhbXtQ8YPqekW1lPbSWEFsRNcmJldJJmPGxsjEo/I1jf8Ij4u/6Bmmf+DBv/AI1XslFddLHV6UVCD0Xkjvo5liaEFTpysl5I8b/4RHxd/wBAzTP/AAYN/wDGqP8AhEfF3/QM0z/wYN/8ar2SitP7TxP834I1/tnF/wA34L/I8b/4RHxd/wBAzTP/AAYN/wDGqP8AhEfF3/QM0z/wYN/8ar2Sij+08T/N+CD+2cX/ADfgv8jxv/hEfF3/AEDNM/8ABg3/AMaqfS/B3if+3tInvbPT4ba1u0nkZLwyNhc8AeWMnn1r12ipnmGIqRcZS0fkiKma4qpFwlLR+SCqes2z3mj31rDjzJoJI13HAyVIGfzq5RXEeceUWHh7xba2NtbnSdMYxRrHu/tEjOBjP+qqf+xvFv8A0B9N/wDBkf8A41XqFFdX1yt3/I8F8NZa3d0/xl/meX/2N4t/6A+m/wDgyP8A8ao/sbxb/wBAfTf/AAZH/wCNV6hRR9drd/yF/qxlv/Pv8Zf5nl/9jeLf+gPpv/gyP/xqu48GabPo/g/QtMuyhubKwgtpShyu5I1U4PpkGtiisqtadW3O9j0MDlmGwHN9XjbmtfVvb19QrzXVfD3iKPxPrt3p9jY3NpfXMc8bSXhiYYt4oyCuw94z3716VRXn4zBUcdS9jXV4/NfkenSqypS5obnmP9j+Lf8AoD6b/wCDI/8Axqj+x/Fv/QH03/wZH/41Xp1FeR/qrlf/AD7/APJpf5nT/aFf+b8EeY/2P4t/6A+m/wDgyP8A8arrvAel3ejeFrSy1FYlukeZ3WJ96jfK7gA4GeGHaugor0MBlGEy9ylho2b31b/NmNbE1KySm72CvL/iF4R17VfGB1PSILKa2ewhtiJrkxMrpJMx4CHIxIPyNeoUV2YjD08TTdKqrxf/AA5wYrC0sXSdCsrxe/yd+h4h/wAIN4v/AOgfpf8A4Ht/8bo/4Qbxf/0D9L/8D2/+N17fRXl/6v4D+T8X/meP/qtln/Pv/wAml/meIf8ACDeL/wDoH6X/AOB7f/G6P+EG8X/9A/S//A9v/jde30Uf6v4D+T8X/mH+q2Wf8+//ACaX+Z5J4Q8GeI7Lxfpeo6nbWENpaGVmMV0ZGO6NkAA2Du3rXrdFFelhsNTwtP2VJWR62DwdHBUlRoK0V8/zCiiiug6gooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACivEPj7/yUn4Sf9hY/+jravb6ACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACsPQPFei+INS1fT9IvPtF3pM3kXsflOnlPuZcZYANyjcjI4+lbleIfAL/kpPxb/7Cw/9HXNAHt9FFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB4h8ff8AkpPwk/7Cx/8AR1tXt9eIfH3/AJKT8JP+wsf/AEdbV7fQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBzPxD8Z2HgTw6dZ1W3vLi3EyQeXaIryFnOBgMyj9areHvHlrqcF3Pquk6v4ZhgaNFk16KO1WZn3YEZ3kEjbyOOorF/aB8K6r4x+Hr6VoVqt1eG7hm8pphEGVWy3zEjFcfD4L1MfDnxZotj8NoNMuNTSKKKCfxAb5JG+b96Wc5Ty+GG3liR6ZoA9pk1vSo2vVk1OxVrIBroNcIDbg9DJz8o+uKgtfE+g3elS6na63pc+mxMFku47uNoUOQMFwcA5IHXvXg2nfCjxRYfDfVPDkunWN5fQaxBqf2o3A261ErAmKXcSVIxj5ht6e5LvEvw38UeItA+IVxZ+HbbQZdchsILXSEuYTvaGZXeV2Q+WDgHHOev4gHv8ApWtaXq7XK6TqVlfNbP5c4tp0lMTf3W2k7Tx0NQav4l0LRbmG31jWtM0+4mGY4rq6jiZ+3yhiCfwrjfCXgqTw/wDFvxDq1hptpYaDeafbwwrbBI1MqE7vkXpx3xXD/FzwD4n1fx5fan4V0d2nu4oIGu7m4tZrKRFABEsEql1xyPk3Z64BzQB6lpvjzS7nXfE+nXrR6dHoM8MEtzdTKkchlTcME4x6c1dtfFFsbzW11A2tjZaY8Sm7lvYSjhxkEgNmPkgAPjOeM14t4m+Ffiq78f634qgggvFi1ayvrbS5ZUEF+qR7JCcn5XU/dLcdeDmqvxk8PappfgT4xatqFsILTWLjS5bX94rMQkkStkAnBB4oA99g8T6BcQ3stvrmlyxWRC3TpdxssBJwA5B+U59cVWuvFulNpurXGkX+n6pcabGXmt4L6EFCAcK7FtsecHliBXz98U/DGrjRfHvim88PW/hnTjosGmRWMU0TtcOLqNzMwi+UYA2jPOMVtT+AvEXiGfxDqdr4atfD8M3hd9GtbVLiEtfSsQwkbyztVeMfNg9PwAPaX8W6JaWNvPrGq6ZpkksEdw0VzexDYHHHzbsEZ4DDg9qt6p4h0bSYLabVdX06yhuTiCS5uUjWU8fdLEbuo6eteOS/C7Ub7VLqbVNIsrqIeC4tJtzOY5Nl6qkYXP3SP74/Oua1u0b4e6n4D1HxRb6LfNa+Gv7LfTdRvFjEEiMC00ZKsrcEIQuWI6A0AfSdhe2uo2kd1p9zBdWsmdk0EgdGwSDhhweQR+FeMfAL/kpPxb/7Cw/9HXNdD+zPaz2fwP8ADEV1C8MpSeTa4wdr3EjKfoVYEexrnvgF/wAlJ+Lf/YWH/o65oA9vooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKjE8TTtAJUMyqGaMMNwB6Ejrjg0AeKfH3/kpPwk/7Cx/9HW1e314h8ff+Sk/CT/sLH/0dbV7ZPNFbwvLPIkUSDLO7BVUepJoAfRQCCAQcg9CKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKZLGk0ZSVFdD1VhkH8KfRQA2SNJUKSoroeqsMg04DAwOlFFABUc0EU4AmiSQA5AdQcH8akoJwCcZ9hQAV4h8Av+Sk/Fv/sLD/0dc16Rofjzw5rN/Lp9vqUUOqQuYpbG5/czo46rtbG7HquR715j8DbmCz+IPxenu54oIE1UF5JXCqo8655JPAoGe60Vznh3xponiTU7qz0C7/tD7KoM9xAhMKE9F8zoxPJ+XPQ10dAgooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArzv40+CpvFPh37bory23iTTQ0tjPA5SRv70W4c/MOnvj3r0SigD4D1P4g+J9SvNDuNW1F7u60Ofz7N541LI+5D8xxluY1+9mvXvgdpmvfEzxE/iTxrqN1qGk6bIPJgmbEUtx1GIxhQFyCcAcleozXM/tB+AJ9M+JsDaPblofEMge3jUceeWAdB9WYN/wL2r6n8D+HLbwl4U03RbPBS1iCs4GPMc8u34sSaBm7RRRQIKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigD50/aq8BLNaR+MdNiAmh2w36qPvJ0ST6g4U+xX0r5v021vdX1GDT7MST3V7MqJHu/wBZITgZ9/mPJ9TX6I6rp9tqumXen30YltbqJoZUP8SsMH+dfO/7P/w0l0f4j+IbzVY966FM1pbMw4eRhneP+2ZB/wC2goHc9r+G/hG08EeErPR7PazoN9xMB/rpiPmb+g9AAK6eiigQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFRXU8drbTXE7bYYkMjtgnCgZJwKAJaK4lPih4WdFZLnUmVhkEaReEEf8Afqnf8LN8L/8APfU//BPef/Gqv2U/5Wa+xqfyv7jtKK4v/hZvhf8A576n/wCCe8/+NUf8LN8L/wDPfU//AAT3n/xqn7Kf8r+4PYVP5X9x2lFcX/ws3wv/AM99T/8ABPef/GqP+Fm+F/8Anvqf/gnvP/jVHsp/yv7g9hU/lf3HaUVxf/CzfC//AD31P/wT3n/xqiH4m+GJzIIJ9TkMbbHCaPeHa2AcHEXBwQfoRSdOa3TM6qdGPNU0XnodpRXIf8LF8Pf3tX/8Et7/APGqP+Fi+Hv72r/+CW9/+NUuSXY5/rVD+dfejf1PR7HU7vTbm9gWSbT5zcW7H+ByjJn8mP4gHtWhXIf8LF8Pf3tX/wDBLe//ABqj/hYvh7+9q/8A4Jb3/wCNUckuwfWqH86+9HX0VxifEvw08skaS6o0keN6jRrwlc9MjyuKk/4WL4e9dX/8Et7/APGq554ilCXLOaT9UdEYua5oq6Z19Fch/wALF8Peur/+CW9/+NUf8LF8Peur/wDglvf/AI1U/W6H86+9Fezn2Z19FcNH8VfCUiho72/ZT3XSbsj/ANFU/wD4Wl4U/wCfrUf/AAUXn/xqq+sUv5l96OV4minZzX3o7aiuJ/4Wl4U/5+tR/wDBRef/ABqj/haXhT/n61H/AMFF5/8AGqPrFL+dfehfWqH86+9HbUVxP/C0vCn/AD9aj/4KLz/41W74Z8S6V4lguJtHnllSCTypRJbyQsrYDY2yKp6EHpVRq05u0ZJ/MuFenUdoSTfkzZooorQ1CiiigAooooAKKKKACiiigAooooAKKK5BviR4VV3X+0pCVYqStpOwyDg8hMHkU1FvYcYuWyOvorj/APhZPhX/AKCE3/gDcf8AxFH/AAsnwr/0EJv/AABuP/iKr2cuxfsp/wArOworj/8AhZPhX/oITf8AgDcf/EUf8LJ8K/8AQQm/8Abj/wCIo9nLsHsp/wArOworj/8AhZPhX/oITf8AgDcf/EUf8LJ8K/8AQQm/8Abj/wCIo9nLsHsp/wArOwpqoqsxVQC5yxA6nGMn8AB+FcgnxK8KyOyR6hM7oAWVbK4JGemfk9j+VS/8LD8Nf8/l1/4AXH/xusJVqcHyykk/Unkl2Osork/+Fh+Gv+fy6/8AAC4/+N0f8LD8Nf8AP5df+AFx/wDG6n6xS/nX3oOSXY6yiuMHxO8IksBqkhKkqcWc/BHUH5OtL/ws3wn/ANBOX/wCn/8AiKr21P8AmX3mDrU4uzkr+p2VFcb/AMLN8J/9BOX/AMAp/wD4ij/hZvhP/oJy/wDgFP8A/EUvbU/5l94vrFL+ZfejsqK43/hZvhP/AKCcv/gFP/8AEVr+HPFOjeI5LlNGvDcPbBGlUxPGVD7tpwyjrsbp6VUakJO0WmVGrCbtGSfzNuiiirNAooooAKKKKACiiigAooooAKKKKACiiigArN8T/wDIt6t/16S/+gGtKs3xP/yLerf9ekv/AKAaAPDtI/5BNl/1wT/0EVbqppH/ACCbL/rgn/oIq3X3EPhR+jw+FFbVJnt9Nu54seZHC7rn1CkivNvhx4t1fX7+w+36mjCVXaS2XTXQcBsYm+71AP6V6beQLdWk9u5IWVGQkdQCMVy/hbwa/h17RbfXdTmsrcMFtJSnlkEHrhc9Tnr1rnqwqOpFx26/h5r9TlrwqyrQlH4Vv9681+voQeEdf1jUPGPiLS9YjtolsFhMccBLAb1zyxwTxjtXaVymi+DzpfiS51n+2b+4nusC4SUR7ZQFKqDhQRjjGMdOa6utKCmo2nvd/dfQ0wyqKDVTe7+6+n4BTvBv/Hz4h/7CC/8ApNBTad4N/wCPnxD/ANhBf/SaCs8VtH1/Rnw/iV/yJv8At+P5M6WvFfAnxG1jX9atLe91XSoDJdmI2a6fOXZQe0gygJHqa9qrgfCvgC88NSxJYeKL/wDs9ZzO1mYI9j5OSCcZwfrXBVU3KPLt1PxTA1MNClVVa3M7ct/nfo/Lt6oo6vr3ivQvGeh2d3daVfW+rXrQixt4WWWGDP8ArdxPO1eTkY649R6ZXndr8Oby28TXOuReKtQ+2XLgyM0ETnYDnywSCVXtgY/SvRKdJSV+YnHyoyUPZNNpatJrX0svS/XdmLpH/Iy69/2w/wDQDXEfE7x1qfh3xjp+lWl5YWNpPZmd57m0luCGDMMAR89vSu30j/kZde/7Yf8AoBrK8U+CpdZ8TWmu2Ot3WlX1tbG2VoIkfKkkn7wPrX4jnM8PTz7EPE/Drv35Vbo/yZ+45ApvJ8Pyb8qMPXvEPiCDwfp+tW2uaZFbPCzSTppk8jTSZYqFj6ouB1bvXWfD7WLzX/BulapqSWyXdzGWcWzho/vEDByecAZGeDkdqz9Q8L6/Nb2qWfjO/tpkhMM8htYn875id2CMK2DjI7AVr+DfDlp4U8O2mj6e0jwQA/PIcs7Ekkn8SeK8TFVcNLDcsLc/NdWXTXd8sfLv6R2ftU4zU7va34/e/wCu5xug/wDILj/3n/8AQ2pPEV5Lp/h/U7232ma2tZZk3DI3KhIz7ZFLoP8AyC4/95//AENqk1eyXUtKvbF3KJdQPAWAyVDKRn9a75OKxDctr/qfzfjHFZhUc9ud39OY4XwP4wutXmR9S1TT/KW3aeaFLSWMxgAZJkb5cDPY1f8ADninUdV8bT2E1vHBpr2JvLYMpEpXeqqzemQScY4BFXNF8JS2Fstld6xc3+liEwfY5YkCFcYxkDP60mm+BNH03xMur2UCxFIfLSBV+VGz98HrnGR+NejVq4JyqWW692y0/KOvyfqd9etlzlV5VuvdstF+EbP5PTqdXXoHwS/1fiT/AK/k/wDREdef16B8Ev8AV+JP+v5P/REddPDH++P/AAv80dnBv+/y/wAL/NHplFFFffH6cFFFFABRRRQAUUUUAFFFFABRRRQAV886J/yDx/11l/8ARjV9DV886J/yDx/11l/9GNXr5N/Fl6fqe9kH8aXp+perG8Z6rPonhbUtStFjee2iLosoJUnPcAg/rWzWZ4m0ldd0G90x5jCtzH5ZkC7ivvivoKnM4Pl3sfT1VJwkob2dvU5H4f8AjDUPEVxKs95ol0VtfO+zWUc0cqvlcBi/y45IOO+O1angLxHqOv3GuRapaQWklhdeQsUTFiox0Zs4Y+4AFT+G9B1jSE8m58RSXtqlv5EETWccflEYCtkcnAGMHrmofCPhS80DVNQu5dZa8W+czTxm2WPdIf4sgnHfjpzXLTVZcnNfrfb/ADZx0o11yc1+t9vl1f5/I6yiiiu09APC3/Ix61/1xtv/AGrXP/Ezx5qHhfxHpem2R0eGK7geVrjUmkVEKnplMnn6da6Dwt/yMetf9cbb/wBq1R8aeCr3XfEuma1pmtR6bdWMLwqJLJbkMG6nDMB0Poa/n7iGWHjxHiHivh8778itsm9/JnhYpTfN7Pe/6mbqvi3X7fwfp2tQ3vhSOCRXNxdytcPblt5CLGAAxyBznuOK6f4e67d+JPB+natqNolpc3KlmjQ5XhiAR3AIGcHpms+60Hxaun2cVh4qtUnjjeOdn0tNkpLEqwUN8pAIGOQeprR8B+GIvCHhqDSYbmS62M0jzOu3e7HJIUdB7V8/ipYV4ZqFufm0tf4dd7peVt/RamVNVOfW9rfjp5nM2X/Hzqn/AF/3H/oxqzvGurT6H4Xv9StEiee3VWVZQSpywHOCD39a0bL/AI+dU/6/7j/0Y1VfFGkLr2g3emPMYFuFCmQLuK4YHp+FehBwWIi6nw3V/Tqfz1mTprOarq/D7R39ObX8Dl/CHjKTUUvLjVNS0V7W2t/OkFpHMrx/72/g9xgc5q54P8TajrPiDWbHULOK0jtFikiTB8wLIu4B+cZxjIAGDkVZsfDFy1lLYa9qzatprRrGts9skIXaQVO5OTjaO9N0DwVp+ieIr3VLQkeeqpFCc4hwuG5JO7PXnpXdVng2qtt2vdstN15R13vp8+7rVMvarW+Jr3bK63XlHV63vHbZ9+prs/gx/wAjP4m/687H/wBDuq4yuz+DH/Iz+Jv+vOx/9Duq34c/31ejOnhL/kYr0Z6zRRRX6EfqgUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVHcQx3NvLBOoeKVSjqe6kYIqSigDjl+GnhRVCrpsoUDAAvZ8Af990v/AArbwr/0D5v/AAOuP/i67Cir9pLuX7WfdnH/APCtvCv/AED5v/A64/8Ai6P+FbeFf+gfN/4HXH/xddhRR7SXcftZ/wAzOP8A+FbeFf8AoHzf+B1x/wDF0f8ACtvCv/QPm/8AA64/+LrsKKPaS7h7Wf8AMzj/APhW3hX/AKB83/gdcf8AxdLD8N/CcO8ppCku25maeViTgDkliegA/CuvopOcnuyJyc1aWqOV/wCFe+Fv+gRH/wB/H/8AiqP+Fe+Fv+gRH/38f/4quqopcz7mXsodkcr/AMK98Lf9AiP/AL+P/wDFUf8ACvfC3/QIj/7+P/8AFV1VFHM+4eyh2RyY+HfhRWZho0IZsZId8n6/NTv+FfeFv+gRH/38f/4quqorN04Sd2jVNpWRyv8Awr7wt/0CI/8Av4//AMVR/wAK+8Lf9AiP/v4//wAVXVUUvZU/5V9w+aXc5Bfht4QUYXQ7cD0DP/jTv+Fb+Ef+gJb/APfb/wCNdbRT9nDsZOlB7pHJf8K38I/9AS3/AO+3/wAaP+Fb+Ef+gJb/APfb/wCNdbRR7OHZC9lD+Vfccl/wrfwj/wBAS3/77f8AxrZ0HQNL8PwSw6NZx2kUr+ZIqEnc2AMnJ9AK1KKahFapFKEY6pBRRRVFBRRRQAUUUUAFFFFABRRRQAUUUUAFcg3w38Ks7t/ZsgLMWIW7nUZJyeA+Bya6+impNbDjJx2Zx/8Awrbwr/0D5v8AwOuP/i6P+FbeFf8AoHzf+B1x/wDF12FFV7SXcv2s/wCZnH/8K28K/wDQPm/8Drj/AOLo/wCFbeFf+gfN/wCB1x/8XXYUUe0l3D2s/wCZnH/8K28K/wDQPm/8Drj/AOLo/wCFbeFf+gfN/wCB1x/8XXYUUe0l3D2s/wCZnGJ8M/C8czyw2l/A7gBzDql3HuAzjO2UZxk/nUn/AArrw96av/4Or3/47XX0VzTw9KpLmnFN+aQvaT7s5D/hXXh701f/AMHV7/8AHaP+FdeHvTV//B1e/wDx2uvoqfqlD+Rfcg9pPuzio/hf4RTdjTZyWYuzPf3DMzE5JJMmSaf/AMKy8J/9AyX/AMDZ/wD4uuyoq/Y0/wCVfcc7o05O7ir+hxv/AArLwn/0DJf/AANn/wDi6P8AhWXhP/oGS/8AgbP/APF12VFHsaf8q+4X1el/KvuRxv8AwrLwn/0DJf8AwNn/APi61/DnhbRvDkly+jWZt3uQiysZXkLBN20ZZj03t09a26KqNOEXeKSKjShB3jFL5BRRRVmgUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVR1t9Rj0m6fRYbafUgmYI7lykbN6MQCQPwq9VHW7i+tNJup9JsF1C+jTMNq04hErem8ghfrigDy74SfFPVPFmi63r/iWz0nSNA0ySS3kuEuHZhKgRjkEY27X65znjFdP4c+KnhHxBJdLYalLGLa1e+d7q1lt0+zqQGlDOoBUbl7968r+HXgXxfpHw18W+Ftf8I2l1DqM730atqqKJmYxKYfl5QhULB84yBxVPw58LfHV9o/ifRbqbUtG8PXemfZrKw1bVY79kuA6spVoxiOP5SpAGcHoewB614f+L3grXtQ+xadqzm4aJ5ohLayxeeiAlmjLKN+ApOBzweK4f4b/ABtm8V+Itdn1C40TTfDOmiaXEkVwtz5KFQspkI8rkuo2cNz09YNG8H+Ndf1/4dx+IPD9roOn+D0+e6S9jma7ZURVEapkqp8sZDdifTBh034TeIbr4M+OPC94IbLUtU1qXULTdMGR0zCy7iucZ8sj2ODQB6d4P+KHhLxdqn9naLqTvfNF58cM9vJA0sf99N6jcPpVTSvjH4C1ZJm07xDHP5NtNeSKtvMGSKJS0jFSmRgAnHU9ga5DQfDPjHxH8SPCGveJNAtvDln4as5IcR3kc73buhT5dmdqDrhucZHOeJPht4A1/Q/2fNe8K6haRRa3eW19HFEsyMGaWMqmWBxycd+KAOgt/jp8Ori5WGPxEg3xGVXe2mRGAGSoJQZb/Z6k8Dniup8D+NNC8caZLf8Ahu9+1QQymGXdG0bI4AOCrAHoQc//AF68msPhv4jh/wCFM+ZZRD/hGvP/ALS/fJ+63eXtxz833T0zXX/B7wnq3hnXfH1zq1ukMOra3Ne2hWRW3xMzEEgHjgjg0ARfHH4oXnw40yOay8P3eoNJtJunXbaR5Yjazg538cDHfr2r1GvHv2jtA8V+MfDS+HPDWhRXdtK0dxJevfJEY3Vj8nlsOeMHOe/SvTPDN5qt/o8Vxr2kppGoMWD2i3S3IQAkA7wADkYPTjNAGrRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAQX32n7DcfYDCLzy28kzAmMPg7d2OducZxzivHPhb8RfFuveIfFsXio+GrXR/DE0tvfTWsU6OWQuN6lnYbB5bE5GcV7HfNcLY3DWKRvdiNjCkrFUZ8fKGI6DOM14d8P8AwF460W98evqlj4blh8Ufablka5kkRJnEhWNhtBMZMmGPXHSgDuPDHxX0LxFdxJa2Wt21lNHJLBqN5YPDazIilmZZDxgBSecdKqaP8avCeq6rYWkX9qQW+oTm2sdQubF47W7kBxtjkPU545A5rzzwX8G/Edtrd6kixeGvDl1p1zZXWn2mpy3aXDSxugdVYDaAWDcknKj1NWLL4Y+ONR0bwj4Q11NFt/D/AId1BLxtQtp3aW6VC21VQqNpw5BJ+vbBALGkfF3V9Z+LOs6e0yaV4X0dz53nabIzNGkbtI0sucRf6tiuRzwBnrXceGvjF4Y1/WbDToU1WzOpFhp9xe2Tww3u3r5Tng/jjsOvFYVt8LdSudQ+LK6jcW8Np4sEQs5ImLNHtWTl1wO7LwDyM1kaR8PfG2q3fgHT/FEWjWWkeDpI5UuLOd5JLwxBRHhSo2jCLuz1yT7UAd9pnxW8M6l4ouPD1m99JqdvfPp8qLaOUSRSQSXA2hcqRknmuft/2gvA0wspfM1VLO6lMAu3sJBDHJ/dZvU9cDPHXFa/wn8G6n4V1vxzd6m1sYta1mW/tvJcsRGzMRuyBg8jjmvObL4N+JofhF4b8NPJp39o6f4hTVJiJm8swgODg7clvmHGPxoA9Z8CfEbQ/GuoapYaUL2C900r58F7btBJtb7rBTzg++DyMjkUvj5vHJltY/A50CGDy3e5uNW8w7WGNqoEPfnJI4xWX4Y8G6npnxo8ZeKrhrY6Zq1vbRW4VyZAY40Vtwxgcqe5ql8ctA8d+KNPt9J8GXVha6XMpGoGWdopZhnHlhgpwpGc45PTpkEAvfAnx3ffELwO2q6raQ215BdyWkht8+VKVCnemSTj5sdTyDXolcT8J9L1zQ/DY0rXNL0PS7e0ISzg0mSR02dSWL8liSTnvkk8121ABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAf/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Through mechanisms poorly understood, the same transcript can be spliced in multiple ways, resulting in different isoforms. Therefore, although there are \"only\" ~28,000 genes, there are actually many more types of protein.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_17_25872=[""].join("\n");
var outline_f25_17_25872=null;
var title_f25_17_25873="Esophageal cancer HFUS";
var content_f25_17_25873=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F65394&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F65394&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    High frequency ultrasound catheter examination of a T2 esophageal adenocarcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 333px; height: 308px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Esophageal adenocarcinoma with invasion into the muscularis propria (T2) demonstrated with a high frequency ultrasound probe.",
"    <div class=\"footnotes\">",
"     MP: muscularis propria; TU: tumor.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Maurits Wiersema, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_17_25873=[""].join("\n");
var outline_f25_17_25873=null;
var title_f25_17_25874="Ultrasound of ectopia cordis";
var content_f25_17_25874=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F56859&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F56859&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 603px\">",
"   <div class=\"ttl\">",
"    Ultrasound of ectopia cordis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 583px; height: 173px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sagittal view of a fetus at 20 weeks of gestation with Pentalogy of Cantrell.",
"    <br>",
"     (A) The thick arrow points to the omphalocele and the thin arrow to the ectopia cordis.",
"     <br>",
"      (B) The ectopia cordis is seen with color Doppler enhancement.",
"      <br>",
"       (C) Three-dimensional rendering demonstrating the omphalocele (thick arrow) and ectopia cordis (thin arrow).",
"       <div class=\"footnotes\">",
"       </div>",
"       <div class=\"reference\">",
"        Courtesy of Ana Monteagudo, MD.",
"       </div>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_17_25874=[""].join("\n");
var outline_f25_17_25874=null;
var title_f25_17_25875="Palifermin: Patient drug information";
var content_f25_17_25875=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Palifermin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/15/36084?source=see_link\">",
"     see \"Palifermin: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F205729\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Kepivance&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F12785448\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Kepivance&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10029302\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691424",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop and lower mouth sores from forming.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10029301\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702667",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to palifermin,",
"       <i>",
"        E. coli",
"       </i>",
"       -derived proteins, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10029306\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10029307\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697934",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in taste.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698306",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698191",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Itching.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698081",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Fever.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698298",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698364",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3731787",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mouth tingling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698374",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in tongue color.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10029309\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698631",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Color change or thick tongue.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10029304\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696018",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given for 3 days before and after chemo.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10029311\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11405 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-210.101.131.231-1C6C0C3C8D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_17_25875=[""].join("\n");
var outline_f25_17_25875=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205729\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12785448\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029302\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029301\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029306\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029307\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029309\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029304\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029311\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?35/15/36084?source=related_link\">",
"      Palifermin: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_17_25876="Hyponatremia and hyperkalemia in adrenal insufficiency";
var content_f25_17_25876=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hyponatremia and hyperkalemia in adrenal insufficiency",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/17/25876/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/17/25876/contributors\">",
"     David B Mount, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/17/25876/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/17/25876/contributors\">",
"     Richard H Sterns, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/17/25876/contributors\">",
"     Andre Lacroix, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/17/25876/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/17/25876/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/17/25876/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The electrolyte disturbances in primary adrenal insufficiency are due to diminished secretion of cortisol and aldosterone. A major function of aldosterone is to increase urinary potassium secretion. As a result, hypoaldosteronism can be associated with hyperkalemia and mild metabolic acidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25876/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Sodium wasting is a variable feature of this disorder. It is not prominent in adults with isolated hypoaldosteronism, probably because aldosterone secretion is only modestly reduced. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/44/9930?source=see_link\">",
"     \"Etiology, diagnosis, and treatment of hypoaldosteronism (type 4 RTA)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although aldosterone normally enhances sodium reabsorption, other sodium-retaining factors (such as angiotensin II and norepinephrine) are able to compensate for the decreased availability of aldosterone [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25876/abstract/1\">",
"     1",
"    </a>",
"    ]. However, patients with primary adrenal insufficiency may have severe hypoaldosteronism, leading to salt wasting and possibly hypotension and adrenal crisis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33800?source=see_link\">",
"     \"Clinical manifestations of adrenal insufficiency in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other causes of hyponatremia and hyperkalemia, as well as the evaluation of patients with hyponatremia or hyperkalemia, are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/30/3562?source=see_link\">",
"     \"Causes of hyponatremia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/5/33882?source=see_link\">",
"     \"Causes and evaluation of hyperkalemia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/20/21832?source=see_link\">",
"     \"Evaluation of the patient with hyponatremia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HYPONATREMIA AND HYPERKALEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyponatremia and hyperkalemia are the two major electrolyte abnormalities of primary adrenal insufficiency. Hyponatremia is mediated by increased release of antidiuretic hormone (ADH) which results in water retention and a reduction in the plasma sodium concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25876/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Both cortisol and aldosterone deficiency contribute to this problem:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The hypersecretion of ADH seen in cortisol deficiency may be due in part to the reductions in systemic blood pressure and cardiac output induced (via an unknown mechanism) by the lack of cortisol. However, a more important mechanism may be that cortisol deficiency results in increased hypothalamic secretion of corticotropin releasing hormone (CRH), an ADH secretagogue [",
"      <a class=\"abstract\" href=\"UTD.htm?25/17/25876/abstract/5-8\">",
"       5-8",
"      </a>",
"      ]. Cortisol feeds back negatively on CRH and ACTH, an inhibitory effect that is removed with adrenal insufficiency [",
"      <a class=\"abstract\" href=\"UTD.htm?25/17/25876/abstract/5,9\">",
"       5,9",
"      </a>",
"      ]. In addition, cortisol appears to directly suppress ADH secretion [",
"      <a class=\"abstract\" href=\"UTD.htm?25/17/25876/abstract/10-12\">",
"       10-12",
"      </a>",
"      ]. Thus, ADH levels increase when plasma cortisol levels are low.",
"     </li>",
"     <li>",
"      The hypersecretion of ADH induced by aldosterone deficiency is caused by renal salt wasting with resultant volume depletion. Hypovolemia increases ADH levels by reducing the osmotic threshold for ADH release from the hypothalamus and by increasing the magnitude of ADH release for a given change in plasma osmolality [",
"      <a class=\"abstract\" href=\"UTD.htm?25/17/25876/abstract/13,14\">",
"       13,14",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16552?source=see_link\">",
"       \"Chapter 6B: Antidiuretic hormone and water balance\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Hyponatremia is most often seen with primary adrenal insufficiency; it can occur with ACTH deficiency (secondary or tertiary adrenal insufficiency) but is less common [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25876/abstract/3,15,16\">",
"     3,15,16",
"    </a>",
"    ]. In the latter setting, both the general preservation of aldosterone release and the generally less prominent reduction in cortisol secretion account for the lower prevalence of hyponatremia.",
"   </p>",
"   <p>",
"    Hyperkalemia in adrenal insufficiency is entirely due to hypoaldosteronism since one of the major functions of aldosterone is to promote the urinary excretion of dietary potassium [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25876/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/20/2376?source=see_link\">",
"     \"Chapter 6C: Aldosterone\"",
"    </a>",
"    .) However, available data suggest that only 50 to 60 percent of patients with primary adrenal insufficiency develop hyperkalemia [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25876/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]. The normokalemia found in many hypoadrenal patients is attributable to aldosterone-independent regulation of potassium secretion by the distal nephron. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/5/33882?source=see_link\">",
"     \"Causes and evaluation of hyperkalemia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyponatremia in adrenal insufficiency is rapidly corrected by cortisol and volume repletion, which shuts off ADH release and allows excess water to be excreted [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25876/abstract/3,20\">",
"     3,20",
"    </a>",
"    ]. Rarely, the rate of rise in the plasma sodium concentration is so rapid that it leads to osmotic demyelination syndrome, a severe neurologic disease. In contrast, the administration of saline alone is relatively ineffective in the presence of isolated cortisol deficiency (ie, ACTH deficiency) since the elevated ADH levels and consequent impairment in water excretion will persist [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25876/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/53/10074?source=see_link&amp;anchor=H7#H7\">",
"     \"Osmotic demyelination syndrome and overly rapid correction of hyponatremia\", section on 'Rapid rate of correction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Physiologic cortisol replacement with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    (or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/16/39174?source=see_link\">",
"     cortisone acetate",
"    </a>",
"    , which is converted to hydrocortisone) also may increase potassium excretion, indicating that cortisol can act as a mineralocorticoid in the absence of aldosterone [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25876/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/56/40838?source=see_link\">",
"     \"Apparent mineralocorticoid excess syndromes (including chronic licorice ingestion)\"",
"    </a>",
"    .) However, other forms of glucocorticoid replacement (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ) do not have significant mineralocorticoid activity.",
"   </p>",
"   <p>",
"    Mineralocorticoid replacement is required in most patients with primary adrenal insufficiency. The adequacy of mineralocorticoid replacement can be monitored by asking about symptoms of postural hypotension and by measuring supine and upright blood pressure and pulse, serum potassium, and plasma renin activity [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25876/abstract/22\">",
"     22",
"    </a>",
"    ]. We measure plasma renin activity when first initiating therapy and in patients who develop salt craving or nausea despite normal potassium and normal hemodynamics since these symptoms may suggest that mineralocorticoid levels are deficient. In addition, we routinely measure plasma renin activity on an annual basis. The dose of mineralocorticoid, but not glucocorticoid, should be increased in patients with elevated plasma renin activity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/47/42745?source=see_link&amp;anchor=H11#H11\">",
"     \"Treatment of adrenal insufficiency in adults\", section on 'Mineralocorticoid replacement'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4642270\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The major electrolyte disturbances in primary adrenal insufficiency (hyponatremia and hyperkalemia) are due to diminished secretion of cortisol and aldosterone. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hyponatremia is mediated by increased release of antidiuretic hormone (ADH) which results in water retention and a reduction in the plasma sodium concentration. Both cortisol and aldosterone deficiency contribute to this problem. Hyponatremia is most often seen with primary adrenal insufficiency; it can also occur with corticotropin (ACTH) deficiency (secondary or tertiary adrenal insufficiency). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Hyponatremia and hyperkalemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hyperkalemia in adrenal insufficiency is entirely due to hypoaldosteronism since one of the major functions of aldosterone is to promote the urinary excretion of dietary potassium. However, only 50 to 60 percent of patients with primary adrenal insufficiency develop hyperkalemia. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Hyponatremia and hyperkalemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hyponatremia in adrenal insufficiency is rapidly corrected by cortisol and volume repletion. Although physiologic cortisol replacement with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"       hydrocortisone",
"      </a>",
"      (or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/16/39174?source=see_link\">",
"       cortisone acetate",
"      </a>",
"      , which is converted to hydrocortisone) also may increase potassium excretion, mineralocorticoid replacement is required in most patients with primary adrenal insufficiency. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H374733360\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The author and editors would like to thank Dr. Lynnette Nieman, who contributed to previous versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25876/abstract/1\">",
"      DeFronzo RA. Hyperkalemia and hyporeninemic hypoaldosteronism. Kidney Int 1980; 17:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25876/abstract/2\">",
"      Szylman P, Better OS, Chaimowitz C, Rosler A. Role of hyperkalemia in the metabolic acidosis of isolated hypoaldosteronism. N Engl J Med 1976; 294:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25876/abstract/3\">",
"      Oelkers W. Hyponatremia and inappropriate secretion of vasopressin (antidiuretic hormone) in patients with hypopituitarism. N Engl J Med 1989; 321:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25876/abstract/4\">",
"      Ishikawa S, Schrier RW. Effect of arginine vasopressin antagonist on renal water excretion in glucocorticoid and mineralocorticoid deficient rats. Kidney Int 1982; 22:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25876/abstract/5\">",
"      Wolfson B, Manning RW, Davis LG, et al. Co-localization of corticotropin releasing factor and vasopressin mRNA in neurones after adrenalectomy. Nature 1985; 315:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25876/abstract/6\">",
"      Kalogeras KT, Nieman LK, Friedman TC, et al. Inferior petrosal sinus sampling in healthy subjects reveals a unilateral corticotropin-releasing hormone-induced arginine vasopressin release associated with ipsilateral adrenocorticotropin secretion. J Clin Invest 1996; 97:2045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25876/abstract/7\">",
"      Papanek PE, Raff H. Physiological increases in cortisol inhibit basal vasopressin release in conscious dogs. Am J Physiol 1994; 266:R1744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25876/abstract/8\">",
"      Schrier RW. Body water homeostasis: clinical disorders of urinary dilution and concentration. J Am Soc Nephrol 2006; 17:1820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25876/abstract/9\">",
"      Raff H. Glucocorticoid inhibition of neurohypophysial vasopressin secretion. Am J Physiol 1987; 252:R635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25876/abstract/10\">",
"      Watts AG, Tanimura S, Sanchez-Watts G. Corticotropin-releasing hormone and arginine vasopressin gene transcription in the hypothalamic paraventricular nucleus of unstressed rats: daily rhythms and their interactions with corticosterone. Endocrinology 2004; 145:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25876/abstract/11\">",
"      Kov&aacute;cs KJ, F&ouml;ldes A, Sawchenko PE. Glucocorticoid negative feedback selectively targets vasopressin transcription in parvocellular neurosecretory neurons. J Neurosci 2000; 20:3843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25876/abstract/12\">",
"      Ma XM, Aguilera G. Differential regulation of corticotropin-releasing hormone and vasopressin transcription by glucocorticoids. Endocrinology 1999; 140:5642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25876/abstract/13\">",
"      Robertson GL, Aycinena P, Zerbe RL. Neurogenic disorders of osmoregulation. Am J Med 1982; 72:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25876/abstract/14\">",
"      Mount DB. The brain in hyponatremia: both culprit and victim. Semin Nephrol 2009; 29:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25876/abstract/15\">",
"      Diederich S, Franzen NF, B&auml;hr V, Oelkers W. Severe hyponatremia due to hypopituitarism with adrenal insufficiency: report on 28 cases. Eur J Endocrinol 2003; 148:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25876/abstract/16\">",
"      Olchovsky D, Ezra D, Vered I, et al. Symptomatic hyponatremia as a presenting sign of hypothalamic-pituitary disease: a syndrome of inappropriate secretion of antidiuretic hormone (SIADH)-like glucocorticosteroid responsive condition. J Endocrinol Invest 2005; 28:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25876/abstract/17\">",
"      Males JL, Spitler AL, Townsend JL. Addison's disease. A review of thirty-two cases. J Okla State Med Assoc 1971; 64:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25876/abstract/18\">",
"      Nerup J. Addison's disease--clinical studies. A report fo 108 cases. Acta Endocrinol (Copenh) 1974; 76:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25876/abstract/19\">",
"      De Rosa G, Corsello SM, Cecchini L, et al. A clinical study of Addison's disease. Exp Clin Endocrinol 1987; 90:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25876/abstract/20\">",
"      Ahmed AB, George BC, Gonzalez-Auvert C, Dingman JF. Increased plasma arginine vasopressin in clinical adrenocortical insufficeincy and its inhibition by glucosteroids. J Clin Invest 1967; 46:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25876/abstract/21\">",
"      van Buren M, Rabelink TJ, Koppeschaar HP, Koomans HA. Role of glucocorticoid in excretion of an acute potassium load in patients with Addison's disease and panhypopituitarism. Kidney Int 1993; 44:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25876/abstract/22\">",
"      Oelkers W, Diederich S, B&auml;hr V. Diagnosis and therapy surveillance in Addison's disease: rapid adrenocorticotropin (ACTH) test and measurement of plasma ACTH, renin activity, and aldosterone. J Clin Endocrinol Metab 1992; 75:259.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2314 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-222.190.118.195-3C09538E6E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_17_25876=[""].join("\n");
var outline_f25_17_25876=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H4642270\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HYPONATREMIA AND HYPERKALEMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4642270\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H374733360\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/56/40838?source=related_link\">",
"      Apparent mineralocorticoid excess syndromes (including chronic licorice ingestion)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/5/33882?source=related_link\">",
"      Causes and evaluation of hyperkalemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/30/3562?source=related_link\">",
"      Causes of hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16552?source=related_link\">",
"      Chapter 6B: Antidiuretic hormone and water balance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/20/2376?source=related_link\">",
"      Chapter 6C: Aldosterone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33800?source=related_link\">",
"      Clinical manifestations of adrenal insufficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/44/9930?source=related_link\">",
"      Etiology, diagnosis, and treatment of hypoaldosteronism (type 4 RTA)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/20/21832?source=related_link\">",
"      Evaluation of the patient with hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/53/10074?source=related_link\">",
"      Osmotic demyelination syndrome and overly rapid correction of hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/47/42745?source=related_link\">",
"      Treatment of adrenal insufficiency in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_17_25877="Phentermine and topiramate: Patient drug information";
var content_f25_17_25877=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Phentermine and topiramate: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/46/10983?source=see_link\">",
"     see \"Phentermine and topiramate: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F15057041\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Qsymia&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F15068840\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3914629",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You can only get this drug through the Qysmia&trade; certified pharmacy network.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F15068842\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691993",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat obesity.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F15068841\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3914630",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to phentermine, topiramate or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3914642",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Glaucoma or overactive thyroid disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F15068846\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be habit-forming with long-term use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been taking this drug for many weeks, talk with your doctor before stopping. You may want to slowly stop this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697307",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have mental illness, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698413",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often if you have heart disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697801",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may not be alert. Avoid driving and doing other tasks or actions until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your use of caffeine (for example, tea, coffee, cola) and chocolate. Use with this drug may cause nervousness, shakiness, and a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F15068847\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697975",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to sleep.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698288",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Numbness and tingling.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F15068848\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699075",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low mood (depression), thoughts of killing yourself, nervousness, emotional ups and downs, thinking that is not normal, anxiety, or lack of interest in life.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure or a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699112",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698605",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Back pain, belly pain, or blood in the urine. May be signs of a kidney stone.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698985",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not sweating during activities or in warm temperatures.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698697",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If seizures are new or worse after starting this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698670",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, if you get pregnant while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F15068844\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696213",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use this drug early in the day to stop sleep problems.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695913",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F15068845\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F15068849\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F15068850\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 86612 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-11633CD92E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_17_25877=[""].join("\n");
var outline_f25_17_25877=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15057041\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15068840\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15068842\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15068841\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15068846\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15068847\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15068848\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15068844\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15068845\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15068849\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15068850\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?10/46/10983?source=related_link\">",
"      Phentermine and topiramate: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_17_25878="Flow-volume loops";
var content_f25_17_25878=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Flow-volume loops",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/17/25878/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/17/25878/contributors\">",
"     Loutfi Sami Aboussouan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/17/25878/contributors\">",
"     James K Stoller, MS, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/17/25878/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/17/25878/contributors\">",
"     Peter J Barnes, DM, DSc, FRCP, FRS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/17/25878/contributors\">",
"     Robert A Wood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/17/25878/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/17/25878/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/17/25878/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spirometry, which includes measurement of forced expiratory volume in one second (FEV1) and forced vital capacity (FVC), is the most readily available and most useful pulmonary function test. The flow-volume loop (also called a spirogram) is a plot of inspiratory and expiratory flow (on the Y-axis) against volume (on the X-axis) during the performance of maximally forced inspiratory and expiratory maneuvers.",
"   </p>",
"   <p>",
"    The normal expiratory portion of the flow-volume curve is characterized by a rapid rise to the peak flow rate, followed by a nearly linear fall in flow as the patient exhales toward residual volume (",
"    <a class=\"graphic graphic_figure graphicRef55880 \" href=\"UTD.htm?22/59/23486\">",
"     figure 1",
"    </a>",
"    ). The inspiratory curve, in contrast, is a relatively symmetrical, saddle-shaped curve. The flow rate at the midpoint of exhalation (between total lung capacity and residual volume) is normally approximately equivalent to the flow rate at the midpoint of inspiration.",
"   </p>",
"   <p>",
"    Changes in the contour of the loop can aid in the diagnosis and localization of airway obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25878/abstract/1\">",
"     1",
"    </a>",
"    ]. Characteristic flow-volume loop patterns are also often found in certain forms of restrictive disease, although flow-volume studies are not considered primary diagnostic aids in the evaluation of these disorders.",
"   </p>",
"   <p>",
"    An overview of flow-volume loops will be presented here. A general review of pulmonary function testing, including the indications for spirometry, is provided separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/53/4952?source=see_link\">",
"     \"Overview of pulmonary function testing in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OBSTRUCTIVE PULMONARY DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;A frequently recognized abnormality in the flow-volume loop is the concave upward or \"scooped-out,\" or \"coved\" pattern encountered in asthma or chronic obstructive pulmonary disease (COPD) (",
"    <a class=\"graphic graphic_figure graphicRef55880 \" href=\"UTD.htm?22/59/23486\">",
"     figure 1",
"    </a>",
"    ). Maximal expiratory flow rates during the latter two-thirds of an expiratory maneuver are largely effort independent (ie, flow cannot be accelerated by increased expiratory effort), and vary directly with the elastic recoil of the lung and inversely with the airway resistance upstream of the equal pressure point.",
"   </p>",
"   <p>",
"    Two changes are present in emphysema that will reduce flow rate during this phase of respiration: the elastic recoil of the lung is decreased due to loss of lung parenchyma; and airway resistance is increased due to secretions, bronchospasm, or loss of small airways.",
"   </p>",
"   <p>",
"    The concave upward appearance of the flow-volume loop in obstructive lung disease probably results from the following two factors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Compression of the major central airway with a precipitous decline in flows. This process is often referred to as",
"      <strong>",
"       negative effort-dependence",
"      </strong>",
"      and results in premature airway closure. This may be more prominent in patients with emphysema, and is due to loss of airway support from the tethering effect of the surrounding parenchyma.",
"     </li>",
"     <li>",
"      A disproportionate decrease in flow later in expiration. Specifically, the heterogeneity of lung disease results in the more rapid and earlier emptying of areas with higher elastic recoil or lower airway resistance, compared to the slower emptying of more diseased areas.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     UPPER AIRWAY OBSTRUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The utility of flow-volume loops for detection of obstructing lesions of the upper airway (defined as that portion of the airway extending from the mouth to the lower trachea) was first reported by Miller and Hyatt, who described three distinct patterns: variable extrathoracic obstruction; variable intrathoracic obstruction; and fixed obstruction (",
"    <a class=\"graphic graphic_figure graphicRef76811 \" href=\"UTD.htm?34/31/35325\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25878/abstract/2\">",
"     2",
"    </a>",
"    ]. The upper airway is divided into intra- and extrathoracic components by the thoracic inlet, which projects 1 to 3 cm above the suprasternal notch on the anterior chest at the level of the first thoracic vertebra.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Variable extrathoracic obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;This flow-volume loop pattern is also known as dynamic or non-fixed extrathoracic obstruction. The pattern consists of a truncation of the envelope of the maximal",
"    <strong>",
"     inspiratory",
"    </strong>",
"    curve (",
"    <a class=\"graphic graphic_figure graphicRef76811 \" href=\"UTD.htm?34/31/35325\">",
"     figure 2",
"    </a>",
"    ). During thoracic expansion with inspiration, the combination of atmospheric extraluminal pressure and negative (subatmospheric) intraluminal pressure results in decreased luminal size of the extrathoracic portion of the upper airway, thus accentuating the effect of any obstructive lesion in this region (",
"    <a class=\"graphic graphic_figure graphicRef65386 \" href=\"UTD.htm?17/3/17470\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Turbulent flow and a Venturi effect also contribute to the drop in intratracheal pressure, producing further narrowing and flow limitation. In addition, the ratio of expiratory to inspiratory flow at 50 percent vital capacity &mdash; FEF(50",
"    <span class=\"nowrap\">",
"     percent)/FIF(50",
"    </span>",
"    percent) &mdash; is elevated, with an average value of 2.2 (normal ratio: 1) (",
"    <a class=\"graphic graphic_figure graphicRef76811 \" href=\"UTD.htm?34/31/35325\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25878/abstract/3\">",
"     3",
"    </a>",
"    ]. Diseases that exhibit this pattern include laryngomalacia and tracheomalacia of the extrathoracic trachea, as well as structural or functional vocal cord abnormalities. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/11/16567?source=see_link\">",
"     \"Paradoxical vocal cord motion\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Variable intrathoracic obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;This pattern, also known as dynamic or non-fixed intrathoracic obstruction, demonstrates truncation of the envelope of the maximal",
"    <strong>",
"     expiratory",
"    </strong>",
"    curve, resulting from expiratory flow limitation (",
"    <a class=\"graphic graphic_figure graphicRef76811 \" href=\"UTD.htm?34/31/35325\">",
"     figure 2",
"    </a>",
"    ). The pleural pressure surrounding the intrathoracic trachea is negative relative to the intratracheal pressure during inspiration, thereby producing no restraint to inspiratory airflow. In contrast, flow limitation is encountered during forced expiration, when the pleural pressure becomes positive relative to airway pressure, and the effect of any obstructive lesion in this region is accentuated (",
"    <a class=\"graphic graphic_figure graphicRef55931 \" href=\"UTD.htm?14/54/15214\">",
"     figure 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Once again, turbulent flow and a Venturi effect may result in a further drop in airway pressure, leading to airway narrowing and flow limitation. The FEF(50",
"    <span class=\"nowrap\">",
"     percent)/FIF(50",
"    </span>",
"    percent) ratio is reduced, with an average value of 0.32 (",
"    <a class=\"graphic graphic_figure graphicRef76811 \" href=\"UTD.htm?34/31/35325\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25878/abstract/3\">",
"     3",
"    </a>",
"    ]. This pattern may occur with tracheomalacia of the intrathoracic airway, bronchogenic cysts, or with tracheal lesions, which are often malignant [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25878/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Fixed upper airway obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Firm tracheal lesions may limit the modulating effect of transmural pressures on airway luminal diameter. In this pattern, flow is limited during both",
"    <strong>",
"     inspiration and expiration",
"    </strong>",
"    , with flattening of both limbs of the flow-volume loop. An FEF(50",
"    <span class=\"nowrap\">",
"     percent)/FIF(50",
"    </span>",
"    percent) ratio close to 1.0 (average 0.9) has been observed as a characteristic of fixed upper airway obstruction (",
"    <a class=\"graphic graphic_figure graphicRef76811 \" href=\"UTD.htm?34/31/35325\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25878/abstract/3\">",
"     3",
"    </a>",
"    ]. Dynamic narrowing of airway segments adjacent to the obstructive lesion may skew this ratio depending upon its location. One report, for example, evaluated patients with rigid thoracic lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25878/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A ratio greater than 1.3 was noted in three of six patients with rigid extrathoracic lesions. Cinefluoroscopy suggested that the greater inspiratory limitation resulted from dynamic compression of the normal extrathoracic trachea between the stenotic segment and the thoracic inlet (ie, caudad to the stenosis).",
"     </li>",
"     <li>",
"      A ratio below 0.5 was seen in one patient with rigid intrathoracic lesion. Cinefluoroscopy confirmed that the greater expiratory limitation was secondary to dynamic narrowing of the normal intrathoracic trachea between the stenotic segment and the thoracic inlet (ie, cephalad to the stenosis).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A ratio of 1.0 would be expected for fixed lesions at the thoracic inlet or with a noncompliant trachea [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25878/abstract/5\">",
"     5",
"    </a>",
"    ]. Examples of fixed upper airway obstruction include tracheal stenosis (as from prolonged intubation) or a goiter compressing the trachea.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Extraluminal airway obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extraluminal airway obstruction may cause a pattern of fixed airway obstruction or an atypical pattern of extrathoracic obstruction. As an example, one series described the flow-volume loops of patients with bulky mediastinal adenopathy due to Hodgkin lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25878/abstract/6\">",
"     6",
"    </a>",
"    ]. None of these patients had evidence of extrathoracic airway involvement on computed tomographic studies. Fourteen of 25 patients (56 percent) had abnormal flow-volume loops consisting of flattening of both limbs of the flow-volume loop (7 patients), or of the inspiratory loop only (7 patients). While the former pattern is consistent with a fixed airway obstruction, the latter is unexpected in intrathoracic disease. Moreover, the FEF(50",
"    <span class=\"nowrap\">",
"     percent)/FIF(50",
"    </span>",
"    percent) was unexpectedly elevated in all, including those with a fixed pattern of obstruction. It is possible that the bulky mediastinal adenopathy resulted in external splinting of the airway, which may have prevented the usual dynamic changes outlined in figure 4, limiting both the narrowing of the intrathoracic airway in expiration and the widening of the airway in inspiration (",
"    <a class=\"graphic graphic_figure graphicRef55931 \" href=\"UTD.htm?14/54/15214\">",
"     figure 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25878/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Variable obstruction at the thoracic inlet",
"    </span>",
"    &nbsp;&mdash;&nbsp;This form of upper airway obstruction may result in a double hump (also called twin hump) of the expiratory curve as the narrowing moves from an intrathoracic to a relative extrathoracic location toward the end of expiration (",
"    <a class=\"graphic graphic_figure graphicRef54799 \" href=\"UTD.htm?17/12/17612\">",
"     figure 5",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25878/abstract/3,7\">",
"     3,7",
"    </a>",
"    ]. Interestingly, repeated flow-volume loops may show first an intrathoracic and then an extrathoracic location, as the lesion moves within the chest with neck flexion and outside the thoracic inlet with neck extension (",
"    <a class=\"graphic graphic_figure graphicRef78259 \" href=\"UTD.htm?7/3/7229\">",
"     figure 6",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25878/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Examples of such lesions include low posttracheostomy scars or strictures that may be located at or above the suprasternal notch [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25878/abstract/3,7\">",
"     3,7",
"    </a>",
"    ]. A similar double hump pattern in the contour of the expiratory curve has been described in a patient with vocal cord dysfunction characterized by initial adduction and subsequent abduction of the vocal cords in mid-expiration [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25878/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Mainstem bronchial obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several abnormalities in the expiratory flow-volume loop have been described in patients with unilateral mainstem bronchial obstruction. Total functional obstruction of a mainstem bronchus results in an apparent restrictive ventilatory pattern of the expiratory curve, reflecting the loss of function of the affected side (",
"    <a class=\"graphic graphic_figure graphicRef76796 \" href=\"UTD.htm?16/0/16397\">",
"     figure 7",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25878/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On the other hand, a partially occluded bronchus may result in a mixed obstructive and restrictive pattern (",
"    <a class=\"graphic graphic_figure graphicRef80922 \" href=\"UTD.htm?35/63/36860\">",
"     figure 8",
"    </a>",
"    ). This would presumably result from initial normal emptying of the unaffected side, followed by slow emptying of the affected side. The net effect is an increasing upward concavity at lower lung volumes, as occurs with asthma or emphysema [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25878/abstract/9\">",
"     9",
"    </a>",
"    ]. However, these patterns may be masked in patients with underlying emphysema [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25878/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other patterns that may be seen with differential emptying include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      An end-inspiratory tail (",
"      <a class=\"graphic graphic_figure graphicRef74178 \" href=\"UTD.htm?12/0/12300\">",
"       figure 9",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?25/17/25878/abstract/11,12\">",
"       11,12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A biphasic spirogram, with an initial normal curvature of the expiratory loop and a \"straight line\" appearance at end-expiration (",
"      <a class=\"graphic graphic_figure graphicRef74178 \" href=\"UTD.htm?12/0/12300\">",
"       figure 9",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?25/17/25878/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A flattening or plateau of the initial portion of the expiratory flow curve [",
"      <a class=\"abstract\" href=\"UTD.htm?25/17/25878/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25782803\">",
"    <span class=\"h2\">",
"     Saw-tooth pattern",
"    </span>",
"    &nbsp;&mdash;&nbsp;A so-called saw-tooth pattern has been described that consists of small, rapid oscillations in flow during both expiration and inspiration (",
"    <a class=\"graphic graphic_figure graphicRef56090 \" href=\"UTD.htm?2/51/2877\">",
"     figure 10",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25878/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Detecting the saw-tooth pattern is subjective and artifacts in the resonance frequency of the recording equipment can have a similar appearance [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25878/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Conditions associated with a saw-tooth pattern on the flow-volume loop include neuromuscular diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25878/abstract/18\">",
"     18",
"    </a>",
"    ], Parkinson disease [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25878/abstract/19\">",
"     19",
"    </a>",
"    ], laryngeal dyskinesia [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25878/abstract/20\">",
"     20",
"    </a>",
"    ], pedunculated tumors of the upper airway [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25878/abstract/21\">",
"     21",
"    </a>",
"    ], tracheobronchomalacia [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25878/abstract/22\">",
"     22",
"    </a>",
"    ], upper airway burns [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25878/abstract/23\">",
"     23",
"    </a>",
"    ], and obstructive sleep apnea (OSA) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25878/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. The saw-tooth pattern has also been described in 31 percent of snorers without sleep apnea and in 10 percent of normal individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25878/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Among 401 patients referred for evaluation of snoring, the sensitivity and specificity of the saw-tooth pattern for OSA were 11 and 94 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25878/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another feature of flow-volume loops sometimes seen in patients with OSA is an increased ratio of forced expiratory flow at 50 percent of vital",
"    <span class=\"nowrap\">",
"     capacity/forced",
"    </span>",
"    inspiratory flow at 50 percent of vital capacity (FEF[50",
"    <span class=\"nowrap\">",
"     percent]/FIF[50",
"    </span>",
"    percent]). Normally, the FEF[50",
"    <span class=\"nowrap\">",
"     percent]/FIF[50",
"    </span>",
"    percent] is &le;1.0, but in patients with sleep apnea, it is often &gt;1.0. When this criterion was examined in a group of 405 patients referred for evaluation of OSA, the sensitivity and specificity were 12 and 86 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25878/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Accuracy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The flow-volume loop is an",
"    <strong>",
"     insensitive",
"    </strong>",
"    test for upper airway obstruction, as lesions must narrow the tracheal lumen to less than 8 mm (a reduction of the tracheal area by at least 80 percent) before abnormalities can be detected (",
"    <a class=\"graphic graphic_figure graphicRef73686 \" href=\"UTD.htm?27/40/28302\">",
"     figure 11",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25878/abstract/2\">",
"     2",
"    </a>",
"    ]. This is supported by a report that found exertional dyspnea and a precipitous decline in peak expiratory flow rate occurred with tracheal diameters under 8 mm [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25878/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional evidence that flow-volume loops are insensitive for detecting upper airway obstruction includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 475 flow-volume loops, the aggregate sensitivity of several quantitative and visual criteria for upper airway obstruction was 69.4 percent and the areas of the receiver operating curves for all the individual criteria were low (ie, ROC &lt;0.522) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/17/25878/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study of 226 patients who underwent laryngoscopy, the accuracy of flow-volume loops for detecting vocal cord dysfunction was evaluated [",
"      <a class=\"abstract\" href=\"UTD.htm?25/17/25878/abstract/27\">",
"       27",
"      </a>",
"      ]. Assessment of flow-volume loops by a pulmonologist had low predictive value (ROC &lt;0.68), leading to the conclusion that a normal flow-volume loop should not preempt laryngoscopy when vocal cord dysfunction is suspected.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The flow-volume loop therefore indicates the functional (rather than anatomic) severity of the obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25878/abstract/28\">",
"     28",
"    </a>",
"    ]. Despite this limitation, the test is simple and readily available, so that a flow-volume loop is useful whenever an upper airway lesion is suspected [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25878/abstract/29\">",
"     29",
"    </a>",
"    ]. However, its poor sensitivity suggests that further evaluation (such as bronchoscopy or laryngoscopy) is warranted when clinical suspicion is high despite a preserved flow-volume loop. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37351?source=see_link\">",
"     \"Diagnosis and management of central airway obstruction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     RESTRICTIVE DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The flow-volume loop has a recognizable pattern in those restrictive lung or chest wall diseases that are associated with increased elastic recoil of the respiratory system. The characteristic pattern, which is seen most frequently with interstitial lung disease, is a decrease in vital capacity, with supernormal expiratory flows when corrected for lung volume. The resulting shape of the flow-volume curve is a tall, \"witch's hat\" appearance with a steep descending limb (",
"    <a class=\"graphic graphic_figure graphicRef55880 \" href=\"UTD.htm?22/59/23486\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3160783\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The flow-volume loop is a plot of inspiratory and expiratory flow (on the Y-axis) against volume (on the X-axis) during the performance of maximal forced inspiratory and expiratory maneuvers. The contour of the flow-volume loop provides additional information about the location of airway constriction, beyond that provided by the numeric values for forced expiratory volume in one second (FEV1) and forced vital capacity (FVC). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with airflow limitation due to asthma or chronic obstructive pulmonary disease (COPD) often have a concave upward or \"scooped-out,\" or \"coved\" pattern on the expiratory portion of the flow-volume loop (",
"      <a class=\"graphic graphic_figure graphicRef55880 \" href=\"UTD.htm?22/59/23486\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Obstructive pulmonary disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The contour of the flow-volume loop is particularly useful for defining whether an obstructing lesion of the upper airway is intrathoracic or extrathoracic and also whether it is fixed (eg, tracheal stenosis, goiter, tumor) or dynamic (eg, structural and functional vocal cord abnormalities, laryngomalacia, extrathoracic tracheomalacia) (",
"      <a class=\"graphic graphic_figure graphicRef65386 \" href=\"UTD.htm?17/3/17470\">",
"       figure 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef55931 \" href=\"UTD.htm?14/54/15214\">",
"       figure 4",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Upper airway obstruction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The upper airway is defined as that portion of the airway extending from the mouth to the lower trachea and is further divided into intra- and extrathoracic components by the thoracic inlet, which projects 1 to 3 cm above the suprasternal notch on the anterior chest at the level of the first thoracic vertebra. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Upper airway obstruction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      However, the flow-volume loop is an insensitive test for upper airway obstruction, as lesions must narrow the tracheal lumen to less than 8 mm (a reduction of the tracheal area by at least 80 percent) before abnormalities can be detected (",
"      <a class=\"graphic graphic_figure graphicRef73686 \" href=\"UTD.htm?27/40/28302\">",
"       figure 11",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Accuracy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The characteristic flow-volume loop pattern of restrictive disease (seen most frequently with interstitial lung disease) is a decrease in vital capacity combined with supernormal expiratory flows when corrected for lung volume. The resulting shape of the flow-volume curve is a tall, \"witch's hat\" appearance with a steep descending limb (",
"      <a class=\"graphic graphic_figure graphicRef55880 \" href=\"UTD.htm?22/59/23486\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Restrictive disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25878/abstract/1\">",
"      Aboussouan LS, Stoller JK. Diagnosis and management of upper airway obstruction. Clin Chest Med 1994; 15:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25878/abstract/2\">",
"      Miller RD, Hyatt RE. Obstructing lesions of the larynx and trachea: clinical and physiologic characteristics. Mayo Clin Proc 1969; 44:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25878/abstract/3\">",
"      Miller RD, Hyatt RE. Evaluation of obstructing lesions of the trachea and larynx by flow-volume loops. Am Rev Respir Dis 1973; 108:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25878/abstract/4\">",
"      Sharief N, Wiseman NW, Higgins M, Chernick V. Abnormal flow-volume loop leading to the diagnosis of bronchogenic cyst. Pediatr Pulmonol 1999; 27:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25878/abstract/5\">",
"      Gamsu G, Borson DB, Webb WR, Cunningham JH. Structure and function in tracheal stenosis. Am Rev Respir Dis 1980; 121:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25878/abstract/6\">",
"      Vander Els NJ, Sorhage F, Bach AM, et al. Abnormal flow volume loops in patients with intrathoracic Hodgkin's disease. Chest 2000; 117:1256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25878/abstract/7\">",
"      Harrison BD. Upper airway obstruction--a report on sixteen patients. Q J Med 1976; 45:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25878/abstract/8\">",
"      Bahrainwala AH, Simon MR, Harrison DD, et al. Atypical expiratory flow volume curve in an asthmatic patient with vocal cord dysfunction. Ann Allergy Asthma Immunol 2001; 86:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25878/abstract/9\">",
"      Gelb AF, Tashkin DP, Epstein JD, et al. Physiologic characteristics of malignant unilateral main-stem bronchial obstruction. Diagnosis and Nd-YAG laser treatment. Am Rev Respir Dis 1988; 138:1382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25878/abstract/10\">",
"      Gelb AF, Tashkin DP, Epstein JD, et al. Diagnosis and Nd-YAG laser treatment of unsuspected malignant tracheal obstruction. Chest 1988; 94:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25878/abstract/11\">",
"      Gascoigne AD, Corris PA, Dark JH, Gibson GJ. The biphasic spirogram: a clue to unilateral narrowing of a mainstem bronchus. Thorax 1990; 45:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25878/abstract/12\">",
"      Rhodes, ML. End inspiratory plateau: Flow volume loop (FVL) in localized bronchial stenosis. Am Rev Respir Dis 1980; 121:s182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25878/abstract/13\">",
"      Neagos, GR, Martinez, FJ, Deeb, GM, et al. Diagnosis of unilateral mainstem bronchial obstruction following single-lung transplantation with routine spirometry. Chest 1993; 103:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25878/abstract/14\">",
"      Haponik EF, Bleecker ER, Allen RP, et al. Abnormal inspiratory flow-volume curves in patients with sleep-disordered breathing. Am Rev Respir Dis 1981; 124:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25878/abstract/15\">",
"      Sanders MH, Martin RJ, Pennock BE, Rogers RM. The detection of sleep apnea in the awake patient. The 'saw-tooth' sign. JAMA 1981; 245:2414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25878/abstract/16\">",
"      Hoffstein V, Wright S, Zamel N. Flow-volume curves in snoring patients with and without obstructive sleep apnea. Am Rev Respir Dis 1989; 139:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25878/abstract/17\">",
"      Zamel N. Flow volume curve: the \"saw-tooth\" sign. Eur J Respir Dis 1986; 69:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25878/abstract/18\">",
"      Vincken WG, Gauthier SG, Dollfuss RE, et al. Involvement of upper-airway muscles in extrapyramidal disorders. A cause of airflow limitation. N Engl J Med 1984; 311:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25878/abstract/19\">",
"      Schiffman PL. A \"saw-tooth\" pattern in Parkinson's disease. Chest 1985; 87:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25878/abstract/20\">",
"      Ram&iacute;rez J, Le&oacute;n I, Rivera LM. Episodic laryngeal dyskinesia. Clinical and psychiatric characterization. Chest 1986; 90:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25878/abstract/21\">",
"      Rendleman N, Quinn SF. The answer is blowing in the wind: a pedunculated tumour with saw tooth flow-volume loop. J Laryngol Otol 1998; 112:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25878/abstract/22\">",
"      Garcia-Pachon E. Tracheobronchomalacia: a cause of flow oscillations on the flow-volume loop. Chest 2000; 118:1519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25878/abstract/23\">",
"      Haponik EF, Munster AM, Wise RA, et al. Upper airway function in burn patients. Correlation of flow-volume curves and nasopharyngoscopy. Am Rev Respir Dis 1984; 129:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25878/abstract/24\">",
"      Katz I, Zamel N, Slutsky AS, et al. An evaluation of flow-volume curves as a screening test for obstructive sleep apnea. Chest 1990; 98:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25878/abstract/25\">",
"      Al-Bazzaz F, Grillo H, Kazemi H. Response to exercise in upper airway obstruction. Am Rev Respir Dis 1975; 111:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25878/abstract/26\">",
"      Modrykamien AM, Gudavalli R, McCarthy K, et al. Detection of upper airway obstruction with spirometry results and the flow-volume loop: a comparison of quantitative and visual inspection criteria. Respir Care 2009; 54:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25878/abstract/27\">",
"      Watson MA, King CS, Holley AB, et al. Clinical and lung-function variables associated with vocal cord dysfunction. Respir Care 2009; 54:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25878/abstract/28\">",
"      Couriel JM, Hibbert M, Olinsky A. Assessment of proximal airway obstruction in children by analysis of flow-volume loops. Br J Dis Chest 1984; 78:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25878/abstract/29\">",
"      Guntupalli KK, Bandi V, Sirgi C, et al. Usefulness of flow volume loops in emergency center and ICU settings. Chest 1997; 111:481.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1465 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-110.170.48.130-B1CD8C1B47-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_17_25878=[""].join("\n");
var outline_f25_17_25878=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H3160783\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OBSTRUCTIVE PULMONARY DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      UPPER AIRWAY OBSTRUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Variable extrathoracic obstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Variable intrathoracic obstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Fixed upper airway obstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Extraluminal airway obstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Variable obstruction at the thoracic inlet",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Mainstem bronchial obstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25782803\">",
"      Saw-tooth pattern",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Accuracy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      RESTRICTIVE DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3160783\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/1465\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1465|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/59/23486\" title=\"figure 1\">",
"      Flow volume loops in lung disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/31/35325\" title=\"figure 2\">",
"      Flow volume loops in airway obstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/3/17470\" title=\"figure 3\">",
"      Effect of dynamic extrathoracic airway obstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/54/15214\" title=\"figure 4\">",
"      Effects of dynamic intrathoracic airway obstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/12/17612\" title=\"figure 5\">",
"      Thoracic inlet obstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/3/7229\" title=\"figure 6\">",
"      Effect of neck flexion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/0/16397\" title=\"figure 7\">",
"      Mainstem bronchial obstr",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/63/36860\" title=\"figure 8\">",
"      Partial mainstem bronchial obs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/0/12300\" title=\"figure 9\">",
"      End inspiratory tail",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/51/2877\" title=\"figure 10\">",
"      Saw tooth pattern in OSA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/40/28302\" title=\"figure 11\">",
"      Upper airway obstruction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37351?source=related_link\">",
"      Diagnosis and management of central airway obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/53/4952?source=related_link\">",
"      Overview of pulmonary function testing in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/11/16567?source=related_link\">",
"      Paradoxical vocal cord motion",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_17_25879="Evaluation of the patient with hand pain";
var content_f25_17_25879=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation of the patient with hand pain",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/17/25879/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/17/25879/contributors\">",
"     Bruce C Anderson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/17/25879/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/17/25879/contributors\">",
"     Robert H Shmerling, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/17/25879/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/17/25879/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/17/25879/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major nontraumatic disorders that cause hand pain will be reviewed here. Thumb and wrist pain are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/44/9928?source=see_link\">",
"     \"Evaluation of the patient with thumb pain\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/21/12632?source=see_link\">",
"     \"Evaluation of the adult with acute wrist pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The bones of the hand include five metacarpals, two phalanges in the thumb, and three phalanges in each of the other fingers. The joints of each finger include the metacarpophalangeal (MP), the proximal interphalangeal (PIP), and the distal interphalangeal (DIP); the thumb has only one interphalangeal (IP) joint.",
"   </p>",
"   <p>",
"    Extrinsic muscles of the hand originate in the forearm and elbow area. The flexor tendons for each digit travel in a fibro-osseous tunnel between the metacarpal and the DIP joint. The superficialis tendon attaches to the middle phalanges, and the profundus tendon attaches to the distal phalanges. The extensor tendons pass over the dorsum of the wrist in six separate compartments.",
"   </p>",
"   <p>",
"    Intrinsic muscles of the hand include the thenar, hypothenar, interosseous, and lumbricals. The thenar muscles control adduction and opposition of the thumb; other thumb movements are controlled by forearm muscles. The interosseous and lumbrical muscles flex the MP joints, help extend the IP joints, and abduct and adduct the fingers.",
"   </p>",
"   <p>",
"    The ulnar nerve provides the motor supply to the intrinsic hand muscles (other than the two radial lumbricals and the thenar muscles); it also provides sensation to the little finger and one-half of the ring finger. The median nerve is the motor supply to the thenar muscles and the two radial lumbricals; it is the sensory supply to the palmar aspect of the first three fingers and the radial half of the ring finger. The radial nerve is the sensory supply to the dorsum of the hand.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ETIOLOGY/PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient&rsquo;s affected joint and loss of function are the strongest clues to the etiology of hand pain. Multiple joint involvement suggests either osteoarthritis or inflammatory arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25879/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Osteoarthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteoarthritis (OA) of the hands is a common disorder, most often presenting in patients over 40 years of age. The principal symptom associated with OA is pain, which is typically exacerbated by activity and is relieved by rest. With more advanced disease, pain may be noted with progressively less activity, eventually occurring at rest and at night. Pain in OA is not caused directly by cartilage damage since cartilage is aneural. As a result, osteoarthritic radiologic changes are often noted in patients without symptoms at affected sites; patients may complain more about the appearance of the joints rather than pain or loss of function.",
"   </p>",
"   <p>",
"    Osteoarthritic enlargements of the distal and proximal interphalangeal joints are referred to as Heberden&rsquo;s and Bouchard&rsquo;s nodes, respectively. There appears to be a genetic predisposition to the development of the former [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25879/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. The first carpometacarpal joint is also a common area affected in OA. By comparison, involvement of the MP joint is relatively uncommon. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/49/12056?source=see_link\">",
"     \"Clinical manifestations of osteoarthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Rheumatoid arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The onset of rheumatoid arthritis (RA) is usually insidious, with the predominant symptoms being pain, stiffness, and swelling of many joints. The hands are a common site of early involvement, particularly the MP and PIP joints [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25879/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Symmetrical involvement is a characteristic feature, although this may be less apparent early in the disease. Symptoms limited to the DIP joints are usually due to OA, while PIP involvement can reflect either RA or OA.",
"   </p>",
"   <p>",
"    Morning stiffness or stiffness after any prolonged period of inactivity is seen in virtually all inflammatory arthropathies and myopathies [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25879/abstract/6\">",
"     6",
"    </a>",
"    ]. However, morning stiffness lasting more than one hour reflects a severity of joint inflammation which rarely occurs in diseases other than RA. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/46/13033?source=see_link\">",
"     \"Clinical features of rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Trigger finger",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fibro-osseous tunnel, through which the flexor tendon of each digit travels, provides nutrition to the tendon, as well as mechanical stability. Irritation or inflammation of the fibro-osseous tunnel can occur as the result of repetitive use or direct pressure; swelling of the tunnel proximally at the MP joint results in trigger finger (flexor tenosynovitis).",
"   </p>",
"   <p>",
"    Nodule formation on the flexor tendon prevents smooth gliding of the tendon under the A-1 pulley, the specialized ligament that anchors the tendon to the bone. The tendon may &ldquo;catch&rdquo; at the MP joint, causing the finger to lock in flexion. Patients often complain of pain and a sensation of &ldquo;snapping;&rdquo; the pain radiates into the palm or the distal finger. The patient rubs over the tendon in the palm or actually demonstrates the locking phenomenon when describing the condition. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19141?source=see_link\">",
"     \"Trigger finger (stenosing flexor tenosynovitis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Tendon cyst",
"    </span>",
"    &nbsp;&mdash;&nbsp;A tendon cyst is an abnormal collection of tenosynovial fluid, either within or adjacent to the tendon. Direct nonpenetrating trauma causes damage to the tendon or tendon sheath, leading to an overproduction of fluid and cyst formation.",
"   </p>",
"   <p>",
"    In contrast to the mechanical locking of trigger finger, active and passive movements of the digit are unimpaired. Patients complain of a lump in the palm of the hand that may be mildly tender.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Dupuytren's contracture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dupuytren&rsquo;s contracture is a relatively common disorder that presents as a nodular fibrosing lesion within the palmar fascia and related structures. It produces contractures that draw one or more fingers into flexion at the MP joint. It occurs primarily in white males over the age of 50 and appears to have a pronounced genetic predisposition.",
"   </p>",
"   <p>",
"    The incidence of Dupuytren&rsquo;s contracture is two to five times higher among workers exposed to repetitive handling tasks or vibration compared with those not exposed such trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25879/abstract/7\">",
"     7",
"    </a>",
"    ]. It also occurs more frequently in patients with diabetes mellitus [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25879/abstract/8,9\">",
"     8,9",
"    </a>",
"    ] and may be associated with cigarette smoking and with alcohol abuse [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25879/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients complain of painless nodular lesions on the palmar fascia, usually affecting the fourth and fifth digits, with puckering and tethering of the overlying skin. Over time, the tendon thickening causes stiffness and loss of full extension. The patient often rubs the palm and fingers in an attempt to straighten them out as the condition is described. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/54/39783?source=see_link\">",
"     \"Dupuytren's contracture\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Mallet finger",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mallet finger is an avulsion injury of the extensor tendon of the DIP joint. The injury occurs due to acute forceful passive flexion of the DIP joint during concomitant active joint extension. The finger deformity can result from stretching or partial tearing the extensor tendon, from complete rupture, or from rupture with avulsion fracture of the distal phalanx. Patients complain of the obvious deformity plus pain over the DIP joint and an inability to actively extend the joint. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38390?source=see_link\">",
"     \"Extensor tendon injury of the distal interphalangeal joint (mallet finger)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Mucinoid cyst",
"    </span>",
"    &nbsp;&mdash;&nbsp;Excessive amounts of synovial fluid produced by an osteoarthritic DIP or PIP joint may leak into the subcutaneous tissues, causing the formation of a 4 to 5 mm cyst atop the DIP or, less commonly, PIP joint.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Traumatic MP arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Isolated arthritic involvement of the MP joint is uncommon, usually affecting the second and third MP joints as the result of remote and often unrecognized trauma. Patients complain of pain or swelling in the affected joint or of an inability to make a closed fist.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Carpal tunnel syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carpal tunnel syndrome (CTS) is the most common nerve entrapment disorder. It is caused by increased pressure and consequent compression of the median nerve within the carpal tunnel. Median nerve impingement may result from diseases that invade the carpal tunnel, from swelling of tendon sheaths within the tunnel, from stenosis of the tunnel by bone enlargement, or from thickening and degeneration of the volar carpal ligament. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/22/23911?source=see_link\">",
"     \"Etiology of carpal tunnel syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical features of carpal tunnel syndrome are variable but usually include pain and paresthesia in the thumb, the first two fingers, and the medial half of the ring finger (the distribution of the median nerve). Paresthesia and sensory deficits may involve the entire palm area in some cases due to variable nerve innervation. In addition, pain may radiate proximally into the forearm and, occasionally, to the shoulder. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/15/42230?source=see_link\">",
"     \"Clinical manifestations and diagnosis of carpal tunnel syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Efficient examination of the hand begins by assessing overall function of the small joints followed by specific maneuvers used to define the most common conditions (",
"    <a class=\"graphic graphic_table graphicRef72098 \" href=\"UTD.htm?40/40/41612\">",
"     table 1",
"    </a>",
"    ). Testing the overall function of the hand readily separates focal musculoskeletal process from the more encompassing rheumatologic conditions, determines the number of affected joints, and assesses the severity of the condition.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pain, stiffness, and bony enlargement of multiple DIP joints suggest the presence of OA. Bony enlargement, rather than synovial thickening or swelling, is the key physical finding when palpating the lateral joint lines.",
"     </li>",
"     <li>",
"      Pain, swelling, and fusiform enlargement of multiple hand joints are the classic features of inflammatory arthritis. Involvement of the DIP joints is seen with psoriatic arthritis, and PIP and MP involvement is seen with RA. Compressible synovial thickening and swelling are the key physical findings when palpating the lateral joint lines.",
"     </li>",
"     <li>",
"      Localized tenderness over a single MP joint in the palm, with or without loss of smooth digit motion, is the classic physical finding of flexor tenosynovitis (trigger finger).",
"     </li>",
"     <li>",
"      Tendon cysts and Dupuytren&rsquo;s contracture present as relatively painless nodules that form in or along the flexor tendons in the palm. A firm nodule located adjacent to a single MP joint is characteristic of a benign tendon cyst; despite their size, these rarely interfere with the function of the digit or hand. In contrast, multiple nodules adjacent to several MP joints in the palm are characteristic of Dupuytren&rsquo;s contracture; this progressive scarring of the palmar fascia does affect finger function, gradually interfering with extension of the digit.",
"     </li>",
"     <li>",
"      Pain localized to the dorsum of a single MP joint is typically due to posttraumatic arthritis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Overall hand function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overall hand function is assessed by opening and closing the hand and by measuring grip strength.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Opening and closing the hand",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asking the patient to open and close the hand assesses the full and smooth movement of the small joints of the hand (",
"    <a class=\"graphic graphic_picture graphicRef69129 \" href=\"UTD.htm?23/8/23695\">",
"     picture 1",
"    </a>",
"    ). Full function of the hand requires normal joint function, normally functioning flexor and extensor tendons, and an intact median and ulnar nerve. Arthritis from any cause, trigger finger, and Dupuytren&rsquo;s contracture can all affect hand movement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Grip strength",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gripping provides an objective measurement of the integrity and strength of the intrinsic muscles of the hand and of the forearm muscles. Grip strength can be crudely estimated by manual gripping of the examiner&rsquo;s fingers (",
"    <a class=\"graphic graphic_picture graphicRef80580 \" href=\"UTD.htm?26/46/27375\">",
"     picture 2",
"    </a>",
"    ). Physical measurement using a dynamometer is more accurate and reproducible (",
"    <a class=\"graphic graphic_picture graphicRef56541 \" href=\"UTD.htm?3/18/3360\">",
"     picture 3",
"    </a>",
"    ). The differential diagnosis of reduced grip strength includes disuse atrophy, arthritis, carpal tunnel syndrome, severe epicondylitis, and radiculopathy involving motor function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Maneuvers assessing specific conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who have mild joint pain and stiffness, minimal impairment of range of motion, and no contractures or deformities can be treated empirically without further investigation. Empiric treatment includes avoiding repetitious gripping and grasping, avoiding vibration exposure, avoiding prolonged contact with cold, wearing thick leather gloves for protection, direct application of heat, and gentle range of motion exercises in flexion and extension to prevent contractures.",
"   </p>",
"   <p>",
"    Patients with persistent or chronic symptoms despite these measures or those who have more severe initial symptoms such as palpable swelling, nodularity, synovial thickening, or early joint contracture should have a more comprehensive examination for specific conditions, as well as possible x-rays",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    blood work.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Simple inspection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hands are inspected for alignment, for fusiform swelling, for bony enlargement, for joint deformity including ankylosis or contracture, and for the presence of cysts or nodules (",
"    <a class=\"graphic graphic_picture graphicRef52133 \" href=\"UTD.htm?35/25/36255\">",
"     picture 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Palpation of the DIP and PIP joints",
"    </span>",
"    &nbsp;&mdash;&nbsp;The DIP and PIP joints are palpated to determine the extent of arthritic involvement of the joints and to determine whether the enlargement is due to bony changes, inflammatory synovial thickening, or both (",
"    <a class=\"graphic graphic_picture graphicRef76825 \" href=\"UTD.htm?10/41/10896\">",
"     picture 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef76902 \" href=\"UTD.htm?20/31/20977\">",
"     picture 6",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     MP joint evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The MP joints are squeezed to determine involvement of these joints (",
"    <a class=\"graphic graphic_picture graphicRef70187 \" href=\"UTD.htm?0/59/944\">",
"     picture 7",
"    </a>",
"    ). The joints are also observed for swelling (",
"    <a class=\"graphic graphic_picture graphicRef60459 \" href=\"UTD.htm?5/33/5648\">",
"     picture 8",
"    </a>",
"    ). The differential diagnosis of pain with squeezing or MP swelling includes posttraumatic arthritis (single joint involvement) and rheumatoid arthritis (multiple joint involvement).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Palpation of the flexor tendon",
"    </span>",
"    &nbsp;&mdash;&nbsp;The flexor tendon is palpated for tenderness or cyst formation (",
"    <a class=\"graphic graphic_picture graphicRef78638 \" href=\"UTD.htm?18/33/18960\">",
"     picture 9",
"    </a>",
"    ). Active tenosynovitis (trigger finger) is characterized by local tenderness aggravated by passive stretching of the tendon in extension. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19141?source=see_link\">",
"     \"Trigger finger (stenosing flexor tenosynovitis)\"",
"    </a>",
"    .) The majority of flexor tendon cysts occur within one centimeter of the flexor creases at the base of the fingers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Palpation of the palmar fascia for nodularity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Palpation of the palmar fascia is used to assess the degree of palmar fibrosis (",
"    <a class=\"graphic graphic_picture graphicRef69444 graphicRef70486 \" href=\"UTD.htm?12/17/12567\">",
"     picture 10A-B",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/54/39783?source=see_link\">",
"     \"Dupuytren's contracture\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Inspection of mallet finger",
"    </span>",
"    &nbsp;&mdash;&nbsp;The integrity of the extensor profundus tendon is assessed in patients with a history of direct blows to the tip of the finger and with the characteristic mallet finger deformity. Patients are unable to actively extend the affected DIP joint against resistance (",
"    <a class=\"graphic graphic_picture graphicRef65406 \" href=\"UTD.htm?25/30/26095\">",
"     picture 11",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Inspection of the dorsum of the hand",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dorsum of the hand is inspected for the presence of mucinous cysts (",
"    <a class=\"graphic graphic_picture graphicRef80546 \" href=\"UTD.htm?33/58/34734\">",
"     picture 12",
"    </a>",
"    ). The differential diagnosis of cystic swelling in this location includes herpetic whitlow, foreign body reaction, abscess, or dermatofibroma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Clinical pearls",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The earliest sign of Dupuytren&rsquo;s contracture is a triangular &ldquo;puckering&rdquo; of the dermal tissue over the flexor tendon just proximal to the flexor crease of the finger. As the scarring process progresses, nodules form, and the finger gradually loses its flexibility.",
"     </li>",
"     <li>",
"      A comprehensive hand examination is the most important method of evaluating patients complaining of generalized hand arthralgia. Radiographic and serologic testing is nearly always normal unless the specific maneuvers of the hand demonstrate objective findings of bony enlargement, synovial thickening, or joint swelling.",
"     </li>",
"     <li>",
"      An efficient screening examination for rheumatoid arthritis includes general hand inspection, grip measurement, palpation of the PIP joints for tenderness, the MP squeeze sign, extension and flexion of the wrists, observation of gait and of walking on tiptoes, and the metatarsophalangeal (MTP) squeeze sign.",
"     </li>",
"     <li>",
"      Tenosynovitis of the flexor tendons always precedes the mechanical symptoms of triggering. However, not all patients demonstrate active tenosynovitis at the time they are examined. As the patient tries to avoid the triggering phenomenon (by using the finger less and less), the tenosynovial signs gradually subside, leaving the patient with a relatively painless mechanical triggering. In some cases, flexor tenosynovitis and mechanical triggering can be so dramatic as to preclude movement of the finger from a flexed position; this is referred to as a &ldquo;fixed-locked&rdquo; digit.",
"     </li>",
"     <li>",
"      As mentioned, despite their size, tendon cysts rarely lead to mechanical dysfunction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     CONFIRMATORY MANEUVERS AND PROCEDURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Radiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plain films of the hand are indicated in patients with suspected inflammatory arthritis, with posttraumatic arthritis, or, in some patients, with osteoarthritis. X-rays are also warranted in patients with a mallet finger deformity to identify an avulsion fracture of the distal phalanx.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      OA of the hands is a clinical diagnosis that rarely requires x-ray documentation; most diagnostic tools do not incorporate x-ray findings to make the diagnosis of hand OA. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/32/33287?source=see_link&amp;anchor=H17#H17\">",
"       \"Diagnosis and classification of osteoarthritis\", section on 'Osteoarthritis of the hand'",
"      </a>",
"      .) X-rays are indicated when the patient presents with unusual degrees of joint swelling or synovial thickening, suggesting the concomitant presence of an inflammatory arthritis (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef55802 \" href=\"UTD.htm?30/52/31567\">",
"       image 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      X-rays of the hands of patients with inflammatory arthritis are often normal in the early stages of the disease. Juxtaarticular osteoporosis, reflecting increased blood flow to the joints, is the early radiographic change. Late findings include symmetrical wear of the articular cartilage, generalized osteopenia, erosive changes, angulation, and ankylosis (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef53662 \" href=\"UTD.htm?4/33/4624\">",
"       image 2",
"      </a>",
"      ). Erosions, typically in the MP and PIP joints, are present in 15 to 30 percent of patients in the first year of RA. There is a subsequent cumulative increase in frequency of joint erosions over time (greater than 90 percent after the first two years) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/17/25879/abstract/11,12\">",
"       11,12",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/55/6010?source=see_link\">",
"       \"Diagnosis and differential diagnosis of rheumatoid arthritis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      X-rays may confirm rupture of the extensor profundus tendon and avulsion fracture of the distal phalanx in patients with a mallet finger deformity (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef64713 \" href=\"UTD.htm?31/1/31774\">",
"       image 3",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Confirming the presence of trigger finger",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanical function of the affected finger is assessed in patients with suspected trigger finger to document the severity of triggering (",
"    <a class=\"graphic graphic_picture graphicRef63023 \" href=\"UTD.htm?21/20/21839\">",
"     picture 13",
"    </a>",
"    ). Passive stretching in extension should also be performed to confirm the presence of active inflammation; pain with stretching is consistent with tenosynovitis (",
"    <a class=\"graphic graphic_picture graphicRef55130 \" href=\"UTD.htm?14/31/14847\">",
"     picture 14",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Cyst puncture",
"    </span>",
"    &nbsp;&mdash;&nbsp;A presumptive diagnosis of a tendon cyst is based upon the size and location of the nodule. Simple cyst puncture can be used to confirm the presence of a benign tenosynovial cyst (",
"    <a class=\"graphic graphic_picture graphicRef63337 \" href=\"UTD.htm?33/62/34784\">",
"     picture 15",
"    </a>",
"    ) or mucinoid cyst. Cysts that fail to decompress with puncture may be giant cell tumors; surgical removal may be necessary to determine the diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Local anesthetic block",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of MP joint arthritis is usually based upon the characteristic swelling and loss of range of motion of the MP joint. Occasionally, local anesthetic block is required to distinguish this disorder from flexor tenosynovitis or from injury to the supporting ligaments. Involvement of the MP joint is confirmed by pain relief with local anesthetic block (",
"    <a class=\"graphic graphic_picture graphicRef80531 \" href=\"UTD.htm?16/43/17072\">",
"     picture 16",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Blood tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute phase reactants, particularly the erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), are relatively nonspecific tests that should not be used as a substitute for a comprehensive examination and appropriate imaging. The ESR and CRP are normal in the noninflammatory conditions, such as osteoarthritis. Most patients with inflammatory arthritis will have elevated levels, although such findings lack diagnostic specificity. Acute phase reactants may also be elevated in the setting of concurrent non-rheumatologic inflammatory conditions. Normal results of acute phase reactants may occur early in the course of inflammatory rheumatic disease, especially if only a modest degree of inflammation is present. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/42/38569?source=see_link\">",
"     \"Acute phase reactants\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rheumatoid factors occur in 70 to 80 percent of patients with RA. Their diagnostic specificity is similarly limited, however, because rheumatoid factors are also found in about 70 percent of patients with Sj&ouml;gren&rsquo;s syndrome, in 20 to 30 percent of those with systemic lupus erythematosus, occasionally in patients with virus infections, and in 5 to 10 percent of healthy, especially older, individuals. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/41/42648?source=see_link\">",
"     \"Origin and utility of measurement of rheumatoid factors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/55/6010?source=see_link\">",
"     \"Diagnosis and differential diagnosis of rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?7/11/7347?source=see_link\">",
"       \"Patient information: Hand pain (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27852590\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The patient&rsquo;s affected joint and loss of function are the strongest clues to the etiology of hand pain. An understanding of the anatomy is essential. Both the medical history and physical examination are useful in identifying features which help distinguish joint from tendon involvement and inflammatory from noninflammatory disease, and they provide specific clues to the diagnosis. Numerous conditions should be considered in the differential diagnosis of hand pain (",
"      <a class=\"graphic graphic_table graphicRef72098 \" href=\"UTD.htm?40/40/41612\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Anatomy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Etiology/presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Efficient examination of the hand begins by assessing overall function, which separates focal musculoskeletal processes from the more encompassing rheumatologic conditions, which determines the number of affected joints, and which assesses the severity of the condition. Asking the patient to open and close the hand assesses the full and smooth movement of the small joints of the hand; full hand function requires normal joint function, normally functioning flexor and extensor tendons, and an intact median and ulnar nerve. Gripping provides an objective measurement of the integrity and strength of the intrinsic muscles of the hand and of the forearm muscles. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Examination'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Overall hand function'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Specific maneuvers are used to define the most common conditions (",
"      <a class=\"graphic graphic_table graphicRef72098 \" href=\"UTD.htm?40/40/41612\">",
"       table 1",
"      </a>",
"      ) following assessment of overall hand function. Potentially affected joints, tendons, and other soft tissues should undergo inspection and palpation. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Examination'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Maneuvers assessing specific conditions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We obtain plain films of the hand in patients with suspected inflammatory arthritis, with posttraumatic arthritis, or, in some patients, with osteoarthritis. Radiographs are also warranted in patients with a mallet finger deformity to identify an avulsion fracture of the distal phalanx. Radiographic and serologic testing is nearly always normal unless the specific maneuvers of the hand demonstrate objective findings of bony enlargement, synovial thickening, or joint swelling. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Confirmatory maneuvers and procedures'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H27\">",
"       'Radiography'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acute phase reactants, particularly the erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), are relatively nonspecific tests, limiting diagnostic and prognostic utility. Elevated levels are nonspecific, and normal results may be observed in patients with modest inflammation. (See",
"      <a class=\"local\" href=\"#H31\">",
"       'Blood tests'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Anderson BC. Office Orthopedics for Primary Care: Diagnosis and Treatment, 3rd Edition, Elsevier Company, Philadelphia 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25879/abstract/2\">",
"      Cicuttini FM, Spector TD. Genetics of osteoarthritis. Ann Rheum Dis 1996; 55:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25879/abstract/3\">",
"      Spector TD, Cicuttini F, Baker J, et al. Genetic influences on osteoarthritis in women: a twin study. BMJ 1996; 312:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25879/abstract/4\">",
"      Fleming A, Crown JM, Corbett M. Early rheumatoid disease. I. Onset. Ann Rheum Dis 1976; 35:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25879/abstract/5\">",
"      Jacoby RK, Jayson MI, Cosh JA. Onset, early stages, and prognosis of rheumatoid arthritis: a clinical study of 100 patients with 11-year follow-up. Br Med J 1973; 2:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25879/abstract/6\">",
"      Edworthy SM. Morning stiffness: sharpening an old saw? J Rheumatol 1999; 26:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25879/abstract/7\">",
"      Liss GM, Stock SR. Can Dupuytren's contracture be work-related?: review of the evidence. Am J Ind Med 1996; 29:521.",
"     </a>",
"    </li>",
"    <li>",
"     Sibbitt WL. Fibrosing syndromes: diabetic stiff hand syndrome, Dupuytren's contracture and plantar fasciitis. In: Arthritis and Allied Conditions, 11th Edition, McCarty DJ (Ed), Lea &amp; Febiger, Philadelphia 1989.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25879/abstract/9\">",
"      Noble J, Heathcote JG, Cohen H. Diabetes mellitus in the aetiology of Dupuytren's disease. J Bone Joint Surg Br 1984; 66:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25879/abstract/10\">",
"      Burge P, Hoy G, Regan P, Milne R. Smoking, alcohol and the risk of Dupuytren's contracture. J Bone Joint Surg Br 1997; 79:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25879/abstract/11\">",
"      van der Heijde DM, van Leeuwen MA, van Riel PL, et al. Biannual radiographic assessments of hands and feet in a three-year prospective followup of patients with early rheumatoid arthritis. Arthritis Rheum 1992; 35:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25879/abstract/12\">",
"      Fuchs HA, Kaye JJ, Callahan LF, et al. Evidence of significant radiographic damage in rheumatoid arthritis within the first 2 years of disease. J Rheumatol 1989; 16:585.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1830 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-197.136.42.3-3357F5F93E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_17_25879=[""].join("\n");
var outline_f25_17_25879=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27852590\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ETIOLOGY/PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Trigger finger",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Tendon cyst",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Dupuytren's contracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Mallet finger",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Mucinoid cyst",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Traumatic MP arthritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Carpal tunnel syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Overall hand function",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Opening and closing the hand",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Grip strength",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Maneuvers assessing specific conditions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Simple inspection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Palpation of the DIP and PIP joints",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - MP joint evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Palpation of the flexor tendon",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Palpation of the palmar fascia for nodularity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Inspection of mallet finger",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Inspection of the dorsum of the hand",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Clinical pearls",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      CONFIRMATORY MANEUVERS AND PROCEDURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Radiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Confirming the presence of trigger finger",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Cyst puncture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Local anesthetic block",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Blood tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27852590\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/1830\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/1830|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?30/52/31567\" title=\"diagnostic image 1\">",
"      DIP osteoarthritis xray",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?4/33/4624\" title=\"diagnostic image 2\">",
"      Inflammatory arthritis xray",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?31/1/31774\" title=\"diagnostic image 3\">",
"      Avulsion fracture mallet finger",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/1830|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/8/23695\" title=\"picture 1\">",
"      General hand function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/46/27375\" title=\"picture 2\">",
"      Manual testing grip strength",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/18/3360\" title=\"picture 3\">",
"      Dynamometry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/25/36255\" title=\"picture 4\">",
"      Hand inspection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/41/10896\" title=\"picture 5\">",
"      DIP joint palpation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/31/20977\" title=\"picture 6\">",
"      PIP joint palpation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/59/944\" title=\"picture 7\">",
"      MP squeeze sign",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/33/5648\" title=\"picture 8\">",
"      MP joint swelling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/33/18960\" title=\"picture 9\">",
"      Palpation of flexor tendon",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/18/6433\" title=\"picture 10A\">",
"      Palpation of palmar fascia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/58/36770\" title=\"picture 10B\">",
"      Dupuytrens contracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/30/26095\" title=\"picture 11\">",
"      Mallet finger deformity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/58/34734\" title=\"picture 12\">",
"      Mucinous cyst",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/20/21839\" title=\"picture 13\">",
"      Mechanical triggering",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/31/14847\" title=\"picture 14\">",
"      Passive stretch tenosynovitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/62/34784\" title=\"picture 15\">",
"      Tenosynovial cyst puncture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/43/17072\" title=\"picture 16\">",
"      Local anesthetic block MP joint",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/1830|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/40/41612\" title=\"table 1\">",
"      Hand examination",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/42/38569?source=related_link\">",
"      Acute phase reactants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/46/13033?source=related_link\">",
"      Clinical features of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/15/42230?source=related_link\">",
"      Clinical manifestations and diagnosis of carpal tunnel syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/49/12056?source=related_link\">",
"      Clinical manifestations of osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/32/33287?source=related_link\">",
"      Diagnosis and classification of osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/55/6010?source=related_link\">",
"      Diagnosis and differential diagnosis of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/54/39783?source=related_link\">",
"      Dupuytren's contracture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/22/23911?source=related_link\">",
"      Etiology of carpal tunnel syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/21/12632?source=related_link\">",
"      Evaluation of the adult with acute wrist pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/44/9928?source=related_link\">",
"      Evaluation of the patient with thumb pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38390?source=related_link\">",
"      Extensor tendon injury of the distal interphalangeal joint (mallet finger)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/41/42648?source=related_link\">",
"      Origin and utility of measurement of rheumatoid factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/11/7347?source=related_link\">",
"      Patient information: Hand pain (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19141?source=related_link\">",
"      Trigger finger (stenosing flexor tenosynovitis)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_17_25880="Specific issues related to hematopoietic cell transplantation in beta thalassemia";
var content_f25_17_25880=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Specific issues related to hematopoietic cell transplantation in beta thalassemia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/17/25880/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/17/25880/contributors\">",
"     Emanuele Angelucci, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/17/25880/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/17/25880/contributors\">",
"     Robert S Negrin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/17/25880/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/17/25880/contributors\">",
"     Stephen A Landaw, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/17/25880/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with homozygous beta thalassemia require chronic blood transfusions in order to survive; however, these transfusions cause iron overload that is ultimately fatal if not continuously treated. Despite the first attempts at using gene therapy in humans, hematopoietic cell transplantation (HCT) is the only available curative therapy for this disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25880/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With regard to HCT, patients with beta thalassemia have features that make clinical management different from that of patients with leukemia. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Tissue damage, especially hepatic, related to iron overload",
"     </li>",
"     <li>",
"      Absence of previous chemotherapy and immunosuppression",
"     </li>",
"     <li>",
"      Absence of a malignant clone",
"     </li>",
"     <li>",
"      Presence of a chronically expanded erythropoietic compartment",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This review will emphasize the specific issues related to HCT that must be addressed in patients with beta thalassemia, including the pretransplant evaluation, conditioning regimens, recurrence of thalassemia, and chimerism. The efficacy of HCT in this disorder and the care of the patient post-HCT are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/25/5529?source=see_link\">",
"     \"Efficacy of hematopoietic cell transplantation in beta thalassemia major\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/36/43591?source=see_link\">",
"     \"Long-term management of the thalassemic patient after hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The term \"hematopoietic cell transplantation\" (HCT) will be used throughout this review as a general term to cover transplantation of progenitor cells from any source (eg, bone marrow, peripheral blood, cord blood). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38682?source=see_link\">",
"     \"Sources of hematopoietic stem cells\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EVALUATION BEFORE TRANSPLANTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main purpose of the pretransplant evaluation is assessment of the patient's risk, an important determinant of outcome after HCT (",
"    <a class=\"graphic graphic_table graphicRef67387 \" href=\"UTD.htm?17/2/17451\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef61453 \" href=\"UTD.htm?28/20/29003\">",
"     table 2",
"    </a>",
"    ). This information clearly indicates the importance of iron overload and associated tissue damage as factors that strongly affect transplant outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25880/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/25/5529?source=see_link\">",
"     \"Efficacy of hematopoietic cell transplantation in beta thalassemia major\"",
"    </a>",
"    .) Consequently, in evaluating thalassemia patients before HSCT all of the possible consequences of chronic transfusional therapy should be carefully studied prior to transplantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Liver",
"    </span>",
"    &nbsp;&mdash;&nbsp;The liver is the main site of iron deposition in beta thalassemia and other iron overload syndromes and therefore represents a &ldquo;window&rdquo; through which the patient&rsquo;s iron status can be most appropriately evaluated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/60/28617?source=see_link\">",
"     \"Clinical manifestations of hereditary hemochromatosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    None of the available noninvasive diagnostic techniques, such as ultrasonography, magnetic resonance imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25880/abstract/2\">",
"     2",
"    </a>",
"    ], or magnetic susceptibility [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25880/abstract/3\">",
"     3",
"    </a>",
"    ], provides adequate and complete information on hepatic status. Thus, all patients should be submitted to liver biopsy before considering bone marrow transplantation. An exception in our institution is that thalassemic patients aged three years or less do not undergo routine liver biopsy before transplantation and risk class is assessed on the basis of only two criteria.",
"   </p>",
"   <p>",
"    Liver biopsy permits an accurate evaluation of fibrosis, iron deposition (",
"    <a class=\"graphic graphic_picture graphicRef70985 graphicRef50096 \" href=\"UTD.htm?30/58/31658\">",
"     picture 1A-B",
"    </a>",
"    ), and chronic hepatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25880/abstract/4\">",
"     4",
"    </a>",
"    ]. In our experience, the risk of nonfatal bleeding after this procedure in patients with thalassemia is 0.5 percent without ultrasound guidance [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25880/abstract/4\">",
"     4",
"    </a>",
"    ] and less than 0.1 percent with ultrasound guidance.",
"   </p>",
"   <p>",
"    The Fibroscan has the potential to substitute for liver biopsy in diagnosing cirrhosis, although its utility in this disease setting has not yet been adequately tested, especially since it may not be able to discriminate among the varying degrees of liver fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25880/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/59/30650?source=see_link&amp;anchor=H3#H3\">",
"     \"Noninvasive assessment of hepatic fibrosis\", section on 'Liver stiffness'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Stage A cirrhosis (compensated) is not a contraindication to allogeneic HCT (",
"    <a class=\"graphic graphic_table graphicRef78401 \" href=\"UTD.htm?8/21/8540\">",
"     table 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25880/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Seropositivity for hepatitis B and C virus is similarly not a contraindication to HCT; nevertheless, serologic tests for these infections should be performed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/18/42279?source=see_link\">",
"     \"Serologic diagnosis of hepatitis B virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41849?source=see_link\">",
"     \"Screening for and diagnosis of chronic hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Spleen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many thalassemic patients have splenomegaly. Hypersplenism can complicate the post-transplant course by increasing the duration of cytopenia and the need for platelet and red blood cell transfusions. In one study these adverse post-transplant changes were minimized when splenectomy was performed pre-transplant, although this procedure was also associated with a shortening in overall survival [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25880/abstract/8\">",
"     8",
"    </a>",
"    ]. Additional experience with this procedure is required before it can be routinely recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25880/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Streptococcus pneumoniae and Neisseria meningitidis vaccination is recommended if splenectomy is to be performed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21705?source=see_link\">",
"     \"Pneumococcal vaccination in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Heart",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac evaluation should include a 12 lead ECG, 24-hour Holter monitor, and resting echocardiogram. More accurate diagnostic tests, such as cardiac T2* magnetic resonance imaging and low dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    stress echocardiography can identify cardiac iron deposition and reductions in cardiac contractility in asymptomatic patients, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25880/abstract/10\">",
"     10",
"    </a>",
"    ]. However, these early alterations do not have a statistically significant influence on transplant outcome. A previous episode of heart failure does not represent a contraindication to HCT (see",
"    <a class=\"local\" href=\"#H13\">",
"     'Cardiac complications'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Endocrine",
"    </span>",
"    &nbsp;&mdash;&nbsp;A complete endocrine evaluation should be performed in patients older than 10 years of age to detect possible deficiencies induced by iron deposition in the pituitary, thyroid, and pancreas. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/60/28617?source=see_link\">",
"     \"Clinical manifestations of hereditary hemochromatosis\"",
"    </a>",
"    .) This includes thyroid function tests, growth hormone releasing hormone stimulation test for hypothalamic-anterior pituitary function, and a fasting blood glucose. Sperm bank storage is recommended in male patients with normal semen analyses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Hematology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patient and donor hemoglobin synthesis must be studied to identify the status of the patient (eg, beta (0) or beta (+) thalassemic status, presence of heterozygosity for hemoglobinopathies, etc) and of the donor (normal, thalassemia minor). A sibling with thalassemia minor can be a bone marrow donor since the posttransplant course is similar to that from a normal donor, except for mild anemia and microcytosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     ISSUES RELATED TO TRANSPLANTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of issues must be addressed when HCT is performed in a patient with beta thalassemia. These include the conditioning regimen, graft-versus-host disease prophylaxis, infectious disease prophylaxis, and hepatic and cardiac complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Conditioning regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conditioning regimens for marrow transplantation in patients with diseases other than aplastic anemia must achieve two objectives:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Eradication of the diseased marrow",
"     </li>",
"     <li>",
"      Establishment of a tolerant environment that will permit the survival of donor stem cells",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although total body irradiation can achieve these results, there are many reasons to avoid the use of this modality, such as a growth-retarding effect in young children [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25880/abstract/11\">",
"     11",
"    </a>",
"    ] and an increased risk of secondary malignancy. Thus, chemotherapy-only regimens are preferred.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/10/10408?source=see_link\">",
"     Busulfan",
"    </a>",
"    is an alkylating agent with exquisite specificity for the most primitive precursors of the myeloid-erythroid axis. It is able to eradicate an expanded erythron but, if used alone, is not likely to be sufficiently immunosuppressive to permit sustained allogeneic engraftment.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     Cyclophosphamide",
"    </a>",
"    provides adequate immunosuppression to permit allogeneic engraftment. The combination of oral busulfan (16",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    and cyclophosphamide (200",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    has been the most widely used non-radiation-containing preparative regimen used for HCT. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/34/25130?source=see_link\">",
"     \"Preparative regimens for hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Experience in the use of \"chemotherapy-only\" transplant regimens for the treatment of malignancy has been pivotal in developing regimens appropriate for the treatment of thalassemia. The combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/10/10408?source=see_link\">",
"     busulfan",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    (BU 14",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    and CY 200",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    given over four days) can both eradicate the expanded thalassemic erythron and permit sustained allogeneic engraftment [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25880/abstract/12\">",
"     12",
"    </a>",
"    ]. A lower cyclophosphamide dose (120 to 160",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    is used in high risk patients because of their higher transplant-related mortality.",
"   </p>",
"   <p>",
"    Pharmacokinetic parameters of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/10/10408?source=see_link\">",
"     busulfan",
"    </a>",
"    have been assessed in thalassemia patients: mean absorption half time = 26 &plusmn; 17 minutes, average steady-state serum concentration = 478 &plusmn; 266",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    mean elimination half time = 1.9 &plusmn; 0.9 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25880/abstract/13\">",
"     13",
"    </a>",
"    ]. A large study from India demonstrated a significant relationship between busulfan pharmacokinetics and the risk of thalassemia recurrence following HCT [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25880/abstract/14\">",
"     14",
"    </a>",
"    ]. In this study a busulfan first dose trough level (Cmin 1) less than 150",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    was a significant risk factor for graft failure.",
"   </p>",
"   <p>",
"    Intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/10/10408?source=see_link\">",
"     busulfan",
"    </a>",
"    has an effect comparable to oral busulfan, along with superior stability, and may be able to substitute for oral busulfan in the conditioning regimen in patients with thalassemia [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25880/abstract/15\">",
"     15",
"    </a>",
"    ]. Prospective studies of the busulfan derivative intravenous treosulfan will determine whether this agent will be able to replace oral busulfan [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25880/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Graft-versus-host disease prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with beta thalassemia, there is no need for a graft-versus-leukemia effect and there is no evidence for graft-versus-thalassemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/58/16298?source=see_link\">",
"     \"Immunotherapy for the prevention and treatment of relapse following hematopoietic cell transplantation\"",
"    </a>",
"    .) This should be kept in mind in choosing immunosuppressive prophylaxis and treatment.",
"   </p>",
"   <p>",
"    We use",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    for graft-versus-host disease (GVHD) prophylaxis along with a \"short",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    \" regimen consisting of methotrexate (10",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on days 1, 3, and 6 after transplantation). Cyclosporine is continued for one year after transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25880/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Infectious disease prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the risk of blood borne infections from prior transfusions, thalassemia patients do not have an increased risk of infectious diseases when compared with other patients undergoing HCT. In our experience, no specific infection has been associated with iron overload or its severity. A low incidence of cytomegalovirus infection and associated mortality has been encountered in very young patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25880/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    During the course of transplantation, patients receive standard intravenous antibiotic prophylaxis:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Third generation cephalosporin intravenously from day -1 to neutrophil recovery to",
"      <span class=\"nowrap\">",
"       &gt;500/microL",
"      </span>",
"     </li>",
"     <li>",
"      An aminoglycoside (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/16/34056?source=see_link\">",
"       amikacin",
"      </a>",
"      15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      intravenously) from day -1 to neutrophil recovery to",
"      <span class=\"nowrap\">",
"       &gt;500/microL",
"      </span>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"       Acyclovir",
"      </a>",
"      &mdash; 15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day intravenously form day -7 to day +21",
"     </li>",
"     <li>",
"      Intravenous polyspecific immune globulin &mdash; 500",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      on day -1 and 250",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      intravenously on days +8 and +22.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Cytomegalovirus (CMV) infection is monitored weekly via early CMV antigen detection (phosphoprotein pp65) or CMV DNA by the polymerase chain reaction, starting on day + 14, independent of the initial CMV status of the donor or recipient. In case of positivity, preemptive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    is given.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Liver complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite prior liver damage due to iron overload or viral hepatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25880/abstract/19\">",
"     19",
"    </a>",
"    ], hepatic venoocclusive disease has not been a major problem after HCT in patients with beta thalassemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/4/40009?source=see_link\">",
"     \"Pathogenesis and clinical features of hepatic sinusoidal obstruction syndrome (veno-occlusive disease) following hematopoietic cell transplantation\"",
"    </a>",
"    .) On the other hand, marrow transplantation can acutely aggravate the course of iron-induced liver failure. Thus, the differential diagnosis of hyperbilirubinemia must include hepatic failure, particularly in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25880/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Cardiac complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Impaired cardiac function secondary to iron overload can lead to fluid accumulation after HCT. However, in our experience, heart failure is a rare cause of mortality, being the major cause of death in only one patient in over 1000 consecutive transplants.",
"   </p>",
"   <p>",
"    A particular complication encountered in transplanting thalassemia patients is cardiac tamponade, occurring in 1.4 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25880/abstract/21\">",
"     21",
"    </a>",
"    ]. It is characterized by the sudden onset of hypotension or cardiac arrest due to rapid fluid accumulation in the pericardial space, without concurrent myocardial disease [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25880/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. The fluid is a sterile, colorless transudate. Tamponade may be an early complication occurring immediately after",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    infusion or as late as day +62 after transplant. Treatment consists of emergency pericardiocentesis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19273?source=see_link\">",
"     \"Cardiac tamponade\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     GRAFT REJECTION AND THALASSEMIA RECURRENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a variable percentage of cases, the patient rejects the graft after marrow transplantation. Rejection can be followed by persistent aplasia, which is relatively rare and can be reversed only by a second transplant, or by return of the thalassemic state.",
"   </p>",
"   <p>",
"    The incidence of recurrent thalassemia varies with the conditioning regimen and the general condition of the patient. With the standard conditioning regimen (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/10/10408?source=see_link\">",
"     busulfan",
"    </a>",
"    14",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    200",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    in children, recurrent thalassemia occurred in 7 percent of class 1 patients, 4 percent of class 2 patients, and 13 percent of class 3 patients (",
"    <a class=\"graphic graphic_table graphicRef61453 \" href=\"UTD.htm?28/20/29003\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25880/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. However, when the dose of cyclophosphamide was decreased to 120 to 160",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    in class 3, the incidence of recurrence rose significantly to 35 percent (",
"    <a class=\"graphic graphic_table graphicRef61453 \" href=\"UTD.htm?28/20/29003\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25880/abstract/24\">",
"     24",
"    </a>",
"    ]. The importance of cyclophosphamide dose was probably related to a higher number of persistent host cells at lower doses (see",
"    <a class=\"local\" href=\"#H17\">",
"     'Transient mixed chimerism'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Adults had a much lower incidence of recurrence (4 percent) than children. The latest recurrence of thalassemia developed 30 months after HCT. There were no recurrences two years or later after transplant (",
"    <a class=\"graphic graphic_table graphicRef68788 \" href=\"UTD.htm?10/59/11195\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    By analogy to the behavior of malignant tissue, it might be supposed that a largely expanded hematopoietic tissue mass would be difficult to eradicate and therefore more likely to recur after transplantation. However, leukemic relapse is characterized by the reappearance of leukemia in the presence of a persistent immune system of donor origin. In contrast, the return of thalassemia usually occurs in the context of a return of host-type immune reconstitution. This event has aspects of both rejection and relapse.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18716002\">",
"    <span class=\"h2\">",
"     Use of antithymocyte globulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Using a myeloablative preparative regimen that included only",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/10/10408?source=see_link\">",
"     busulfan",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , we have noted graft",
"    <span class=\"nowrap\">",
"     failure/thalassemia",
"    </span>",
"    recurrence rates of 7 and 4 percent in children of pretransplant risk classes 1 and 2, respectively, receiving transplants from matched sibling donors (",
"    <a class=\"graphic graphic_table graphicRef61453 \" href=\"UTD.htm?28/20/29003\">",
"     table 2",
"    </a>",
"    ). However, graft failure rates have been higher than this in several centers outside of Italy, especially in their early experience with this treatment modality in children with beta thalassemia [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25880/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of centers have been employing antithymocyte globulin (ATG) as part of their preparative regimen in an attempt to reduce graft failure rates [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25880/abstract/25-28\">",
"     25-28",
"    </a>",
"    ]. However, no randomized trials have been performed to date in order to substantiate this potential benefit of ATG. Accordingly, we have reserved ATG only for use in high-risk settings (eg, class 3 children, adults, unrelated donors, second transplants) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25880/abstract/20,29,30\">",
"     20,29,30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Second transplant",
"    </span>",
"    &nbsp;&mdash;&nbsp;After recurrence of thalassemia, a second transplant can be proposed to patients starting at least two years after the first transplant. However, second transplants are associated with higher rates of rejection and mortality. Through May 1999, 21 second transplants were performed in Pesaro; the probability of cure of thalassemia was 29 percent in this group [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25880/abstract/31\">",
"     31",
"    </a>",
"    ]. Another limited series with 16 patients has been reported with improved results (79 percent overall survival) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25880/abstract/29\">",
"     29",
"    </a>",
"    ]. However, due to limited experience, a second transplant is not routinely recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     MIXED CHIMERIC STATE",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the field of HCT, mixed chimerism is defined as the concurrent presence of donor and recipient hematopoietic cells. Several methods have been used to assess mixed chimerism after hematopoietic cell transplantation, including determination of the variable number of tandem repeats (VNTR) by restriction fragment length polymorphism (RFLP) analysis, polymerase chain reaction (PCR), and, if applicable, fluorescence in situ hybridization (FISH) for the Y chromosome [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25880/abstract/32,33\">",
"     32,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Engraftment status was routinely analyzed in the bone marrow at one, two, six, and 12 months after HCT. In a prospective study, mixed chimerism was observed in 28 percent of patients within the first two months after the transplant [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25880/abstract/34\">",
"     34",
"    </a>",
"    ]. By the second year after the transplant:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      43 percent of the chimeric patients evolved to complete engraftment (ie, residual host cells were no longer detectable)",
"     </li>",
"     <li>",
"      35 percent showed a progressive loss of donor-engrafted cells and had recurrence of thalassemia",
"     </li>",
"     <li>",
"      22 percent (12 percent of all survivors) had persistent mixed chimerism",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    After the second year, the chimeric state remained stable in all patients in long follow-up. During the same period of observation, no patient who had complete engraftment (ie, 100 percent donor cells) at the second month of follow-up subsequently developed graft failure or recurrence of thalassemia. On the basis of these findings, we have defined two conditions:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Transient mixed chimerism (in the first 24 months after transplant)",
"     </li>",
"     <li>",
"      Persistent mixed chimerism (after 24 months of follow-up)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Transient mixed chimerism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transient chimerism is a dynamic condition limited to the first two years after HCT. One risk factor is the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    dose used in the conditioning regimen, with mixed chimerism being less frequent at the full dose of 200",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    than at lower doses [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25880/abstract/35,36\">",
"     35,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although many factors can determine the evolution of mixed chimerism, the number of residual host cells is an important factor determining transplant outcome. The rate of recurrence of thalassemia was 95 percent for transient chimerism with residual host cells &gt;25 percent, 20 percent for transient chimerism with residual host cells &lt;25 percent, and zero percent for complete engraftment at the second month following HCT. Similar results have been obtained by others [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25880/abstract/37\">",
"     37",
"    </a>",
"    ]. A kinetic analysis of the mixed chimera state with different implications has been reported when cord blood is used for transplantation in thalassemic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25880/abstract/1,38\">",
"     1,38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Persistent mixed chimerism",
"    </span>",
"    &nbsp;&mdash;&nbsp;After the second year of follow up, the persistently chimeric patients were submitted to yearly assessment of chimerism status for 2 to 11 years. Although the percentage of donor-engrafted cells was variable (30 to 90 percent), all patients survived in a state of persistent mixed chimerism with a stable hemoglobin concentration between 10 and 13",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25880/abstract/33\">",
"     33",
"    </a>",
"    ]. The patients were in excellent clinical condition and transfusion-free.",
"   </p>",
"   <p>",
"    Mixed chimerism was present in bone marrow at the same level as in the peripheral blood, with the exception of one patient in whom there were 25 percent donor cells in the bone marrow, but approximately 70 percent donor cells in the peripheral blood [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25880/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In some of these patients with mixed chimerism, there were a large number of recipient myeloid and erythroid progenitor cells (as demonstrated by PCR-VNTR analyses of the DNA extracted from single plucked BFU-E and CFU-GM colonies). Thus, a relatively low number of donor erythroid progenitors (down to 30 percent of the total BFU-E) carrying \"normal\" hemoglobin genes is able to produce large numbers of red cells with a sufficient amount of hemoglobin to avoid the need for transfusion.",
"   </p>",
"   <p>",
"    The presence of &ldquo;split&rdquo; chimerism between mature erythrocytes and their progenitors has been demonstrated in patients with persistent mixed chimerism [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25880/abstract/39\">",
"     39",
"    </a>",
"    ]. In these patients red cells in the peripheral blood were predominantly from the donor while the proportions of erythroid precursors (BFU-E) and nucleated red cells of donor and host origin in the bone marrow were roughly equivalent. This observation confirms that limited stem cell engraftment (up to 20 percent) is able to provide a sufficient amount of normal hemoglobin. Moreover, the small component of normal donor-derived erythropoiesis is able to inhibit, through unknown mechanisms, expansion of the ineffective host-derived thalassemic erythropoiesis, along with its well-known associated clinical consequences.",
"   </p>",
"   <p>",
"    Therefore, contrary to what was commonly believed, complete donor hematopoiesis is not essential for sustained engraftment and the prevention of recurrent thalassemia [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25880/abstract/33\">",
"     33",
"    </a>",
"    ]. Two factors appear to contribute to this phenomenon:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      T cell repertoire analysis of chimeric patients revealed the presence of expanded T cell clonotypes that could be responsible of the induction of",
"      <span class=\"nowrap\">",
"       donor/recipient",
"      </span>",
"      tolerance, as well as allowing a normal immune status [",
"      <a class=\"abstract\" href=\"UTD.htm?25/17/25880/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Selective survival of the nonthalassemic red cells",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Regardless of the mechanism, correction of anemia by relatively low degrees of mixed chimerism after HCT provides the rationale for the development of alternative approaches. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Minimally-ablative preparative regimens to obtain partial engraftment but avoiding or significantly diminishing transplant-related morbidity and mortality; this may be particularly important in adults with advanced disease.",
"     </li>",
"     <li>",
"      A gene therapy program, since complete eradication of the thalassemic marrow is not necessary for clinical control of the disease",
"     </li>",
"     <li>",
"      A program of in utero transplantation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10051481\">",
"    <span class=\"h1\">",
"     EVALUATION FOLLOWING TRANSPLANTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation and care of the thalassemic patient post-transplantation are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/36/43591?source=see_link\">",
"     \"Long-term management of the thalassemic patient after hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15928688\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with homozygous beta thalassemia require chronic blood transfusions which cause iron overload that is ultimately fatal if not continuously treated with iron chelation. Currently, hematopoietic cell transplantation (HCT) is the only available curative therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/39/7802?source=see_link\">",
"     \"Treatment of beta thalassemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/25/5529?source=see_link\">",
"     \"Efficacy of hematopoietic cell transplantation in beta thalassemia major\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pretransplant evaluation includes assessment of the patient's risk group, an important determinant of outcome after HCT (",
"      <a class=\"graphic graphic_table graphicRef67387 \" href=\"UTD.htm?17/2/17451\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef61453 \" href=\"UTD.htm?28/20/29003\">",
"       table 2",
"      </a>",
"      ). This includes evaluation of the liver and spleen, heart, and endocrine organs. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Evaluation before transplantation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Transplant-related issues include donor selection, transplant conditioning regimen, prophylaxis against infection and graft-versus-host disease, and potential for hepatic and cardiac complications. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Issues related to transplantation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Post-transplant issues include graft failure with recurrence of thalassemia or presence of the chimeric state (ie, the concurrent presence of donor and recipient hematopoietic cells). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Graft rejection and thalassemia recurrence'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Mixed chimeric state'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25880/abstract/1\">",
"      Angelucci E. Hematopoietic stem cell transplantation in thalassemia. Hematology Am Soc Hematol Educ Program 2010; 2010:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25880/abstract/2\">",
"      Angelucci E, Giovagnoni A, Valeri G, et al. Limitations of magnetic resonance imaging in measurement of hepatic iron. Blood 1997; 90:4736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25880/abstract/3\">",
"      Brittenham GM, Farrell DE, Harris JW, et al. Magnetic-susceptibility measurement of human iron stores. N Engl J Med 1982; 307:1671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25880/abstract/4\">",
"      Angelucci E, Baronciani D, Lucarelli G, et al. Needle liver biopsy in thalassaemia: analyses of diagnostic accuracy and safety in 1184 consecutive biopsies. Br J Haematol 1995; 89:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25880/abstract/5\">",
"      Di Marco V, Bronte F, Cabibi D, et al. Iron overload does not effect the quantification of fibrosis by liver stiffness measurement (abstract). Hepatology 2007; 46:839A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25880/abstract/6\">",
"      Pugh RN, Murray-Lyon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25880/abstract/7\">",
"      Desmet VJ, Gerber M, Hoofnagle JH, et al. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994; 19:1513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25880/abstract/8\">",
"      Mathews V, George B, Lakshmi KM, et al. Impact of pretransplant splenectomy on patients with beta-thalassemia major undergoing a matched-related allogeneic stem cell transplantation. Pediatr Transplant 2009; 13:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25880/abstract/9\">",
"      Bhatia M, Cairo MS. Splenectomy or no splenectomy prior to allogeneic stem-cell transplantation in patients with severe thalassemia: this is the question. Pediatr Transplant 2009; 13:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25880/abstract/10\">",
"      Mariotti E, Agostini A, Angelucci E, et al. Reduced Left Ventricular Contractile Reserve Identified by Low Dose Dobutamine Echocardiography as an Early Marker of Cardiac Involvement in Asymptomatic Patients with Thalassemia Major. Echocardiography 1996; 13:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25880/abstract/11\">",
"      Giorgiani G, Bozzola M, Locatelli F, et al. Role of busulfan and total body irradiation on growth of prepubertal children receiving bone marrow transplantation and results of treatment with recombinant human growth hormone. Blood 1995; 86:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25880/abstract/12\">",
"      Lucarelli G, Galimberti M, Giardini C, et al. Bone marrow transplantation in thalassemia. The experience of Pesaro. Ann N Y Acad Sci 1998; 850:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25880/abstract/13\">",
"      Pawlowska AB, Blazar BR, Angelucci E, et al. Relationship of plasma pharmacokinetics of high-dose oral busulfan to the outcome of allogeneic bone marrow transplantation in children with thalassemia. Bone Marrow Transplant 1997; 20:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25880/abstract/14\">",
"      Chandy M, Balasubramanian P, Ramachandran SV, et al. Randomized trial of two different conditioning regimens for bone marrow transplantation in thalassemia--the role of busulfan pharmacokinetics in determining outcome. Bone Marrow Transplant 2005; 36:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25880/abstract/15\">",
"      Gaziev J, Nguyen L, Puozzo C, et al. Novel pharmacokinetic behavior of intravenous busulfan in children with thalassemia undergoing hematopoietic stem cell transplantation: a prospective evaluation of pharmacokinetic and pharmacodynamic profile with therapeutic drug monitoring. Blood 2010; 115:4597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25880/abstract/16\">",
"      Casper J, Knauf W, Kiefer T, et al. Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation. Blood 2004; 103:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25880/abstract/17\">",
"      Bernardo ME, Zecca M, Piras E, et al. Treosulfan-based conditioning regimen for allogeneic haematopoietic stem cell transplantation in patients with thalassaemia major. Br J Haematol 2008; 143:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25880/abstract/18\">",
"      Baronciani D, Angelucci E, Lucarelli G, et al. Cytomegalovirus infections in thalassemic patients after bone marrow transplantation. Bone Marrow Transplant 1990; 5:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25880/abstract/19\">",
"      Erer B, Angelucci E, Lucarelli G, et al. Hepatitis C virus infection in thalassemia patients undergoing allogeneic bone marrow transplantation. Bone Marrow Transplant 1994; 14:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25880/abstract/20\">",
"      Lucarelli G, Clift RA, Galimberti M, et al. Bone marrow transplantation in adult thalassemic patients. Blood 1999; 93:1164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25880/abstract/21\">",
"      Angelucci E, Mariotti E, Lucarelli G, et al. Sudden cardiac tamponade after chemotherapy for marrow transplantation in thalassaemia. Lancet 1992; 339:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25880/abstract/22\">",
"      Angelucci E, Mariotti E, Lucarelli G, et al. Cardiac tamponade in thalassemia. Bone Marrow Transplant 1994; 13:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25880/abstract/23\">",
"      Lucarelli G, Galimberti M, Polchi P, et al. Bone marrow transplantation in patients with thalassemia. N Engl J Med 1990; 322:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25880/abstract/24\">",
"      Lucarelli G, Clift RA, Galimberti M, et al. Marrow transplantation for patients with thalassemia: results in class 3 patients. Blood 1996; 87:2082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25880/abstract/25\">",
"      Galambrun C, Pondarr&eacute; C, Bertrand Y, et al. French multicenter 22-year experience in stem cell transplantation for beta-thalassemia major: lessons and future directions. Biol Blood Marrow Transplant 2013; 19:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25880/abstract/26\">",
"      Goussetis E, Peristeri I, Kitra V, et al. HLA-matched sibling stem cell transplantation in children with &beta;-thalassemia with anti-thymocyte globulin as part of the preparative regimen: the Greek experience. Bone Marrow Transplant 2012; 47:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25880/abstract/27\">",
"      Ramzi M, Nourani H, Zakerinia M, et al. Results of hematopoietic stem cell transplant in Shiraz: 15 years experience in southern Iran. Exp Clin Transplant 2010; 8:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25880/abstract/28\">",
"      Sabloff M, Chandy M, Wang Z, et al. HLA-matched sibling bone marrow transplantation for &beta;-thalassemia major. Blood 2011; 117:1745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25880/abstract/29\">",
"      Gaziev J, Sodani P, Lucarelli G, et al. Second hematopoietic SCT in patients with thalassemia recurrence following rejection of the first graft. Bone Marrow Transplant 2008; 42:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25880/abstract/30\">",
"      Sodani P, Gaziev D, Polchi P, et al. New approach for bone marrow transplantation in patients with class 3 thalassemia aged younger than 17 years. Blood 2004; 104:1201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25880/abstract/31\">",
"      Gaziev D, Polchi P, Lucarelli G, et al. Second marrow transplants for graft failure in patients with thalassemia. Bone Marrow Transplant 1999; 24:1299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25880/abstract/32\">",
"      Nesci S, Manna M, Andreani M, et al. Mixed chimerism in thalassemic patients after bone marrow transplantation. Bone Marrow Transplant 1992; 10:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25880/abstract/33\">",
"      Andreani M, Manna M, Lucarelli G, et al. Persistence of mixed chimerism in patients transplanted for the treatment of thalassemia. Blood 1996; 87:3494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25880/abstract/34\">",
"      Andreani M, Nesci S, Lucarelli G, et al. Long-term survival of ex-thalassemic patients with persistent mixed chimerism after bone marrow transplantation. Bone Marrow Transplant 2000; 25:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25880/abstract/35\">",
"      Manna M, Nesci S, Andreani M, et al. Influence of the conditioning regimens on the incidence of mixed chimerism in thalassemic transplanted patients. Bone Marrow Transplant 1993; 12 Suppl 1:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25880/abstract/36\">",
"      Nesci S, Manna M, Lucarelli G, et al. Mixed chimerism after bone marrow transplantation in thalassemia. Ann N Y Acad Sci 1998; 850:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25880/abstract/37\">",
"      Amrolia PJ, Vulliamy T, Vassiliou G, et al. Analysis of chimaerism in thalassaemic children undergoing stem cell transplantation. Br J Haematol 2001; 114:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25880/abstract/38\">",
"      Lisini D, Zecca M, Giorgiani G, et al. Donor/recipient mixed chimerism does not predict graft failure in children with beta-thalassemia given an allogeneic cord blood transplant from an HLA-identical sibling. Haematologica 2008; 93:1859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25880/abstract/39\">",
"      Andreani M, Testi M, Gaziev J, et al. Quantitatively different red cell/nucleated cell chimerism in patients with long-term, persistent hematopoietic mixed chimerism after bone marrow transplantation for thalassemia major or sickle cell disease. Haematologica 2011; 96:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25880/abstract/40\">",
"      Battaglia M, Andreani M, Manna M, et al. Coexistence of two functioning T-cell repertoires in healthy ex-thalassemics bearing a persistent mixed chimerism years after bone marrow transplantation. Blood 1999; 94:3432.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3551 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-8C269A7C77-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_17_25880=[""].join("\n");
var outline_f25_17_25880=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15928688\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EVALUATION BEFORE TRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Liver",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Spleen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Heart",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Endocrine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Hematology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      ISSUES RELATED TO TRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Conditioning regimen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Graft-versus-host disease prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Infectious disease prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Liver complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Cardiac complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      GRAFT REJECTION AND THALASSEMIA RECURRENCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18716002\">",
"      Use of antithymocyte globulin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Second transplant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      MIXED CHIMERIC STATE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Transient mixed chimerism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Persistent mixed chimerism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10051481\">",
"      EVALUATION FOLLOWING TRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15928688\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/3551\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/3551|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/40/18056\" title=\"picture 1A\">",
"      Iron overload liver Light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/53/3927\" title=\"picture 1B\">",
"      Iron overload liver Perls",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/3551|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/2/17451\" title=\"table 1\">",
"      Pre BMT risk class in beta thal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/20/29003\" title=\"table 2\">",
"      Outcome after BMT in beta thal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/21/8540\" title=\"table 3\">",
"      Child Pugh classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/59/11195\" title=\"table 4\">",
"      GVHD prophylaxis in beta thal",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19273?source=related_link\">",
"      Cardiac tamponade",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/60/28617?source=related_link\">",
"      Clinical manifestations of hereditary hemochromatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/25/5529?source=related_link\">",
"      Efficacy of hematopoietic cell transplantation in beta thalassemia major",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/58/16298?source=related_link\">",
"      Immunotherapy for the prevention and treatment of relapse following hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/36/43591?source=related_link\">",
"      Long-term management of the thalassemic patient after hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/59/30650?source=related_link\">",
"      Noninvasive assessment of hepatic fibrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/4/40009?source=related_link\">",
"      Pathogenesis and clinical features of hepatic sinusoidal obstruction syndrome (veno-occlusive disease) following hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21705?source=related_link\">",
"      Pneumococcal vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/34/25130?source=related_link\">",
"      Preparative regimens for hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41849?source=related_link\">",
"      Screening for and diagnosis of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/18/42279?source=related_link\">",
"      Serologic diagnosis of hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38682?source=related_link\">",
"      Sources of hematopoietic stem cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/39/7802?source=related_link\">",
"      Treatment of beta thalassemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_17_25881="Cardinal movements labor";
var content_f25_17_25881=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F52812&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F52812&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Principal movements in the mechanism of labor and delivery, left occiput anterior position",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 362px; height: 527px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Pritchard, JA, MacDonald, PC. Williams Obstetrics, 16th Edition, Appleton-Century-Crofts, New York 1980. Copyright &copy;1980 McGraw Hill. p. 397.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_17_25881=[""].join("\n");
var outline_f25_17_25881=null;
var title_f25_17_25882="Molecular genetics of acute myeloid leukemia";
var content_f25_17_25882=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Molecular genetics of acute myeloid leukemia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/17/25882/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/17/25882/contributors\">",
"     Wendy Stock, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/17/25882/contributors\">",
"     Michael J Thirman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/17/25882/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/17/25882/contributors\">",
"     Richard A Larson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/17/25882/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/17/25882/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/17/25882/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute myeloid leukemia (AML) develops as the consequence of a series of genetic changes in a hematopoietic precursor cell. These changes alter normal hematopoietic growth and differentiation, resulting in an accumulation of large numbers of abnormal, immature myeloid cells in the bone marrow and peripheral blood. These cells are capable of dividing and proliferating, but cannot differentiate into mature hematopoietic cells (ie, neutrophils).",
"   </p>",
"   <p>",
"    Similar to other malignancies, the genetic alterations in AML include mutation of oncogenes as well as the loss of tumor suppressor genes. In contrast to most solid tumors, many hematologic malignancies are associated with a single characteristic cytogenetic abnormality (eg, the Philadelphia chromosome [t(9;22)] in chronic myeloid leukemia and t(15;17) in acute promyelocytic leukemia).",
"   </p>",
"   <p>",
"    Advances in the identification of recurring chromosomal abnormalities and translocations have provided major insight into the pathobiology of AML. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28536?source=see_link\">",
"     \"Cytogenetic and molecular genetic diagnostic tools\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Specific cytogenetic abnormalities identified by karyotype analysis have considerable prognostic significance for patients with AML and affect treatment planning. Abnormalities in certain genes (eg, mutations in FLT3, nucleophosmin, KIT) as well as gene expression profiles confer prognostic significance in adult patients with AML. Even those patients without obvious abnormalities detected by karyotypic analysis or gene expression profiles have acquired copy number alterations that may help to identify genes important for the pathogenesis of AML [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/55/36730?source=see_link\">",
"     \"Prognosis of acute myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The focus of this topic review will be on the various molecular genetic events involved in the pathogenesis of AML. More general discussions of genetic events in hematologic malignancies are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/5/41049?source=see_link\">",
"     \"Genetic abnormalities in hematologic and lymphoid malignancies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/21/6489?source=see_link\">",
"     \"General aspects of cytogenetic analysis in hematologic malignancies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H91419583\">",
"    <span class=\"h1\">",
"     GENE MUTATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24780405\">",
"    <span class=\"h2\">",
"     Mutations affecting DNA methylation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gene mutations that affect DNA methylation have been identified in patients with AML. These mutations may result in the expression of genes that are normally silenced or in the silencing of genes that are normally expressed.",
"   </p>",
"   <p>",
"    DNA methylation involves the addition of a methyl group to cytosine or adenine residues within DNA and results in impaired gene transcription. Hypermethylated genes are not expressed (ie, silenced). As such, DNA methylation provides an epigenetic method for controlling gene expression. This process is an essential component of normal development and cell differentiation. However, alterations in DNA methylation may result in impaired cell differentiation, such as that seen in AML.",
"   </p>",
"   <p>",
"    DNA methyltransferases (DNMT) are a key family of enzymes responsible for maintaining DNA methylation in mammalian cells. Without DNMTs, cells would gradually lose methyl groups from their DNA leading to the expression of genes that are usually silenced. A DNA sequencing study of 281 patients with de novo AML discovered mutations in DNMT3A in 22 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/3\">",
"     3",
"    </a>",
"    ]. When compared with patients without such mutations, patients with DNMT3A mutations had a significantly shorter median survival (12 versus 41 months). Another DNA sequencing study suggested that the rate of DNMT3A mutations varies by AML subtype, with the highest rate (20 percent) seen among cases of acute monocytic leukemia (ie, FAB M5) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The TET (ten-eleven translocation) family of genes encode proteins that have enzymatic activity that is thought to play a role in the epigenetic control of DNA expression through demethylation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/5\">",
"     5",
"    </a>",
"    ]. Somatic mutations in TET2 occur in approximately 15 percent of myeloid cancers, including AML [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/6\">",
"     6",
"    </a>",
"    ]. Mutations of TET2 result in increased methylation and silencing of genes that are normally expressed. In mice, ablation of TET2 alters the function of hematopoietic stem cells and induces myeloid leukemia [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Tumor suppressor genes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormalities within several of the known tumor suppressor genes have been well characterized in myeloid leukemias:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Progression to blast crisis in CML is commonly associated with p53 mutations [",
"      <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/8-10\">",
"       8-10",
"      </a>",
"      ]. In AML, only about 7 percent of cases have known p53 mutations at the time of diagnosis, although the incidence of p53 abnormalities may be slightly higher in patients with AML evolving from a prior myelodysplastic syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/11\">",
"       11",
"      </a>",
"      ], in cases with 11q23 translocations [",
"      <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/12,13\">",
"       12,13",
"      </a>",
"      ], and in cases with complex karyotype [",
"      <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/14\">",
"       14",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/33/40474?source=see_link&amp;anchor=H7228199#H7228199\">",
"       \"Cellular and molecular biology of chronic myeloid leukemia\", section on 'Progression to acute phase CML'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The Wilms tumor suppressor gene (WT-1) is overexpressed in the leukemic blasts of approximately 75 percent of cases of newly diagnosed AML [",
"      <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/15,16\">",
"       15,16",
"      </a>",
"      ]. The WT-1 gene, located in the 11p13 region, encodes a transcription factor normally expressed in a time and tissue-dependent manner mainly in kidneys and gonads [",
"      <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/17,18\">",
"       17,18",
"      </a>",
"      ], although it is also expressed in normal",
"      <span class=\"nowrap\">",
"       CD34+/CD38-",
"      </span>",
"      hematopoietic progenitor cells [",
"      <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/19\">",
"       19",
"      </a>",
"      ]. In AML, high WT-1 levels at diagnosis have, in some studies, been shown to correlate with lower remission rates and overall survival [",
"      <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/15,16\">",
"       15,16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with neurofibromatosis and mutations of the NF-1 tumor suppressor gene have a high rate of developing neoplasms, including progression of MDS into AML [",
"      <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/20,21\">",
"       20,21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The p16INK4 gene is a critical cell cycle regulatory gene which is frequently deleted in acute lymphoblastic leukemia but only very rarely in AML [",
"      <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Overexpression of the B cell",
"      <span class=\"nowrap\">",
"       leukemia/lymphoma",
"      </span>",
"      2 (BCL-2) gene occurs in a wide variety of lymphoid malignancies as a result of t(14;18) which juxtaposes BCL-2 with the Ig heavy chain locus. BCL-2 overexpression in AML has been reported only rarely; however, in one study of patients with newly diagnosed AML, a multivariate analysis showed that BCL-2 overexpression was associated with lower complete remission rates and a significantly shorter survival [",
"      <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/23\">",
"       23",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/46/25322?source=see_link&amp;anchor=H16#H16\">",
"       \"Clinical manifestations, pathologic features, diagnosis, and prognosis of follicular lymphoma\", section on 'Cytogenetics'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Certain genetic alterations are specific to AML. These include the loss of the long arms of chromosomes 5, 7, and 20, which occur commonly in therapy-related AML and AML associated with prior MDS, and are associated with a poor prognosis (",
"      <a class=\"graphic graphic_table graphicRef60295 \" href=\"UTD.htm?17/14/17643\">",
"       table 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/24-26\">",
"       24-26",
"      </a>",
"      ]. The involved genes have not yet been cloned, although novel tumor genes are likely to be identified at these loci.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     RAS oncogene mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mutations of three closely related RAS (H-RAS, K-RAS, N-RAS) proto-oncogenes occur in human malignancies. Each of these genes encodes a structurally similar 21 kilodalton protein which localizes to the inner plasma membrane and plays an important role in signal transduction [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/27\">",
"     27",
"    </a>",
"    ]. Specific point mutations occur characteristically in each of the three genes, although no consistent karyotypic abnormalities have been associated with RAS mutation and activation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mutations of RAS have been identified in approximately 25 percent of cases of AML [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/28,29\">",
"     28,29",
"    </a>",
"    ], and are observed with higher frequency in MDS (35 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. The majority of the mutations in AML and MDS are in the N-RAS gene; K-RAS and H-RAS mutations occur less frequently. In both AML and MDS, RAS mutations have been reported more frequently in cases with a monocytic morphology (eg, FAB M4 and chronic myelomonocytic leukemia) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/32\">",
"     32",
"    </a>",
"    ]. An association between AML in patients with a variety of occupational exposures and RAS mutations has also been observed [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The significance of RAS mutations in AML remains unclear. RAS mutations have been reported at diagnosis, but not at relapse in some AML cases [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/34\">",
"     34",
"    </a>",
"    ]. Conversely, RAS mutations have been acquired at the time of relapse or disease progression [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/32,35\">",
"     32,35",
"    </a>",
"    ]. However, the presence of RAS mutations has been associated with improved survival [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/29\">",
"     29",
"    </a>",
"    ], possibly related to a lower leukemic cell burden at presentation, or an increased sensitivity to chemotherapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CHROMOSOMAL TRANSLOCATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chromosomal translocations are common in AML. They can affect the cell by one of two mechanisms [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/37\">",
"     37",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Juxtaposition of an intact transcription unit from one chromosome to an enhancer element from a gene on another chromosome. As an example, in t(14;18), the BCL-2 gene translocates into the immunoglobulin heavy chain (IgH) locus, leading to the inappropriate expression of a normal BCL-2 gene product. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/46/25322?source=see_link&amp;anchor=H16#H16\">",
"       \"Clinical manifestations, pathologic features, diagnosis, and prognosis of follicular lymphoma\", section on 'Cytogenetics'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Formation of chimeric fusion proteins. Chromosomal translocations can disrupt two different genes within their coding sequences, leading to the creation of a chimeric protein. For example, the t(9;22) in CML results in the formation of a chimeric",
"      <span class=\"nowrap\">",
"       BCR/ABL",
"      </span>",
"      fusion protein. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/33/40474?source=see_link&amp;anchor=H8#H8\">",
"       \"Cellular and molecular biology of chronic myeloid leukemia\", section on 'The BCR-ABL1 fusion protein'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In AML, the vast majority of chromosomal translocations result in the generation of chimeric fusion genes that are never expressed in wild type cells. Characterization of the genes involved in these translocations has led to the elucidation of many transcriptional regulatory pathways in hematopoiesis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/38-41\">",
"     38-41",
"    </a>",
"    ]. For example, the alpha and beta subunits of core-binding factor have been found to be required for definitive hematopoiesis; both of these subunits are involved in chromosomal translocations in AML.",
"   </p>",
"   <p>",
"    The involvement in chromosomal translocations of several other classes of transcription factors has been recognized, including those that contain zinc fingers, ring fingers, leucine zippers, basic helix-loop-helix motifs, and ETS domains [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/42\">",
"     42",
"    </a>",
"    ]. Homologues of these transcription factors have been well characterized in animal models such as Drosophila, including the AML1 homologue \"runt\", and the MLL homologue \"trithorax\". Several other proteins with well-defined hematopoietic functions have been recognized at chromosomal translocation breakpoints, including retinoic acid receptors and Hox genes. However, structural proteins that do not appear to be specific to myeloid cells have also been identified, including members of the nuclear pore complex and nucleolar phosphoproteins. The functions of many other genes involved in chromosomal translocations remain to be elucidated.",
"   </p>",
"   <p>",
"    Many genes are capable of participating in translocations that involve multiple alternative partner genes. For example, the MLL gene forms chimeric fusion genes with at least 18 known partners and an additional 10 to 15 that have not yet been cloned. These alternative fusions provide an opportunity to contrast the contributions of each component of the fusion gene and thus dissect the motifs within these genes that are critical to tumorigenesis. The fusion of nucleophosmin (NPM) to ALK is a frequent recurring abnormality in anaplastic large cell lymphoma. NPM also fuses to RARa in acute promyelocytic leukemia and to MLF1 in other subtypes of AML. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/47/25337?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of anaplastic large cell lymphoma, ALK positive\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the following sections, we will discuss specific fusion genes in the context of families of fusions that share common features. The recurring involvement of the same genes in multiple different translocations has two important implications:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The genomic structure of these genes may contain \"hot spots\" for chromosomal breakage.",
"     </li>",
"     <li>",
"      Disruption of the pathways regulated by these genes results in malignant transformation, rather than cell death.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Involvement of core binding factor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chromosomal aberrations in AML commonly involve subunits of the core-binding factor (CBF) group of transcription factors [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. Members of the CBF group function as heterodimeric complexes regulating diverse target genes involved in tissue differentiation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/45\">",
"     45",
"    </a>",
"    ]. CBF factors consist of an alpha subunit that binds DNA, and a beta subunit that does not bind DNA directly but enhances binding by the alpha subunit. Three alpha subunits have been identified:",
"    <span class=\"nowrap\">",
"     AML1/CBFA2/PEBP2aB,",
"    </span>",
"    <span class=\"nowrap\">",
"     AML2/CBFA3/PEBP2aC,",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     AML3/CBFA1/PEBP2aA.",
"    </span>",
"    In view of its pivotal role in both normal hematopoiesis and leukemia, we will refer to",
"    <span class=\"nowrap\">",
"     AML1/CBFA2/PEBP2aB",
"    </span>",
"    as AML1. As will be described below, both the alpha and beta subunits of CBF are disrupted in common subtypes of AML and form chimeric fusion transcripts with genes not normally expressed in hematopoietic cells [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In hematopoietic cells, CBF binding sites have been observed in genes specific to both the lymphoid lineage (T-cell receptor enhancers, CD3e, and LCK proximal promoter) and myeloid lineage (M-CSF receptor, IL-3, GM-CSF, myeloperoxidase, granzyme B, and neutrophil elastase) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/38,47\">",
"     38,47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The AML1 subunit has been studied extensively in hematopoiesis. Multiple splice variants have been identified; AML1B contains the runt domain and a transactivation domain, whereas AML1A lacks the transactivation domain [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/48\">",
"     48",
"    </a>",
"    ]. Disruption of AML1 by gene targeting in embryonic stem cells results in embryonic lethality due to an absence of fetal liver hematopoiesis and to central nervous system hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/49\">",
"     49",
"    </a>",
"    ]. The knockout of CBFbeta results in a similar phenotype, indicating that both the alpha and beta subunits of CBF are essential for definitive but not primitive hematopoiesis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/43,50\">",
"     43,50",
"    </a>",
"    ]. The role of CBF in later stages of hematopoietic differentiation is not yet clear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Familial platelet disorder with predisposition to AML",
"    </span>",
"    &nbsp;&mdash;&nbsp;Familial platelet disorder with predisposition to myelodysplasia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    acute myeloid leukemia",
"    <span class=\"nowrap\">",
"     (FPD/AML)",
"    </span>",
"    is an autosomal dominant disorder characterized by qualitative and quantitative platelet defects, a decrement in megakaryocyte colony formation, and an approximately 37 percent incidence of acute myeloid leukemia (AML) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/51-54\">",
"     51-54",
"    </a>",
"    ]. In six pedigrees with this disorder along with evidence of linkage to markers on chromosome 21q, nonsense mutations or intragenic deletion of one allele of AML1 (also called RUNX1 or CBFA2) were seen in four and missense mutations in two [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a three-generation family with",
"    <span class=\"nowrap\">",
"     FDP/AML,",
"    </span>",
"    a missense mutation in the Runt DNA-binding domain of the CBFA2 gene",
"    <span class=\"nowrap\">",
"     (RUNX1/AML1)",
"    </span>",
"    was found [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/56\">",
"     56",
"    </a>",
"    ], three residues away from the one noted above [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/55\">",
"     55",
"    </a>",
"    ]. One family member with AML underwent successful transplantation with cells from his HLA-matched sister. Subsequently, he developed MDS progressing to AML, with malignant cells of donor origin. Concurrently, the donor, who had the same genetic defect as her brother, developed MDS progressing to AML, and was successfully transplanted using a matched unrelated donor.",
"   </p>",
"   <p>",
"    Since some family members with this disorder may have normal platelet counts",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    function, it would seem prudent to screen young patients with",
"    <span class=\"nowrap\">",
"     MDS/AML",
"    </span>",
"    for RUNX1 mutations before considering them for sibling hematopoietic cell transplantation, in order to detect those whose family members might also be at risk for developing",
"    <span class=\"nowrap\">",
"     MDS/AML",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Of interest, a mouse model heterozygous for the RUNX1 null mutation, considered to be genetically comparable to human",
"    <span class=\"nowrap\">",
"     FPD/AML",
"    </span>",
"    patients, was not associated with the development of leukemia, suggesting the requirement for additional genetic or epigenetic alterations. Insertion of a RUNX1 mutation into BXH2 mice, which develop myeloid leukemia following random integration of a murine retrovirus, resulted in a shortening of the latency period for the development of leukemia [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Other causes of familial AML",
"    </span>",
"    &nbsp;&mdash;&nbsp;A family has been described in which three members were affected by AML associated with an identical mutation in CEBPA, the gene that encodes CCAAT enhancer binding protein alpha, a granulocytic differentiation factor [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/52,58\">",
"     52,58",
"    </a>",
"    ]. Acquired mutations of this gene have also been described in sporadic, nonfamilial AML [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     AML and MDS and myeloproliferative neoplasms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Point mutations of AML1 (RUNX1) have been infrequently reported in de novo AML or MDS, at incidences varying from zero to 12 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/60-62\">",
"     60-62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study of 132 patients with primary MDS, the presence of these mutations was associated with a significantly higher frequency of chromosome",
"      <span class=\"nowrap\">",
"       7/7q",
"      </span>",
"      deletion as well as shortened overall survival [",
"      <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/62\">",
"       62",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study from Japan, such mutations were found in 6 of 13 Atom-bomb survivors who developed MDS, and in 5 of 13 patients who developed",
"      <span class=\"nowrap\">",
"       AML/MDS",
"      </span>",
"      following alkylating agent treatment with or without supplementary radiation [",
"      <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/60\">",
"       60",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study of 18 patients with myeloproliferative neoplasms (MPNs: polycythemia vera, essential thrombocythemia, primary myelofibrosis) who progressed from chronic phase (CP) to acute leukemia, point mutations of AML1 were detected in five at the time of leukemic transformation but not while they were still in CP [",
"      <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/63\">",
"       63",
"      </a>",
"      ]. Consistent with the leukemogenic potential of AML1 point mutations, when the AML1D171N mutation was transduced into CD34+ cells from patients in the CP of MPNs, this resulted in proliferation of immature myeloid cells, enhanced self-renewal capacity, and proliferation of primitive progenitors.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Cooperating mutations in AML",
"    </span>",
"    &nbsp;&mdash;&nbsp;The t(8;21)(q22;q22) is associated with the FAB-M2 subtype of AML (",
"    <a class=\"graphic graphic_picture graphicRef80200 \" href=\"UTD.htm?13/33/13842\">",
"     picture 1",
"    </a>",
"    ), and was the first recurring chromosomal translocation in AML to be identified [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/64\">",
"     64",
"    </a>",
"    ]. The clinical and morphologic correlations of this subtype of AML include a high propensity to develop extramedullary collections of leukemic blasts (granulocytic sarcomas). Another hallmark of t(8;21) leukemia is the relatively high rate of responsiveness to chemotherapy, particularly to high dose Ara-C [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Leukemic myeloblasts in this subtype have a characteristic morphology, including prominent Auer rods, large cytoplasmic granules, and vacuoles. When the characteristic histologic appearance of these cells is identified in AML blasts that do not contain a t(8;21), the",
"    <span class=\"nowrap\">",
"     AML1/ETO",
"    </span>",
"    fusion can be identified by polymerase chain reaction techniques, indicating that the formation of the molecular fusion is responsible for the morphologic and clinical features of this subtype of AML [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In t(8;21), AML1 fuses to the ETO gene on the der(8) chromosome to form a chimeric fusion protein [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/67\">",
"     67",
"    </a>",
"    ]. The chimeric protein fuses the N-terminus of AML1 including the runt homology domain, but excluding the transactivation domain, to nearly all of ETO. The",
"    <span class=\"nowrap\">",
"     AML1/ETO",
"    </span>",
"    fusion gene has pleiotropic effects in reporter gene assays as it appears to repress several AML1 target genes [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/68,69\">",
"     68,69",
"    </a>",
"    ], but to activate the M-CSF receptor promoter [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/70,71\">",
"     70,71",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/44/6858?source=see_link&amp;anchor=H9#H9\">",
"     \"Regulation of myelopoiesis\", section on 'Transcription factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    By engineering a \"knock-in\" of the ETO cDNA into the murine AML1 locus, a mouse model of t(8;21) has been generated. These mice exhibit a mid-gestation embryonic lethality with an absence of fetal liver hematopoiesis and central nervous system hemorrhage that is similar to the AML1 and CBFb knockout mice [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/72\">",
"     72",
"    </a>",
"    ]. This result suggests that the",
"    <span class=\"nowrap\">",
"     AML1/ETO",
"    </span>",
"    fusion gene can act as a dominant negative of normal AML1 function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     AML1/EAP, MDS1, EVI1 in t(3;21)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The t(3;21)(q26;q22) has been observed in the blast crisis of CML and therapy-related MDS and AML [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/73\">",
"     73",
"    </a>",
"    ]. The AML1 gene has been found to be rearranged in these cases, leading to the formation of alternative fusion transcripts involving the EAP, MDS1, and EVI1 genes [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/74,75\">",
"     74,75",
"    </a>",
"    ]. These fusions contain the N-terminus of AML1, including its runt homology domain, fused to alternative C-terminal sequences derived from partner genes on 3q26. EVI1 is also involved in the inv(3)(q21q26) and t(3;3)(q21;q26) in AML [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/76\">",
"     76",
"    </a>",
"    ]. However the consequence of these chromosome aberrations is the inappropriate expression of the EVI1 transcription unit, whereas in the t(3;21), EVI1 participates in the formation of a fusion gene with AML1. Sequences from another transcription unit, MDS1, are also observed in t(3;21). Although mapping data indicate that the exons of MDS1 and EVI1 are separated by several hundred kilobases, they have been found to be spliced together not only in cases with the t(3;21), but also in normal tissues. The AML1-MDS1 fusion has been shown to transform the Rat1A fibroblast cell line [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     TEL(ETV6) and AML1 in t(12;21)",
"    </span>",
"    &nbsp;&mdash;&nbsp;AML1 is involved in the t(12;21)(p13;q22), resulting in the generation of a chimeric protein with the TEL(ETV6) gene [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/78\">",
"     78",
"    </a>",
"    ]. The t(12;21) fusion is observed commonly in pre B-cell ALL. The TEL(ETV6) gene was originally cloned from a t(5;12)(q33;p13) in CMML where it fuses to the PDGFRb gene and it has also been found to fuse to the ABL gene in t(12;22) in AML [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/79,80\">",
"     79,80",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     CBFb/MYH11 in inv(16) and t(16;16)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The inv(16)(p13q22) and t(16;16)(p13;q22) are observed primarily in the FAB-M4Eo subtype of AML (",
"    <a class=\"graphic graphic_picture graphicRef71045 \" href=\"UTD.htm?18/62/19424\">",
"     picture 2",
"    </a>",
"    ). These patients, similar to those with the t(8;21), have a relatively good prognosis and a high likelihood to respond to high dose Ara-C- containing chemotherapy regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/81\">",
"     81",
"    </a>",
"    ]. The beta subunit of CBF located at 16q22 is disrupted as a result of either the chromosomal inversion or translocation, leading to the formation of a fusion transcript with the gene for smooth muscle myosin heavy chain, MYH11, located at 16p13 [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A mouse model for inv(16) leukemia has been generated through a \"knock-in\" approach [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/83\">",
"     83",
"    </a>",
"    ]. These mice exhibit a mid-gestation embryonic lethality, an absence of fetal liver hematopoiesis, and central nervous system hemorrhage. The chimeric mice generated from embryonic stem cells containing the",
"    <span class=\"nowrap\">",
"     CBFb/MYH11",
"    </span>",
"    did not develop leukemia. However, there was no contribution by the embryonic stem cells to hematopoiesis. Thus, a striking similarity has been observed for the knockouts of AML1 and CBFb, as well as the",
"    <span class=\"nowrap\">",
"     AML1/ETO",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     CBFb/MYH11",
"    </span>",
"    \"knock-in\" mice. This convergence in phenotypes from seemingly disparate gene targeting experiments indicates that AML1 and CBFbeta are both essential for definitive hematopoiesis, and that both are required for the function of the CBF heterodimer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Involvement of the MLL locus",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mixed lineage leukemia (MLL) gene, located at chromosome band 11q23, is frequently involved in translocations in both AML and ALL and is associated with a poor prognosis. Translocations involving 11q23 are the single most common cytogenetic abnormality in infants with acute leukemia, regardless of phenotype, and occur in approximately 70 to 80 percent of cases. 11q23 translocations are also observed frequently in therapy-related leukemias in patients who have previously been treated with drugs that inhibit topoisomerase II, especially the epipodophyllotoxins. This syndrome differs from the therapy-related myeloid leukemias that occur in patients exposed to alkylating agents, which are commonly associated with deletional events on chromosomes 5 and 7. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/42/39594?source=see_link&amp;anchor=H13#H13\">",
"     \"Cytogenetics in acute myeloid leukemia\", section on 'Therapy-related myeloid neoplasms (t-MDS/t-AML)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Partner chromosomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are at least 51 different partner chromosomes involved in recurring reciprocal 11q23 translocations [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/84-87\">",
"     84-87",
"    </a>",
"    ]. This exceeds the number of known translocations affecting the immunoglobulin loci, suggesting that the 11q23 breakpoint region may contain genomically unstable sequences leading to recombination events.",
"   </p>",
"   <p>",
"    The chromosomal partners in 11q23 translocations are usually lineage specific. In AML, t(9;11)(p22;q23), t(11;19)(q23;p13.1) and t(6;11)(q27;q23) are the most common, and in ALL, t(4;11)(q21;q23) and t(11;19)(q23;p13.3) occur predominantly. Translocations at 11q23 have been observed in several FAB subtypes, but occur most commonly in the FAB-M4 myelomonocytic and FAB-M5 monoblastic leukemias [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/85,88,89\">",
"     85,88,89",
"    </a>",
"    ]. Myeloid leukemias with 11q23 translocations often coexpress lymphoid markers, whereas 11q23 lymphoid leukemias often express myeloid or monocytoid markers in addition to B-cell markers. These observations suggest that rearrangements of MLL may affect a pluripotent stem cell or, alternatively, that disruption of MLL may affect a common differentiation pathway shared by lymphoid and myeloid progenitor cells.",
"   </p>",
"   <p>",
"    In a subset of patients with AML and either trisomy 11 or a normal karyotype, a unique pattern of rearrangement of the MLL gene has been observed. As in the translocations that affect MLL, a fusion occurs involving one of the exons in its breakpoint cluster region. However, rather than fusing to a partner gene, the fusion is to 5' sequences from MLL itself [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/90,91\">",
"     90,91",
"    </a>",
"    ]. These partial duplications of MLL appear to occur primarily in older patients, and are infrequent in childhood and therapy-related leukemias. The morphology of the leukemias also differs in that the partial duplication patients usually are classified as FAB M1 or M2, rather than the M4 or M5 typically observed in cases with MLL translocations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Mechanism of action",
"    </span>",
"    &nbsp;&mdash;&nbsp;The MLL gene was isolated from the 11q23 breakpoint by several groups and has been referred to by other names including HRX, ALL-1, and Htrx [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/92-95\">",
"     92-95",
"    </a>",
"    ]. MLL encodes a large protein, with a predicted molecular weight of 430 kD, that contains two regions of extensive homology to the Drosophila trithorax gene [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/96\">",
"     96",
"    </a>",
"    ]. This protein is a histone methyltransferase that plays a critical role in normal embryonic development and hematopoiesis, mainly regulating transcription via epigenetic mechanisms [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/97\">",
"     97",
"    </a>",
"    ]. Translocations involving MLL result in MLL fusion proteins that induce the aberrant expression of downstream mediators, including HOXA proteins and myeloid ecotropic viral integration site 1 (MEIS1) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/98-101\">",
"     98-101",
"    </a>",
"    ]. Both menin and lens epithelium-derived growth factor (LEDGF) appear to be key elements in the interaction between the MLL histone methyltransferase and the nonmethylated CpG DNA to which it binds [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/102\">",
"     102",
"    </a>",
"    ]. The MLL fusion proteins appear to deregulate the RNA polymerase II elongation factor thereby allowing for transcriptional elongation free of the usual checkpoints [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/103,104\">",
"     103,104",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several animal and cell culture models of MLL leukemia have been developed. To create an MLL-AF9 \"knock-in\" mouse model of 11q233 leukemias, the AF9 cDNA was targeted into the murine MLL locus by homologous recombination in embryonic stem cells [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/105\">",
"     105",
"    </a>",
"    ]. The chimeric mice generated from these embryonic stem cells all developed acute myeloid leukemia within 6 to 9 months. Retroviral bone marrow infection has been used to express another 11q23 fusion gene, MLL-ENL, in hematopoietic cells [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/106\">",
"     106",
"    </a>",
"    ]. After transplantation of MLL-ENL transduced bone marrow, recipient mice developed acute myeloid leukemia. Retroviral",
"    <span class=\"nowrap\">",
"     transduction/transplantation",
"    </span>",
"    models using several MLL partner genes have been established [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/107,108\">",
"     107,108",
"    </a>",
"    ]. These models have established the proof of principle that the expression of MLL fusion genes contributes to leukemogenesis, and that the MLL partner genes are essential to this process [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/86,109\">",
"     86,109",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H91419960\">",
"    <span class=\"h2\">",
"     Involvement of the retinoic acid receptor",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cytogenetic hallmark of acute promyelocytic leukemia (APL, FAB-M3), is a translocation involving the retinoic acid receptor-alpha (RARa) locus on chromosome 17 [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/110\">",
"     110",
"    </a>",
"    ]. The vast majority of these cases contain a t(15;17)(q22;q11-12), although several variant translocations involving RARa have been identified. These include PLZF in t(11;17)(q23;q11-12) and NPM in t(5;17)(q35;q11-12). These translocations lead to the formation of chimeric fusion transcripts from each of the derivative chromosomes. The pathobiology of APL is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/35/17976?source=see_link\">",
"     \"Molecular biology of acute promyelocytic leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Other fusion genes in AML",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     DEK/CAN in t(6;9) and SET-CAN",
"    </span>",
"    &nbsp;&mdash;&nbsp;The t(6;9)(p23;q34) is observed usually in the M2 and M4 subtypes of AML, but has also been identified in the M1 subtype and MDS. This translocation is associated with a younger age and a poor prognosis. The CAN gene was also found to be rearranged in a patient with acute undifferentiated leukemia and a normal karyotype. A chimeric transcript containing an alternative CAN partner gene, named SET, was isolated in this case [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/111\">",
"     111",
"    </a>",
"    ]. The SET gene was also localized to 9q34, suggesting that this fusion results from an inversion of chromosome 9 or a cryptic translocation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     TLS/FUS/ERG and t(16;21)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The t(16;21)(p11;q22) has been observed in several FAB subtypes of AML, blast crisis of CML, and MDS [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/112,113\">",
"     112,113",
"    </a>",
"    ]. In this translocation, the",
"    <span class=\"nowrap\">",
"     TLS/FUS",
"    </span>",
"    gene at 16p11 fuses to the ERG gene at 21q22 to generate a chimeric protein. Both",
"    <span class=\"nowrap\">",
"     TLS/FUS",
"    </span>",
"    and ERG are involved in chromosomal translocations with other partner genes in sarcomas [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/114-116\">",
"     114-116",
"    </a>",
"    ]. The striking similarity of the",
"    <span class=\"nowrap\">",
"     TLS/FUS/ERG",
"    </span>",
"    fusion gene in AML to the sarcoma associated fusion genes suggests that disruption of a common differentiation pathway may lead to transformation in multiple cell types.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     NPM/MLF1 in t(3;5)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The t(3;5)(q25.1;q35) has been observed in several FAB subtypes of AML, especially in M6 and MDS [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/117\">",
"     117",
"    </a>",
"    ]. The NPM gene at 5q35 was found to be rearranged in patients with this translocation, resulting in the formation of a fusion gene with the MLF1 (myelodysplasia-myeloid leukemia factor 1) gene at 3q25.1. Previously, the involvement of NPM had been identified in the t(2;5)(p23;q35) in anaplastic large cell lymphoma, where it fuses to the ALK gene [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/118\">",
"     118",
"    </a>",
"    ]. NPM is also rearranged in the t(5;17)(q35;q21) in APL, where it fuses to RARa.",
"   </p>",
"   <p>",
"    The MLF1 protein normally localizes to the cytoplasm, whereas in leukemia cells with t(3;5), the NPM-MLF1 fusion protein is observed primarily in nucleoli. The involvement of NPM in chromosome translocations involving three different partner genes, resulting in three discrete types of hematologic malignancies, suggests that NPM plays an important role in normal hematopoietic differentiation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     EVI1 in inv(3) and t(3;3)",
"    </span>",
"    &nbsp;&mdash;&nbsp;EVI1 (Ecotropic Virus Integration 1) was initially cloned as the gene at a common site of retroviral integration in murine myeloid leukemia. The EVI1 gene is normally expressed only in kidney and ovary. In mice, the retroviral integration at the murine Evi-1 locus leads to its inappropriate expression in hematopoietic cells. A similar phenomenon occurs in human AML with inv(3)(q21q26) and t(3;3)(q21;q26) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/119\">",
"     119",
"    </a>",
"    ]. As a result of these cytogenetic aberrations, the EVI1 gene is juxtaposed to enhancer elements of the Ribophorin gene leading to inappropriate activation of the EVI1 transcription unit, a component of the complex fusion transcripts that involve the AML1 gene in t(3;21).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     MOZ/CBP in t(8;16)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The t(8;16)(p11;p13) has been recognized in the M4 and M5 subtypes of AML that exhibit a characteristic erythrophagocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/120\">",
"     120",
"    </a>",
"    ]. This translocation has been observed in both de novo and therapy-related leukemias. Several variant translocations involving 8p11 have been recognized in monocytic leukemias with erythrophagocytosis, but the genes involved in these translocations have not yet been cloned. CBP is also involved with a fusion to MLL in t(11;16)(q23;p13) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/121\">",
"     121",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     CALM/AF10 in t(10;11)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The t(10;11)(p13;q14) has been recognized in both ALL and AML. In AML, the cases are primarily of the M0 and M1 subtypes [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/122\">",
"     122",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     NUP98/HOXA9 in t(7;11) and NUP98/DDX10 in inv(11)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The t(7;11)(p15;p15) is observed in the M2 and M4 subtypes of AML and CML. The HOXA9 gene was identified at the 7p15 breakpoint and the NUP98 gene at the 11p15 break [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/123\">",
"     123",
"    </a>",
"    ]. In BXH-2 mice, the Hoxa9 gene has been implicated in myeloid leukemia as a result of its activation via proviral insertion. NUP98 has been found to be involved in the inv(11)(p15q22) in AML. This cytogenetic aberration has been recognized in both de novo and therapy-related MDS and AML.",
"   </p>",
"   <p>",
"    In addition, a t(10;11)(q23;p15) translocation involving the NUP98 gene at 11q15 and the hematopoietically expressed homeobox gene (HHEX) at 10q23 has been implicated in AML [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/124\">",
"     124",
"    </a>",
"    ]. Other cases of AML have been identified that demonstrate a NUP98-MLL fusion protein with low levels of HOXA gene expression [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     ANIMAL MODELS OF AML",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several examples of naturally occurring animal models of AML that are caused by retroviruses via one of two mechanisms. The retrovirus can:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Encode for an oncogene that leads to transformation,",
"      <strong>",
"       or",
"      </strong>",
"     </li>",
"     <li>",
"      It can inappropriately activate the expression of a gene adjacent to its integration site.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The characterization of these processes has revealed a number of genes critical to normal hematopoiesis and myeloid leukemias. These animal models have also demonstrated the multistage nature of the evolution of leukemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Myb leukemias",
"    </span>",
"    &nbsp;&mdash;&nbsp;The v-Myb gene is involved in two different avian retroviruses that induce leukemia in chickens. The v-Myb gene was originally identified as the transforming element in the avian myeloblastosis virus (AMV). In the E26 retrovirus, a fusion gene consisting of gag, v-Myb, and v-Ets has been identified [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/125\">",
"     125",
"    </a>",
"    ]. The formation of a fusion gene containing sequences of two transcription factors is reminiscent of the fusions that result from chromosomal translocations in human acute leukemia. In chickens, AMV causes monoblastic leukemias and transforms only myelomonocytic cells in vitro, whereas E26 induces erythroleukemias, but is capable of transforming myeloid, erythroid, and megakaryocytic lineages in vitro [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/126\">",
"     126",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    C-Myb, the normal cellular counterpart of v-Myb, is essential for definitive hematopoiesis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/127\">",
"     127",
"    </a>",
"    ]. Promonocytic leukemias have been induced by priming mice with intraperitoneal injections of pristane, followed by infection with the Moloney murine leukemia virus [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/128\">",
"     128",
"    </a>",
"    ]. The majority of the mice that develop leukemia have undergone insertional mutagenesis at the c-Myb locus [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/129\">",
"     129",
"    </a>",
"    ]. The role of pristane is unknown, but it appears to promote leukemogenesis by mediating an inflammatory response. At this time, there is no evidence for the rearrangement of c-Myb in human leukemias.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Friend virus/SFFV erythroleukemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The erythroleukemia induced by infection with the Friend viral complex is the culmination of a three step process that has become a paradigm for multistage neoplastic transformation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/130\">",
"     130",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Polyclonal proliferation induced by a cytokine",
"     </li>",
"     <li>",
"      Inactivation of a tumor suppressor gene",
"     </li>",
"     <li>",
"      Oncogenic activation of a gene involved in normal hematopoiesis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Infection of susceptible mice with the Friend murine leukemia",
"    <span class=\"nowrap\">",
"     virus/spleen",
"    </span>",
"    focus-forming virus (SFFV) complex induces a polyclonal proliferation of erythroid progenitors within 48 hours. This expansion of erythroid precursors is secondary to the SFFV envelope gene product, the gp55 glycoprotein, which has the capacity to bind and activate the erythropoietin receptor. These erythroid cells are not transformed, and retain the ability to undergo terminal differentiation.",
"   </p>",
"   <p>",
"    After approximately two weeks, a clonal population of transformed erythroblasts emerges which depends on two additional independent genetic events. One of these is the inactivation of the p53 tumor suppressor gene by deletion, mutation, or proviral insertion [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/131,132\">",
"     131,132",
"    </a>",
"    ]. In addition, the activation of either the PU.1 gene, also referred to as Spi-1 (SFFV proviral integration 1), or the Fli-1 gene occur as a result of proviral integration adjacent to these loci [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/133,134\">",
"     133,134",
"    </a>",
"    ]. PU.1 and Fli-1 are members of the ETS family of transcription factors; PU.1 is essential for both myeloid and lymphoid development [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/135\">",
"     135",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     BXH-2 leukemias",
"    </span>",
"    &nbsp;&mdash;&nbsp;BXH-2 mice are derived from a cross of",
"    <span class=\"nowrap\">",
"     C57BL/6J",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     C3H/He",
"    </span>",
"    mice. Although the parental strains have a low incidence of leukemia, more than 95 percent of BXH-2 mice develop myeloid leukemia by one year of age, caused by expression of a horizontally transmitted Ecotropic murine leukemia virus [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/136\">",
"     136",
"    </a>",
"    ]. These retroviruses induce leukemia by insertional activation or mutation of proto-oncogenes adjacent to the viral integration site. One of the most frequent viral integration sites is Evi-2 (Ecotropic viral integration site 2), localized to a large intron within the Nf1 tumor suppressor gene [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/137\">",
"     137",
"    </a>",
"    ]. The consequence of this integration event is the disruption of the normal expression of Nf1 in the affected mice.",
"   </p>",
"   <p>",
"    In humans, the neurofibromatosis type I autosomal dominant disorder is caused by mutation of the NF1 gene [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/138\">",
"     138",
"    </a>",
"    ]. In addition to neurofibromas, patients have an increased risk of developing several types of solid tumors and malignant myeloid disorders, especially juvenile chronic myeloid leukemia (JCML) and the monosomy 7 syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/139\">",
"     139",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mice heterozygous for the Nf1 allele develop myeloid leukemia with loss of the wild type allele, indicating that Nf1 acts as a tumor suppressor gene [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/140\">",
"     140",
"    </a>",
"    ]. In JCML patients without neurofibromatosis, activating RAS mutations are frequently identified. The consequence of either the disruption of NF1 or the activation of RAS has been shown to be an inability to negatively regulate GM-CSF signaling in hematopoietic cells [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/141,142\">",
"     141,142",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because viral integration within the Nf1 gene has been observed in only 15 percent of BXH-2 mice, the identification of additional mutations within other genes associated with myeloid leukemias has been pursued. A proviral tagging approach has been used to identify additional viral integration sites that alter the expression of three genes, Hoxa7, Hoxa9, and Meis-1 [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/143,144\">",
"     143,144",
"    </a>",
"    ]. The HOXA9 gene is involved in t(7;11)(p15;p15) in AML, resulting in the formation of a fusion gene with NUP98. HOX gene overexpression has also been demonstrated in mice with acquired nucleophosmin mutations that result in the cytoplasmic dislocation of nucleophosmin (ie, NPM1c) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/17/25882/abstract/145\">",
"     145",
"    </a>",
"    ]. PBX1 is involved in t(1;19) in ALL, where it fuses to the E2A gene. This underscores a recurring theme of the involvement of similar families of genes in both human and spontaneous animal models of AML.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?33/30/34275?source=see_link\">",
"       \"Patient information: Acute myeloid leukemia (AML) treatment in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H91418851\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute myeloid leukemia (AML) develops as the consequence of a series of genetic changes in a hematopoietic precursor cell. These changes alter normal hematopoietic growth and differentiation, resulting in an accumulation of large numbers of abnormal, immature myeloid cells in the bone marrow and peripheral blood. These cells are capable of dividing and proliferating, but cannot differentiate normally into mature, fully functional hematopoietic cells. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cases of AML demonstrate mutations in oncogenes (eg, NRAS, FLT3) as well as the loss of tumor suppressor genes (eg, P53, WT1&mdash;Wilms tumor suppressor gene). (See",
"      <a class=\"local\" href=\"#H91419583\">",
"       'Gene mutations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In contrast to most solid tumors, many hematologic malignancies are associated with chromosomal translocations that result in the generation of chimeric fusion genes that are never expressed in wild type cells. Chromosomal aberrations in AML commonly involve transcription factors that regulate hematopoiesis. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Chromosomal translocations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The chromosomal aberrations t(8;21)(q22;q22) and the inv(16)(p13q22) in AML involve subunits of the core-binding factor (CBF) group of transcription factors. Members of the CBF group function as heterodimeric complexes regulating diverse target genes involved in tissue differentiation. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Involvement of core binding factor'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The mixed lineage leukemia (MLL) gene, located at chromosome band 11q23, is frequently involved in translocations in AML with different partner chromosomes. The MLL gene is a histone methyltransferase that plays a critical role in normal embryonic development and hematopoiesis, mainly regulating transcription via epigenetic mechanisms. Translocations involving MLL result in MLL fusion proteins that induce the aberrant expression of downstream mediators. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Involvement of the MLL locus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The cytogenetic hallmark of acute promyelocytic leukemia is a translocation involving the retinoic acid receptor-alpha (RARA) locus on chromosome 17. These translocations lead to the formation of chimeric fusion transcripts from each of the derivative chromosomes. The pathobiology of APL is discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/35/17976?source=see_link\">",
"       \"Molecular biology of acute promyelocytic leukemia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/1\">",
"      Walter MJ, Payton JE, Ries RE, et al. Acquired copy number alterations in adult acute myeloid leukemia genomes. Proc Natl Acad Sci U S A 2009; 106:12950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/2\">",
"      Radtke I, Mullighan CG, Ishii M, et al. Genomic analysis reveals few genetic alterations in pediatric acute myeloid leukemia. Proc Natl Acad Sci U S A 2009; 106:12944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/3\">",
"      Ley TJ, Ding L, Walter MJ, et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med 2010; 363:2424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/4\">",
"      Yan XJ, Xu J, Gu ZH, et al. Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nat Genet 2011; 43:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/5\">",
"      Ito S, D'Alessio AC, Taranova OV, et al. Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature 2010; 466:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/6\">",
"      Delhommeau F, Dupont S, Della Valle V, et al. Mutation in TET2 in myeloid cancers. N Engl J Med 2009; 360:2289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/7\">",
"      Li Z, Cai X, Cai CL, et al. Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. Blood 2011; 118:4509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/8\">",
"      Ahuja H, Bar-Eli M, Arlin Z, et al. The spectrum of molecular alterations in the evolution of chronic myelocytic leukemia. J Clin Invest 1991; 87:2042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/9\">",
"      Kelman Z, Prokocimer M, Peller S, et al. Rearrangements in the p53 gene in Philadelphia chromosome positive chronic myelogenous leukemia. Blood 1989; 74:2318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/10\">",
"      Mashal R, Shtalrid M, Talpaz M, et al. Rearrangement and expression of p53 in the chronic phase and blast crisis of chronic myelogenous leukemia. Blood 1990; 75:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/11\">",
"      Mori N, Hidai H, Yokota J, et al. Mutations of the p53 gene in myelodysplastic syndrome and overt leukemia. Leuk Res 1995; 19:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/12\">",
"      Lanza C, Gaidano G, Cimino G, et al. p53 gene inactivation in acute lymphoblastic leukemia of B cell lineage associates with chromosomal breakpoints at 11q23 and 8q24. Leukemia 1995; 9:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/13\">",
"      Lanza C, Gaidano G, Cimino G, et al. Distribution of TP53 mutations among acute leukemias with MLL rearrangements. Genes Chromosomes Cancer 1996; 15:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/14\">",
"      R&uuml;cker FG, Schlenk RF, Bullinger L, et al. TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. Blood 2012; 119:2114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/15\">",
"      Inoue K, Sugiyama H, Ogawa H, et al. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 1994; 84:3071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/16\">",
"      Bergmann L, Miething C, Maurer U, et al. High levels of Wilms' tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome. Blood 1997; 90:1217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/17\">",
"      Call KM, Glaser T, Ito CY, et al. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell 1990; 60:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/18\">",
"      Haber DA, Buckler AJ, Glaser T, et al. An internal deletion within an 11p13 zinc finger gene contributes to the development of Wilms' tumor. Cell 1990; 61:1257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/19\">",
"      Baird PN, Simmons PJ. Expression of the Wilms' tumor gene (WT1) in normal hemopoiesis. Exp Hematol 1997; 25:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/20\">",
"      Stiller CA, Chessells JM, Fitchett M. Neurofibromatosis and childhood leukaemia/lymphoma: a population-based UKCCSG study. Br J Cancer 1994; 70:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/21\">",
"      Shannon KM, O'Connell P, Martin GA, et al. Loss of the normal NF1 allele from the bone marrow of children with type 1 neurofibromatosis and malignant myeloid disorders. N Engl J Med 1994; 330:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/22\">",
"      Hirama T, Koeffler HP. Role of the cyclin-dependent kinase inhibitors in the development of cancer. Blood 1995; 86:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/23\">",
"      Campos L, Rouault JP, Sabido O, et al. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood 1993; 81:3091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/24\">",
"      Le Beau MM, Albain KS, Larson RA, et al. Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes no. 5 and 7. J Clin Oncol 1986; 4:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/25\">",
"      Pedersen-Bjergaard J, Philip P. Two different classes of therapy-related and de-novo acute myeloid leukemia? Cancer Genet Cytogenet 1991; 55:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/26\">",
"      Thirman MJ, Larson RA. Therapy-related myeloid leukemia. Hematol Oncol Clin North Am 1996; 10:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/27\">",
"      Zeleznik-Le NJ, Nucifora G, Rowley JD. The molecular biology of myeloproliferative disorders as revealed by chromosomal abnormalities. Semin Hematol 1995; 32:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/28\">",
"      Ahuja HG, Foti A, Bar-Eli M, Cline MJ. The pattern of mutational involvement of RAS genes in human hematologic malignancies determined by DNA amplification and direct sequencing. Blood 1990; 75:1684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/29\">",
"      Neubauer A, Dodge RK, George SL, et al. Prognostic importance of mutations in the ras proto-oncogenes in de novo acute myeloid leukemia. Blood 1994; 83:1603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/30\">",
"      Bartram CR. Molecular genetic aspects of myelodysplastic syndromes. Hematol Oncol Clin North Am 1992; 6:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/31\">",
"      Nakagawa T, Saitoh S, Imoto S, et al. Multiple point mutation of N-ras and K-ras oncogenes in myelodysplastic syndrome and acute myelogenous leukemia. Oncology 1992; 49:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/32\">",
"      Bos JL. ras oncogenes in human cancer: a review. Cancer Res 1989; 49:4682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/33\">",
"      Taylor JA, Sandler DP, Bloomfield CD, et al. ras oncogene activation and occupational exposures in acute myeloid leukemia. J Natl Cancer Inst 1992; 84:1626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/34\">",
"      L&uuml;bbert M, Mirro J Jr, Kitchingman G, et al. Prevalence of N-ras mutations in children with myelodysplastic syndromes and acute myeloid leukemia. Oncogene 1992; 7:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/35\">",
"      Paquette RL, Landaw EM, Pierre RV, et al. N-ras mutations are associated with poor prognosis and increased risk of leukemia in myelodysplastic syndrome. Blood 1993; 82:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/36\">",
"      Liu ET, Dodge R, Myer A, et al. De novo acute myeloid leukemias harboring ras mutations exhibit preferential sensitivity to dose intensive cytarabine as consolidation therapy. Blood 1995; 86:598a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/37\">",
"      Rabbitts TH. Chromosomal translocations in human cancer. Nature 1994; 372:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/38\">",
"      Tenen DG, Hromas R, Licht JD, Zhang DE. Transcription factors, normal myeloid development, and leukemia. Blood 1997; 90:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/39\">",
"      Sawyers CL. Molecular genetics of acute leukaemia. Lancet 1997; 349:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/40\">",
"      Shivdasani RA, Orkin SH. The transcriptional control of hematopoiesis. Blood 1996; 87:4025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/41\">",
"      Alcalay M, Meani N, Gelmetti V, et al. Acute myeloid leukemia fusion proteins deregulate genes involved in stem cell maintenance and DNA repair. J Clin Invest 2003; 112:1751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/42\">",
"      Nichols J, Nimer SD. Transcription factors, translocations, and leukemia. Blood 1992; 80:2953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/43\">",
"      Wang Q, Stacy T, Miller JD, et al. The CBFbeta subunit is essential for CBFalpha2 (AML1) function in vivo. Cell 1996; 87:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/44\">",
"      Marcucci G, Caligiuri MA, Bloomfield CD. Molecular and clinical advances in core binding factor primary acute myeloid leukemia: a paradigm for translational research in malignant hematology. Cancer Invest 2000; 18:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/45\">",
"      Rodan GA, Harada S. The missing bone. Cell 1997; 89:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/46\">",
"      Michaud J, Scott HS, Escher R. AML1 interconnected pathways of leukemogenesis. Cancer Invest 2003; 21:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/47\">",
"      Wang S, Wang Q, Crute BE, et al. Cloning and characterization of subunits of the T-cell receptor and murine leukemia virus enhancer core-binding factor. Mol Cell Biol 1993; 13:3324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/48\">",
"      Tanaka T, Tanaka K, Ogawa S, et al. An acute myeloid leukemia gene, AML1, regulates hemopoietic myeloid cell differentiation and transcriptional activation antagonistically by two alternative spliced forms. EMBO J 1995; 14:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/49\">",
"      Okuda T, van Deursen J, Hiebert SW, et al. AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell 1996; 84:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/50\">",
"      Sasaki K, Yagi H, Bronson RT, et al. Absence of fetal liver hematopoiesis in mice deficient in transcriptional coactivator core binding factor beta. Proc Natl Acad Sci U S A 1996; 93:12359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/51\">",
"      Heller PG, Glembotsky AC, Gandhi MJ, et al. Low Mpl receptor expression in a pedigree with familial platelet disorder with predisposition to acute myelogenous leukemia and a novel AML1 mutation. Blood 2005; 105:4664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/52\">",
"      Owen C, Barnett M, Fitzgibbon J. Familial myelodysplasia and acute myeloid leukaemia--a review. Br J Haematol 2008; 140:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/53\">",
"      Shinawi M, Erez A, Shardy DL, et al. Syndromic thrombocytopenia and predisposition to acute myelogenous leukemia caused by constitutional microdeletions on chromosome 21q. Blood 2008; 112:1042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/54\">",
"      Owen CJ, Toze CL, Koochin A, et al. Five new pedigrees with inherited RUNX1 mutations causing familial platelet disorder with propensity to myeloid malignancy. Blood 2008; 112:4639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/55\">",
"      Song WJ, Sullivan MG, Legare RD, et al. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet 1999; 23:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/56\">",
"      Buijs A, Poddighe P, van Wijk R, et al. A novel CBFA2 single-nucleotide mutation in familial platelet disorder with propensity to develop myeloid malignancies. Blood 2001; 98:2856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/57\">",
"      Yamashita N, Osato M, Huang L, et al. Haploinsufficiency of Runx1/AML1 promotes myeloid features and leukaemogenesis in BXH2 mice. Br J Haematol 2005; 131:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/58\">",
"      Smith ML, Cavenagh JD, Lister TA, Fitzgibbon J. Mutation of CEBPA in familial acute myeloid leukemia. N Engl J Med 2004; 351:2403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/59\">",
"      Pabst T, Mueller BU, Zhang P, et al. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia. Nat Genet 2001; 27:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/60\">",
"      Harada H, Harada Y, Tanaka H, et al. Implications of somatic mutations in the AML1 gene in radiation-associated and therapy-related myelodysplastic syndrome/acute myeloid leukemia. Blood 2003; 101:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/61\">",
"      Nakao M, Horiike S, Fukushima-Nakase Y, et al. Novel loss-of-function mutations of the haematopoiesis-related transcription factor, acute myeloid leukaemia 1/runt-related transcription factor 1, detected in acute myeloblastic leukaemia and myelodysplastic syndrome. Br J Haematol 2004; 125:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/62\">",
"      Chen CY, Lin LI, Tang JL, et al. RUNX1 gene mutation in primary myelodysplastic syndrome--the mutation can be detected early at diagnosis or acquired during disease progression and is associated with poor outcome. Br J Haematol 2007; 139:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/63\">",
"      Ding Y, Harada Y, Imagawa J, et al. AML1/RUNX1 point mutation possibly promotes leukemic transformation in myeloproliferative neoplasms. Blood 2009; 114:5201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/64\">",
"      Nucifora G, Rowley JD. AML1 and the 8;21 and 3;21 translocations in acute and chronic myeloid leukemia. Blood 1995; 86:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/65\">",
"      Bloomfield CD, Lawrence D, Arthur DC, et al. Curative impact of intensification with high-dose cytarabine (HiDAC) in acute myeloid leukemia (AML) varies by cytogenetic group. Blood 1994; 84:111a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/66\">",
"      Nucifora G, Dickstein JI, Torbenson V, et al. Correlation between cell morphology and expression of the AML1/ETO chimeric transcript in patients with acute myeloid leukemia without the t(8;21). Leukemia 1994; 8:1533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/67\">",
"      Erickson P, Gao J, Chang KS, et al. Identification of breakpoints in t(8;21) acute myelogenous leukemia and isolation of a fusion transcript, AML1/ETO, with similarity to Drosophila segmentation gene, runt. Blood 1992; 80:1825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/68\">",
"      Linggi B, M&uuml;ller-Tidow C, van de Locht L, et al. The t(8;21) fusion protein, AML1 ETO, specifically represses the transcription of the p14(ARF) tumor suppressor in acute myeloid leukemia. Nat Med 2002; 8:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/69\">",
"      Vangala RK, Heiss-Neumann MS, Rangatia JS, et al. The myeloid master regulator transcription factor PU.1 is inactivated by AML1-ETO in t(8;21) myeloid leukemia. Blood 2003; 101:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/70\">",
"      Rhoades KL, Hetherington CJ, Rowley JD, et al. Synergistic up-regulation of the myeloid-specific promoter for the macrophage colony-stimulating factor receptor by AML1 and the t(8;21) fusion protein may contribute to leukemogenesis. Proc Natl Acad Sci U S A 1996; 93:11895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/71\">",
"      Pabst T, Mueller BU, Harakawa N, et al. AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia. Nat Med 2001; 7:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/72\">",
"      Yergeau DA, Hetherington CJ, Wang Q, et al. Embryonic lethality and impairment of haematopoiesis in mice heterozygous for an AML1-ETO fusion gene. Nat Genet 1997; 15:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/73\">",
"      Yin CC, Cortes J, Barkoh B, et al. t(3;21)(q26;q22) in myeloid leukemia: an aggressive syndrome of blast transformation associated with hydroxyurea or antimetabolite therapy. Cancer 2006; 106:1730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/74\">",
"      Nucifora G, Birn DJ, Espinosa R 3rd, et al. Involvement of the AML1 gene in the t(3;21) in therapy-related leukemia and in chronic myeloid leukemia in blast crisis. Blood 1993; 81:2728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/75\">",
"      Mitani K, Ogawa S, Tanaka T, et al. Generation of the AML1-EVI-1 fusion gene in the t(3;21)(q26;q22) causes blastic crisis in chronic myelocytic leukemia. EMBO J 1994; 13:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/76\">",
"      Suzukawa K, Parganas E, Gajjar A, et al. Identification of a breakpoint cluster region 3' of the ribophorin I gene at 3q21 associated with the transcriptional activation of the EVI1 gene in acute myelogenous leukemias with inv(3)(q21q26). Blood 1994; 84:2681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/77\">",
"      Zent CS, Mathieu C, Claxton DF, et al. The chimeric genes AML1/MDS1 and AML1/EAP inhibit AML1B activation at the CSF1R promoter, but only AML1/MDS1 has tumor-promoter properties. Proc Natl Acad Sci U S A 1996; 93:1044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/78\">",
"      Golub TR, Barker GF, Bohlander SK, et al. Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia. Proc Natl Acad Sci U S A 1995; 92:4917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/79\">",
"      Golub TR, Barker GF, Lovett M, Gilliland DG. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 1994; 77:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/80\">",
"      Golub TR, Goga A, Barker GF, et al. Oligomerization of the ABL tyrosine kinase by the Ets protein TEL in human leukemia. Mol Cell Biol 1996; 16:4107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/81\">",
"      Bloomfield CD, Lawrence D, Byrd JC, et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 1998; 58:4173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/82\">",
"      Liu P, Tarl&eacute; SA, Hajra A, et al. Fusion between transcription factor CBF beta/PEBP2 beta and a myosin heavy chain in acute myeloid leukemia. Science 1993; 261:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/83\">",
"      Castilla LH, Wijmenga C, Wang Q, et al. Failure of embryonic hematopoiesis and lethal hemorrhages in mouse embryos heterozygous for a knocked-in leukemia gene CBFB-MYH11. Cell 1996; 87:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/84\">",
"      Thirman MJ, Gill HJ, Burnett RC, et al. Rearrangement of the MLL gene in acute lymphoblastic and acute myeloid leukemias with 11q23 chromosomal translocations. N Engl J Med 1993; 329:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/85\">",
"      Schoch C, Schnittger S, Klaus M, et al. AML with 11q23/MLL abnormalities as defined by the WHO classification: incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases. Blood 2003; 102:2395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/86\">",
"      Basecke J, Whelan JT, Griesinger F, Bertrand FE. The MLL partial tandem duplication in acute myeloid leukaemia. Br J Haematol 2006; 135:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/87\">",
"      Kaltenbach S, Soler G, Barin C, et al. NUP98-MLL fusion in human acute myeloblastic leukemia. Blood 2010; 116:2332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/88\">",
"      Blum W, Mr&oacute;zek K, Ruppert AS, et al. Adult de novo acute myeloid leukemia with t(6;11)(q27;q23): results from Cancer and Leukemia Group B Study 8461 and review of the literature. Cancer 2004; 101:1420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/89\">",
"      Jourdan E, Dastugue N. Adult de novo acute myeloid leukemia with t(6;11)(q27;q23): results from Cancer and Leukemia Group B Study 8461 and review of the literature. Cancer 2005; 103:1316; author reply 1316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/90\">",
"      Schichman SA, Canaani E, Croce CM. Self-fusion of the ALL1 gene. A new genetic mechanism for acute leukemia. JAMA 1995; 273:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/91\">",
"      Caligiuri MA, Strout MP, Schichman SA, et al. Partial tandem duplication of ALL1 as a recurrent molecular defect in acute myeloid leukemia with trisomy 11. Cancer Res 1996; 56:1418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/92\">",
"      Ziemin-van der Poel S, McCabe NR, Gill HJ, et al. Identification of a gene, MLL, that spans the breakpoint in 11q23 translocations associated with human leukemias. Proc Natl Acad Sci U S A 1991; 88:10735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/93\">",
"      Gu Y, Nakamura T, Alder H, et al. The t(4;11) chromosome translocation of human acute leukemias fuses the ALL-1 gene, related to Drosophila trithorax, to the AF-4 gene. Cell 1992; 71:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/94\">",
"      Tkachuk DC, Kohler S, Cleary ML. Involvement of a homolog of Drosophila trithorax by 11q23 chromosomal translocations in acute leukemias. Cell 1992; 71:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/95\">",
"      Djabali M, Selleri L, Parry P, et al. A trithorax-like gene is interrupted by chromosome 11q23 translocations in acute leukaemias. Nat Genet 1993; 4:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/96\">",
"      Mazo AM, Huang DH, Mozer BA, Dawid IB. The trithorax gene, a trans-acting regulator of the bithorax complex in Drosophila, encodes a protein with zinc-binding domains. Proc Natl Acad Sci U S A 1990; 87:2112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/97\">",
"      Liedtke M, Cleary ML. Therapeutic targeting of MLL. Blood 2009; 113:6061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/98\">",
"      Milne TA, Kim J, Wang GG, et al. Multiple interactions recruit MLL1 and MLL1 fusion proteins to the HOXA9 locus in leukemogenesis. Mol Cell 2010; 38:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/99\">",
"      Wang Z, Song J, Milne TA, et al. Pro isomerization in MLL1 PHD3-bromo cassette connects H3K4me readout to CyP33 and HDAC-mediated repression. Cell 2010; 141:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/100\">",
"      Muntean AG, Tan J, Sitwala K, et al. The PAF complex synergizes with MLL fusion proteins at HOX loci to promote leukemogenesis. Cancer Cell 2010; 17:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/101\">",
"      Wang Z, Iwasaki M, Ficara F, et al. GSK-3 promotes conditional association of CREB and its coactivators with MEIS1 to facilitate HOX-mediated transcription and oncogenesis. Cancer Cell 2010; 17:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/102\">",
"      Jin S, Zhao H, Yi Y, et al. c-Myb binds MLL through menin in human leukemia cells and is an important driver of MLL-associated leukemogenesis. J Clin Invest 2010; 120:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/103\">",
"      Mohan M, Lin C, Guest E, Shilatifard A. Licensed to elongate: a molecular mechanism for MLL-based leukaemogenesis. Nat Rev Cancer 2010; 10:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/104\">",
"      Lin C, Smith ER, Takahashi H, et al. AFF4, a component of the ELL/P-TEFb elongation complex and a shared subunit of MLL chimeras, can link transcription elongation to leukemia. Mol Cell 2010; 37:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/105\">",
"      Corral J, Lavenir I, Impey H, et al. An Mll-AF9 fusion gene made by homologous recombination causes acute leukemia in chimeric mice: a method to create fusion oncogenes. Cell 1996; 85:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/106\">",
"      Lavau C, Szilvassy SJ, Slany R, Cleary ML. Immortalization and leukemic transformation of a myelomonocytic precursor by retrovirally transduced HRX-ENL. EMBO J 1997; 16:4226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/107\">",
"      Lavau C, Luo RT, Du C, Thirman MJ. Retrovirus-mediated gene transfer of MLL-ELL transforms primary myeloid progenitors and causes acute myeloid leukemias in mice. Proc Natl Acad Sci U S A 2000; 97:10984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/108\">",
"      Luo RT, Lavau C, Du C, et al. The elongation domain of ELL is dispensable but its ELL-associated factor 1 interaction domain is essential for MLL-ELL-induced leukemogenesis. Mol Cell Biol 2001; 21:5678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/109\">",
"      DiMartino JF, Miller T, Ayton PM, et al. A carboxy-terminal domain of ELL is required and sufficient for immortalization of myeloid progenitors by MLL-ELL. Blood 2000; 96:3887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/110\">",
"      de Th&eacute; H, Chomienne C, Lanotte M, et al. The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus. Nature 1990; 347:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/111\">",
"      von Lindern M, Breems D, van Baal S, et al. Characterization of the translocation breakpoint sequences of two DEK-CAN fusion genes present in t(6;9) acute myeloid leukemia and a SET-CAN fusion gene found in a case of acute undifferentiated leukemia. Genes Chromosomes Cancer 1992; 5:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/112\">",
"      Ichikawa H, Shimizu K, Hayashi Y, Ohki M. An RNA-binding protein gene, TLS/FUS, is fused to ERG in human myeloid leukemia with t(16;21) chromosomal translocation. Cancer Res 1994; 54:2865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/113\">",
"      Panagopoulos I, Aman P, Fioretos T, et al. Fusion of the FUS gene with ERG in acute myeloid leukemia with t(16;21)(p11;q22). Genes Chromosomes Cancer 1994; 11:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/114\">",
"      Rabbitts TH, Forster A, Larson R, Nathan P. Fusion of the dominant negative transcription regulator CHOP with a novel gene FUS by translocation t(12;16) in malignant liposarcoma. Nat Genet 1993; 4:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/115\">",
"      Sorensen PH, Lessnick SL, Lopez-Terrada D, et al. A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG. Nat Genet 1994; 6:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/116\">",
"      Panagopoulos I, H&ouml;glund M, Mertens F, et al. Fusion of the EWS and CHOP genes in myxoid liposarcoma. Oncogene 1996; 12:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/117\">",
"      Yoneda-Kato N, Look AT, Kirstein MN, et al. The t(3;5)(q25.1;q34) of myelodysplastic syndrome and acute myeloid leukemia produces a novel fusion gene, NPM-MLF1. Oncogene 1996; 12:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/118\">",
"      Morris SW, Kirstein MN, Valentine MB, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 1994; 263:1281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/119\">",
"      Lugthart S, Gr&ouml;schel S, Beverloo HB, et al. Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia. J Clin Oncol 2010; 28:3890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/120\">",
"      Hui CH, Suttle J. Erythrophagocytosis associated with AML-M5 and t(8;16). Br J Haematol 2001; 113:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/121\">",
"      Sobulo OM, Borrow J, Tomek R, et al. MLL is fused to CBP, a histone acetyltransferase, in therapy-related acute myeloid leukemia with a t(11;16)(q23;p13.3). Proc Natl Acad Sci U S A 1997; 94:8732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/122\">",
"      Caudell D, Aplan PD. The role of CALM-AF10 gene fusion in acute leukemia. Leukemia 2008; 22:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/123\">",
"      Borrow J, Shearman AM, Stanton VP Jr, et al. The t(7;11)(p15;p15) translocation in acute myeloid leukaemia fuses the genes for nucleoporin NUP98 and class I homeoprotein HOXA9. Nat Genet 1996; 12:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/124\">",
"      Jankovic D, Gorello P, Liu T, et al. Leukemogenic mechanisms and targets of a NUP98/HHEX fusion in acute myeloid leukemia. Blood 2008; 111:5672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/125\">",
"      Metz T, Graf T. Fusion of the nuclear oncoproteins v-Myb and v-Ets is required for the leukemogenicity of E26 virus. Cell 1991; 66:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/126\">",
"      Graf T, McNagny K, Brady G, Frampton J. Chicken \"erythroid\" cells transformed by the Gag-Myb-Ets-encoding E26 leukemia virus are multipotent. Cell 1992; 70:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/127\">",
"      Mucenski ML, McLain K, Kier AB, et al. A functional c-myb gene is required for normal murine fetal hepatic hematopoiesis. Cell 1991; 65:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/128\">",
"      Nazarov V, Hilbert D, Wolff L. Susceptibility and resistance to Moloney murine leukemia virus-induced promonocytic leukemia. Virology 1994; 205:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/129\">",
"      Nazarov V, Wolff L. Novel integration sites at the distal 3' end of the c-myb locus in retrovirus-induced promonocytic leukemias. J Virol 1995; 69:3885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/130\">",
"      Ben-David Y, Bernstein A. Friend virus-induced erythroleukemia and the multistage nature of cancer. Cell 1991; 66:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/131\">",
"      Munroe DG, Peacock JW, Benchimol S. Inactivation of the cellular p53 gene is a common feature of Friend virus-induced erythroleukemia: relationship of inactivation to dominant transforming alleles. Mol Cell Biol 1990; 10:3307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/132\">",
"      Lavigueur A, Bernstein A. p53 transgenic mice: accelerated erythroleukemia induction by Friend virus. Oncogene 1991; 6:2197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/133\">",
"      Moreau-Gachelin F, Ray D, Mattei MG, et al. The putative oncogene Spi-1: murine chromosomal localization and transcriptional activation in murine acute erythroleukemias. Oncogene 1989; 4:1449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/134\">",
"      Paul R, Schuetze S, Kozak SL, et al. The Sfpi-1 proviral integration site of Friend erythroleukemia encodes the ets-related transcription factor Pu.1. J Virol 1991; 65:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/135\">",
"      Scott EW, Simon MC, Anastasi J, Singh H. Requirement of transcription factor PU.1 in the development of multiple hematopoietic lineages. Science 1994; 265:1573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/136\">",
"      Buchberg AM, Bedigian HG, Jenkins NA, Copeland NG. Evi-2, a common integration site involved in murine myeloid leukemogenesis. Mol Cell Biol 1990; 10:4658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/137\">",
"      Largaespada DA, Shaughnessy JD Jr, Jenkins NA, Copeland NG. Retroviral integration at the Evi-2 locus in BXH-2 myeloid leukemia cell lines disrupts Nf1 expression without changes in steady-state Ras-GTP levels. J Virol 1995; 69:5095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/138\">",
"      Cho BC, Shaughnessy JD Jr, Largaespada DA, et al. Frequent disruption of the Nf1 gene by a novel murine AIDS virus-related provirus in BXH-2 murine myeloid lymphomas. J Virol 1995; 69:7138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/139\">",
"      Shannon KM, Watterson J, Johnson P, et al. Monosomy 7 myeloproliferative disease in children with neurofibromatosis, type 1: epidemiology and molecular analysis. Blood 1992; 79:1311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/140\">",
"      Jacks T, Shih TS, Schmitt EM, et al. Tumour predisposition in mice heterozygous for a targeted mutation in Nf1. Nat Genet 1994; 7:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/141\">",
"      Bollag G, Clapp DW, Shih S, et al. Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells. Nat Genet 1996; 12:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/142\">",
"      Largaespada DA, Brannan CI, Jenkins NA, Copeland NG. Nf1 deficiency causes Ras-mediated granulocyte/macrophage colony stimulating factor hypersensitivity and chronic myeloid leukaemia. Nat Genet 1996; 12:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/143\">",
"      Nakamura T, Largaespada DA, Shaughnessy JD Jr, et al. Cooperative activation of Hoxa and Pbx1-related genes in murine myeloid leukaemias. Nat Genet 1996; 12:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/144\">",
"      Nakamura T, Jenkins NA, Copeland NG. Identification of a new family of Pbx-related homeobox genes. Oncogene 1996; 13:2235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/17/25882/abstract/145\">",
"      Vassiliou GS, Cooper JL, Rad R, et al. Mutant nucleophosmin and cooperating pathways drive leukemia initiation and progression in mice. Nat Genet 2011; 43:470.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4502 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-220.255.2.147-47BE18D17D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_17_25882=[""].join("\n");
var outline_f25_17_25882=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H91418851\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H91419583\">",
"      GENE MUTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24780405\">",
"      Mutations affecting DNA methylation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Tumor suppressor genes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      RAS oncogene mutations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CHROMOSOMAL TRANSLOCATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Involvement of core binding factor",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Familial platelet disorder with predisposition to AML",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Other causes of familial AML",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - AML and MDS and myeloproliferative neoplasms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Cooperating mutations in AML",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - AML1/EAP, MDS1, EVI1 in t(3;21)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - TEL(ETV6) and AML1 in t(12;21)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - CBFb/MYH11 in inv(16) and t(16;16)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Involvement of the MLL locus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Partner chromosomes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Mechanism of action",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H91419960\">",
"      Involvement of the retinoic acid receptor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Other fusion genes in AML",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - DEK/CAN in t(6;9) and SET-CAN",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - TLS/FUS/ERG and t(16;21)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - NPM/MLF1 in t(3;5)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - EVI1 in inv(3) and t(3;3)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - MOZ/CBP in t(8;16)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - CALM/AF10 in t(10;11)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - NUP98/HOXA9 in t(7;11) and NUP98/DDX10 in inv(11)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      ANIMAL MODELS OF AML",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Myb leukemias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Friend virus/SFFV erythroleukemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      BXH-2 leukemias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H91418851\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4502\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4502|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/33/13842\" title=\"picture 1\">",
"      AML FAB M2 and t8 21",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/62/19424\" title=\"picture 2\">",
"      AML FAB M4EO",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4502|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/14/17643\" title=\"table 1\">",
"      Prognostic factors AML",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/33/40474?source=related_link\">",
"      Cellular and molecular biology of chronic myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/47/25337?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of anaplastic large cell lymphoma, ALK positive",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/46/25322?source=related_link\">",
"      Clinical manifestations, pathologic features, diagnosis, and prognosis of follicular lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28536?source=related_link\">",
"      Cytogenetic and molecular genetic diagnostic tools",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/42/39594?source=related_link\">",
"      Cytogenetics in acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/21/6489?source=related_link\">",
"      General aspects of cytogenetic analysis in hematologic malignancies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/5/41049?source=related_link\">",
"      Genetic abnormalities in hematologic and lymphoid malignancies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/35/17976?source=related_link\">",
"      Molecular biology of acute promyelocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/30/34275?source=related_link\">",
"      Patient information: Acute myeloid leukemia (AML) treatment in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/55/36730?source=related_link\">",
"      Prognosis of acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/44/6858?source=related_link\">",
"      Regulation of myelopoiesis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_17_25883="EORTC trial 22921 rectal cancer";
var content_f25_17_25883=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F50875&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F50875&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    EORTC trial of neoadjuvant chemoradiotherapy vs radiotherapy prior to surgery for rectal cancer and adjuvant chemotherapy vs no adjuvant chemotherapy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       &nbsp;",
"      </td>",
"      <td class=\"subtitle1\">",
"       Preop RT",
"      </td>",
"      <td class=\"subtitle1\">",
"       Preop RT + adjuvant chemo",
"      </td>",
"      <td class=\"subtitle1\">",
"       Preop CRT + adjuvant chemo",
"      </td>",
"      <td class=\"subtitle1\">",
"       Preop CRT",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Number of patients",
"      </td>",
"      <td>",
"       252",
"      </td>",
"      <td>",
"       253",
"      </td>",
"      <td>",
"       253",
"      </td>",
"      <td>",
"       253",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Treatment-related grade &ge;2 diarrhea, percent",
"      </td>",
"      <td>",
"       17.3",
"      </td>",
"      <td>",
"       17.3",
"      </td>",
"      <td>",
"       37.6",
"      </td>",
"      <td>",
"       37.6",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Sphincter preserving surgery, percent",
"      </td>",
"      <td>",
"       50.5",
"      </td>",
"      <td>",
"       50.5",
"      </td>",
"      <td>",
"       52.8",
"      </td>",
"      <td>",
"       52.8",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       5 year cumulative rate of local relapse, percent",
"      </td>",
"      <td>",
"       17.1",
"      </td>",
"      <td>",
"       9.6",
"      </td>",
"      <td>",
"       7.6",
"      </td>",
"      <td>",
"       8.7",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     RT: radiation therapy; CRT: chemoradiotherapy; chemo: chemotherapy.",
"    </div>",
"    <div class=\"reference\">",
"     Data from Bosset, JF et al, N Engl J Med 2006; 355:1114.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_17_25883=[""].join("\n");
var outline_f25_17_25883=null;
var title_f25_17_25884="Monitoring for metabolic side effects of antipsychotic drugs";
var content_f25_17_25884=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PSYCH%2F74435&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PSYCH%2F74435&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Monitoring for metabolic side effects of antipsychotic drugs",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Baseline",
"       </td>",
"       <td class=\"subtitle1\">",
"        4 weeks",
"       </td>",
"       <td class=\"subtitle1\">",
"        8 weeks",
"       </td>",
"       <td class=\"subtitle1\">",
"        12 weeks",
"       </td>",
"       <td class=\"subtitle1\">",
"        Quarterly",
"       </td>",
"       <td class=\"subtitle1\">",
"        Annually",
"       </td>",
"       <td class=\"subtitle1\">",
"        At least every 5 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Personal or family history",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Weight (body mass index)",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Waist circumference",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Blood pressure",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fasting plasma glucose",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fasting lipid profile",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        &nbsp;*",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        X",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     <p>",
"      * For patients taking olanzapine, quetiapine, clozapine.",
"     </p>",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; 2004 American Diabetes Association. From Diabetes Care, Vol. 27, 2004: 596-601. Reproduced with permission.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_17_25884=[""].join("\n");
var outline_f25_17_25884=null;
var title_f25_17_25885="Low-carb versus conventional diet";
var content_f25_17_25885=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F65417&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F65417&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 535px\">",
"   <div class=\"ttl\">",
"    Weight loss with conventional versus low carbohydrate diet",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 515px; height: 270px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Comparison of mean weight loss in kg between subjects on a conventional diet (red circles) and a low-carbohydrate diet (blue squares). The difference in weight loss was no longer significant at one year.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Stern L, Iqbal N, Seshadri P, et al. The effects of low-carbohydrate versus conventional weight loss diets in severely obese adults: one-year follow-up of a randomized trial. Ann Intern Med 2004; 140:778.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_17_25885=[""].join("\n");
var outline_f25_17_25885=null;
var title_f25_17_25886="ARMS amplification";
var content_f25_17_25886=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F55076&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F55076&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 569px\">",
"   <div class=\"ttl\">",
"    Amplification refractory mutation system",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 549px; height: 375px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This example of amplification refractory mutation system (ARMS) PCR shows how this technique can be used to distinguish between an individual who is homozygous for a normal gene and individuals homozygous or heterozygous for mutation in that gene. In this case separate primers are designed to match the normal gene sequence or the mutant gene sequence. The DNA sequences in red represent the patient DNA; the sequences in green are the primers. The box shows the mutant base and the corresponding altered base on the mutant primer.",
"    <br/>",
"    A an agarose gel is run with the PCR products, and the presence of a band shows whether the normal or mutant DNA sequence was present.",
"    <br/>",
"    Lanes 2 and 3: Individual with the normal gene; only the normal primer gives a PCR product.",
"    <br/>",
"    Lanes 4 and 5: Individual homozygous for the mutation; only the mutant primer gives a PCR product.",
"    <br/>",
"    Lanes 6 and 7: Individual heterozygous for the mutation; both the normal and mutant primers give PCR products.",
"    <br/>",
"    Note: A control DNA product was present in all lanes, verifying that the PCR reaction worked.",
"    <div class=\"footnotes\">",
"     ARMS: amplification refractory mutation system; PCR: polymerase chain reaction.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_17_25886=[""].join("\n");
var outline_f25_17_25886=null;
var title_f25_17_25887="Dilated episcleral vessels";
var content_f25_17_25887=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F80414&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F80414&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Dilated episcleral vessels in a patient with a cavernous dural fistula",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 359px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jeffrey L Bennett, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_17_25887=[""].join("\n");
var outline_f25_17_25887=null;
